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Abstract
Upper urinary tract stones are a major determinant of pain and is suggested to accelerate
disease progression in patients with autosomal dominant polycystic kidney disease
(ADPKD). For these reasons, stones should be optimally managed in patients with
ADPKD. However, the kidney distortions may make managing stones challenging in
patients with ADPKD. Understanding of the epidemiology of upper urinary tract stones
and stone intervention and the outcomes of stone interventions is limited. The aim of this
thesis is to understand the epidemiology of upper urinary tract stones and stone
interventions and consequences of stone management in patients with ADPKD.
To address this knowledge gap, we conducted two systematic reviews to understand the
current knowledge on the prevalence and incidence of upper urinary tract stones, and the
success and complication rate of the three common stone interventions (shockwave
lithotripsy [SWL], ureteroscopy, and percutaneous nephrolithotomy [PCNL]) in patients
with ADPKD. We conducted a chart review to validate International Classification of
Diseases, 10th revision (ICD-10) codes related to ADPKD. We then conducted two cohort
studies using ICES data to determine and compare the rate of stones and rate of stone
intervention, and the complication rate of the most common stone intervention
(ureteroscopy) in patients with ADPKD to patients without ADPKD with similar baseline
health.
Chapter 2 showed that that there is poor consensus on how often patients with ADPKD
develop or undergo intervention for upper urinary tract stones.
Chapter 3 showed that the efficacy and safety of stone interventions in patients with
ADPKD remains uncertain.
Chapter 4 summarized the limitations of the existing literature based on the findings of
the two systematic reviews.
Chapter 5 showed that majority of the patients with ICD-10 codes related to ADPKD
truly have ADPKD according to strict clinical criteria.
i

Chapter 6 showed that patients with ADPKD presented to the hospital with upper urinary
tract stones more, and that urologist were not managing stones in patients with ADPKD
in a similar manner to comparable patients without ADPKD. It also showed that
ureteroscopy is the most commonly performed stone intervention.
Chapter 7 showed ADPKD is associated with a statistically significant increase
emergency department visits in selected patients with ADPKD who received
ureteroscopy for upper urinary tract stones compared to patients without ADPKD.
Results can inform the use of ICD-10 codes to build ADPKD cohorts, inform clinical
practice guidelines, and guide prognostication.
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Summary for Lay Audience
Autosomal dominant polycystic kidney disease is a condition where the kidneys are filled
with many cysts. Over time, the cysts grow in size and number and cause the kidneys to
fail. Upper urinary tract stones are a major reason for pain and may cause kidneys to fail
faster in these patients. For these reasons, stones should be managed well in patients with
ADPKD. However, the kidney cysts in these patients may make this challenging. A
thorough review of the literature shows that little is known about the rate of upper urinary
tract stones and stone interventions, and the outcomes of ureteroscopy (a common
procedure to treat upper urinary tract stones). The aim of this thesis was to fill this
knowledge gap.
We did this by conducting large, follow-up studies using administrative databases. Our
validation studies show that we can confidently use administrative codes to identify
patients with ADPKD. This thesis confirms that hospital encounters with upper urinary
tract stones are a manifestation of ADPKD. From the administrative data, urologists
approach stones in ADPKD in a similar manner compared to patients without ADPKD,
despite the distorted kidney anatomy potentially making stone interventions more
challenging. Of all three commonly used interventions (SWL, ureteroscopy, and PCNL),
ureteroscopy is the most common intervention used to manage stones in both patients
with and without ADPKD. Our final thesis study shows that patients with ADPKD do not
experience more ureteroscopic complications and hospital admission for any reason.
However, they did experience more hospital presentation and emergency department visit
for any reason compared to patients without ADPKD. This may be a consideration for
patient counselling.
The knowledge gained from this thesis identifies knowledge gaps, and lays the
foundation for future studies on ADPKD using healthcare administrative databases. It
also clarifies the rate of hospital encounters with upper urinary tract stones and the rate of
stone interventions, and provides the best evidence we have to date to inform clinical
practice.

iv

Co-Authorship Statement
All studies included in this thesis was primarily conceived, designed, and executed by
Vinusha Kalatharan. Vinusha Kalatharan also wrote the initial draft of all manuscripts
included in this thesis, and integrated feedbacks from co-authors and reviewers. The data
for chapters 5, 6, and 7 were provided by ICES. The supervisory committee, Drs. Amit
Garg, York Pei, Blayne Welk, and Sisira Sarma, and other research team members
provided feedback, data cuts according to ICES regulations, and/or methodological or
content expertise on an as needed basis and were listed as co-authors accordingly. All coauthors contributed and approved the manuscripts. The contributions of Vinusha
Kalatharan and each of the co-authors is detailed below, and recognized as footnotes in
the beginning of each chapter.
Chapter 2: Vinusha Kalatharan and Amit X Garg conceived and actively participated in
the design and coordination of the study. Vinusha Kalatharan developed the
comprehensive search strategy with the help of the librarian, John Costello. Vinusha
Kalatharan and Gary Grewal screened all relevant citations, abstracted information using
a standardized data abstraction form developed by Vinusha Kalatharan, and assessed the
risk of bias of each included study. Danielle M Nash resolved any disagreement between
the two reviewers. Vinusha Kalatharan wrote the first draft of the manuscript, and
integrated all co-authors’ and reviewers’ comments. All authors read and approved the
final article.
Chapter 3: Vinusha Kalatharan and Amit X Garg conceived and actively participated in
the design and coordination of the study. Vinusha Kalatharan developed the
comprehensive search strategy with the help of the librarian, John Costello. Vinusha
Kalatharan and Racquel Jandoc screened all relevant citations and abstracted information
using a standardized data abstraction form developed by Vinusha Kalatharan. Vinusha
Kalatharan and Gary Grewal assessed the risk of bias of each included study. Danielle M
Nash resolved any disagreement between the two reviewers. Vinusha Kalatharan
conducted the analysis, wrote the first draft of the manuscript, and integrated all coauthors’ and reviewers’ comments. All authors read and approved the final article.
v

Chapter 5: Vinusha Kalatharan, York Pei, and Amit X Garg conceived and actively
participated in the design and coordination of the study. Vinusha Kalatharan was the
main reviewer, conducted the main analysis, wrote the first draft of the manuscript, and
integrated the comments of all co-authors and reviewers. Kristin Clemens assisted with
the data collection, and Rebecca K McTavish was the second reviewer. Matthew Rochon
reviewed images of patients that required additional information. Stephanie Dixon
conducted analysis and provided analytical support for the ICES proportion of the data.
All authors read and approved the final article.
Chapter 6: Vinusha, Amit, Blayne, Danielle, and Stephanie actively participated in the
design of the study. Vinusha executed the study, conducted the analyses, and wrote the
first draft of the manuscript as first-author. Stephanie and Justin provided analytical
support. All authors read, critically revised, and approved the final article. Vinusha
integrated the feedbacks of all authors and reviewers.
Chapter 7: Vinusha, Amit, Blayne, Danielle, and Eric actively participated in the design
of the study. Vinusha executed the study, conducted the analyses, and wrote the first draft
of the manuscript as first-author. Eric and Justin provided analytical support. All authors
read, critically revised, and approved the final article. Vinusha integrated the feedbacks
of all authors and reviewers.

vi

Acknowledgments
First, I would like to express my sincerest gratitude to my thesis advisor, Dr. Amit Garg,
for his continual support throughout my doctoral training. I will forever be grateful for
his guidance and the ample amount of opportunities that he provided me that enriched my
training. Being trained under his supervision was an amazing learning experience and I
am a better, and more independent researcher today because of his training and
opportunities.
I would also like to thank my committee members, Drs. Blayne Welk, Sisira Sarma, and
York Pei for their insights and perspective on my research. My sincerest thanks to Dr.
Blayne Welk for going above and beyond while providing me guidance with urological
and epidemiological concepts. Blayne was always generous with his time and provide
answers to all my questions, and I am truly grateful for all that he has done during my
PhD. I also thank Dr. Sisira Sarma for taking time to meet with me and for providing me
with his insights. Dr. Pei was very helpful with providing feedback pertaining to
ADPKD.
I am truly grateful for the opportunity to work alongside the staff at ICES. I’m forever
thankful to Danielle Nash for training me on the ICES processes, and providing guidance
and support in many ways. Danielle has always been generous with her time, and I am
forever grateful for everything she has helped me with. My sincerest thanks to Stephanie
Dixon, Eric McArthur, and Justin Slater for taking the time to clarify any conceptual
doubts and sharing their expertise in biostatistics and SAS programming. I also thank
Jessica Sontrop for providing me with writing resources and tips on how to become a
better writer. I am also grateful for all the other ICES Western graduate students and
post-doctoral fellows for their advice, continued friendship, and for supporting me. A
special thanks to Kristin Clemens, Rey Acedillo, Alvin Li, Ahmed Al-Jaishi, Kyla
Naylor, Steven Habbous, Rebecca McTavish, Aiden Liu, Sebastian Przech, Owen
Litwen, Carina Iskander, and Flory Muanda. Flory has always encouraged me to keep
going when the tides were rough, and was always ready to help explain epidemiological

vii

concepts, provide advice, and hear out my thoughts. Thank you for all the kind words and
motivation.
Many thanks to the Department of Epidemiology and Biostatistics for laying a strong
foundation in Epidemiology and Biostatistics. I am also very thankful for the friends I
met at the Department of Epidemiology and Biostatistics during my graduate training that
enriched my graduate experience.
I would also like to acknowledge the financial support provided by Western Graduate
Research Scholarship, Schulich Graduate Scholarship, Ontario Graduate Scholarship,
Canadian Institute of Health Research Doctoral Scholarship, and the Kidney Research
Scientist Core Education and National Training [KRESCENT] award.
I am very grateful to have met researchers with a diverse background across Canada
through the KRESCENT training program. The training program, mentors (Drs. Adeera
Levin, Sunny Hartwig, and Todd Alexander), and other KRESCENT fellows fostered my
growth as a researcher.
My sincerest thanks and appreciation to my parents (Kalatharan Nagesu and Shasikara
Kalatharan), late grandparents, sisters (Venusha Kalatharan and Abisha Kalatharan) who
constantly encouraged and supported me throughout this process; I would not be where I
am today without them. I also thank my new set of parents and siblings (my in-laws) that
I gained during my PhD for being very supportive. Lastly, my sincerest thanks to my
husband, Sen Sivalinghem, for being my pillar and number one cheerleader.

viii

Table of Contents
Abstract

i

Summary for Lay Audience ........................................................................................ iv
Co-Authorship Statement..............................................................................................v
Acknowledgments...................................................................................................... vii
Table of Contents ........................................................................................................ ix
List of Tables ..............................................................................................................xv
List of Figures ......................................................................................................... xviii
List of Appendices .................................................................................................... xix
Abbreviations ..............................................................................................................xx
Introduction .............................................................................................1
1.1 BURDEN OF UPPER URINARY TRACT STONES IN THE GENERAL
POPULATION ..................................................................................................1
1.2 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
...........................................................................................................................1
1.3 UPPER URINARY TRACT STONES IN ADPKD .........................................3
1.4 UPPER URINARY TRACT STONE MANAGEMENT IN THE GENERAL
POPULATION ..................................................................................................4
1.4.1 Shockwave lithotripsy (SWL) in the general population ........................4
1.4.2 Ureteroscopy in the general population ...................................................5
1.4.3 Percutaneous nephrolithotomy (PCNL) in the general population..........5
1.5 UPPER URINARY TRACT STONE MANAGEMENT IN ADPKD .............6
1.6 OVERALL AIMS .............................................................................................6
1.7 STUDY OBJECTIVES .....................................................................................7
1.8 STRUCTURE OF THESIS ...............................................................................8
1.9 REFERENCES................................................................................................11

ix

Stone prevalence in autosomal dominant polycystic kidney disease: a
systematic review and meta-analysisa ....................................................................15
2.1 INTRODUCTION...........................................................................................16
2.2 METHODS .....................................................................................................16
2.2.1 Design and study selection ....................................................................16
2.2.2 Identifying relevant articles ...................................................................17
2.2.3 Data abstraction .....................................................................................19
2.2.4 Data analysis ..........................................................................................25
2.3 RESULTS .......................................................................................................25
2.3.1 Study selection .......................................................................................25
2.3.2 Description of included studies .............................................................26
2.3.3 Patient population ..................................................................................39
2.3.4 Quality assessment of studies ................................................................45
2.3.5 Prevalence and characteristics of stones and prevalence of stone
intervention .........................................................................................47
2.3.6 Stone incidence ......................................................................................55
2.4 DISCUSSION .................................................................................................55
2.5 CONCLUSION ...............................................................................................58
2.6 ADDENDUM .................................................................................................58
2.7 REFERENCES................................................................................................59
Efficacy and safety of surgical upper urinary tract stone interventions in
autosomal dominant polycystic kidney disease: a systematic review b ..................65
3.1 INTRODUCTION...........................................................................................66
3.2 METHODS .....................................................................................................67
3.2.1 Design and study selection ....................................................................67
3.2.2 Identifying relevant articles ...................................................................68

x

3.2.3 Data abstraction .....................................................................................68
3.2.4 Data analysis ..........................................................................................69
3.3 RESULTS .......................................................................................................77
3.3.1 Quality assessment of studies ................................................................89
3.3.2 Shockwave lithotripsy ...........................................................................89
3.3.3 Ureteroscopy ..........................................................................................91
3.3.4 Percutaneous nephrolithotomy (PCNL) ................................................93
3.4 DISCUSSION .................................................................................................98
3.5 CONCLUSION .............................................................................................101
3.6 ADDENDUM ...............................................................................................101
3.7 REFERENCES..............................................................................................102
Limitations of the existing literature....................................................106
4.1 Limitations of the existing literature .............................................................107
4.2 REFERENCES..............................................................................................110
Positive predictive value of international classification of diseases, 10 th
revision coding algorithms to identify patients with autosomal dominant polycystic
kidney diseasec .....................................................................................................111
5.1 INTRODUCTION.........................................................................................112
5.2 METHODS ...................................................................................................113
5.2.1 Study design ........................................................................................113
5.2.2 Ethics approval and consent to participate ..........................................113
5.2.3 Data sources and database algorithms .................................................114
5.3 METHODS SPECIFIC TO CHART ABSTRACTION STUDY .................115
5.3.1 Patient selection ...................................................................................115
5.3.2 Data collection .....................................................................................116

xi

Abbreviations: family history, Fam Hx; International Classification of Diseases,
10th revision, ICD-10; left kidney, LK; polycystic kidney disease, PKD; right
kidney, RK; ultrasound, U/S .........................................................................120
5.3.3 Clinical definition of ADPKD .............................................................121
5.3.4 Data analysis ........................................................................................122
5.4 METHODS SPECIFIC TO ICES STUDY ...................................................123
5.4.1 Patient Selection ..................................................................................123
5.4.2 Data analysis ........................................................................................123
5.5 RESULTS .....................................................................................................123
5.5.1 Chart abstract study sample .................................................................123
5.5.2 Chart abstraction patient characteristics ..............................................124
5.5.3 Coding algorithm positive predictive value and frequency .................125
5.6 DISCUSSION ...............................................................................................125
5.7 CONCLUSION .............................................................................................127
5.8 ADDENDUM ...............................................................................................128
5.8.1 Rationale for sampling 201 patients ....................................................128
5.8.2 Recommended algorithm for future studies ........................................128
5.9 REFERENCES..............................................................................................129
Risk of hospital encounters with upper urinary tract stones in autosomal
dominant polycystic kidney disease: a cohort studyd...........................................131
6.1 INTRODUCTION.........................................................................................132
6.2 MATERIALS AND METHODS ..................................................................133
6.2.1 Designs and setting ..............................................................................133
6.2.2 Sample size calculations ......................................................................133
6.2.3 Data sources .........................................................................................134
6.2.4 Population and timeline .......................................................................135

xii

6.2.5 Outcomes .............................................................................................137
6.2.6 Data analysis ........................................................................................142
6.3 RESULTS .....................................................................................................147
6.3.1 Cohort selection & baseline characteristics .........................................147
6.3.2 Follow-up period for stone event.........................................................153
6.3.3 Follow-up period for stone intervention event ....................................153
6.3.4 Outcomes .............................................................................................153
6.3.5 Multi-variable risk factor analysis .......................................................162
6.4 DISCUSSION ...............................................................................................164
6.5 CONCLUSION .............................................................................................165
6.6 REFERENCES..............................................................................................167
Ureteroscopic complications in patients with autosomal dominant
polycystic kidney diseasee....................................................................................176
7.1 INTRODUCTION.........................................................................................177
7.2 PATIENTS AND METHODS ......................................................................178
7.2.1 Design and setting ...............................................................................178
7.2.2 Data sources .........................................................................................178
7.2.3 Population and timeline .......................................................................186
7.2.4 Outcomes .............................................................................................188
7.2.5 Data analysis ........................................................................................189
7.3 RESULTS .....................................................................................................191
7.3.1 Cohort selection and baseline characteristics ......................................191
7.3.2 Follow-up.............................................................................................195
7.3.3 Outcome...............................................................................................195
7.4 DISCUSSION ...............................................................................................197
7.5 CONCLUSION .............................................................................................198
xiii

7.6 REFERENCES..............................................................................................199
Discussion and conclusions .................................................................202
8.1 SUMMARY OF KEY FINDINGS ...............................................................203
8.2 IMPLICATIONS...........................................................................................205
8.2.1 Laid the foundation for future research in ADPKD using administrative
databases ...........................................................................................205
8.2.2 Implications for clinical practice guidelines ........................................206
8.2.3 Clinical prognostication .......................................................................207
8.3 STRENGTHS ................................................................................................208
8.4 LIMITATIONS .............................................................................................209
8.5 FUTURE DIRECTIONS ..............................................................................210
8.6 CONCLUSION .............................................................................................211
8.7 TAKE HOME MESSAGE ............................................................................212
8.9 REFERENCES..............................................................................................213
Appendices ………………………………………………………………………..215

xiv

List of Tables
Table 2-1. Search strategy used to identify relevant articles. ........................................... 17
Table 2-2. Data abstraction form ...................................................................................... 20
Table 2-3. Modified Downs and Black Checklist for observational studies .................... 22
Table 2-4. Study Characteristics ....................................................................................... 28
Table 2-5. Patient characteristics ...................................................................................... 40
Table 2-6. Ravine ultrasonographic criteria for diagnosing autosomal dominant
polycystic kidney disease .................................................................................................. 45
Table 2-7. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic
kidney disease (ADPKD) .................................................................................................. 46
Table 2-8. Prevalence of stones and stone intervention in patients with autosomal
dominant polycystic kidney disease and controls ............................................................. 48
Table 2-9. Symptoms and characteristics of stones .......................................................... 52
Table 3-1. Search strategy used to identify relevant articles related to thesis .................. 69
Table 3-2. Data abstraction form ...................................................................................... 71
Table 3-3. Modified Downs and Black checklist............................................................. 74
Table 3-4. Study and patient characteristics of included studies. ..................................... 80
Table 3-5. Outcomes of stone interventions. .................................................................... 83
Table 3-6. Characteristics of shockwave lithotripsy (SWL). ............................................ 90
Table 3-7. Characteristics of ureteroscopy. ...................................................................... 92
Table 3-8. Characteristics of percutaneous nephrolithotomy (PCNL). ............................ 94

xv

Table 5-1. International classification of diseases, 10th revision codes relevant for
autosomal dominant polycystic kidney disease. ............................................................. 115
Table 5-2. Combination of International Classification of Diseases, 10 th revision of the
nine administrative coding algorithms evaluated to identify patients with autosomal
dominant polycystic kidney disease................................................................................ 115
Table 5-3. Data abstraction form to collect relevant clinical information required to
elucidate whether patients have ADPKD or not according to the reference standard. ... 118
Table 5-4. Number and percentage of patients that satisfied each criterion for autosomal
dominant polycystic kidney disease................................................................................ 124
Table 5-5. Positive predictive values and the number of Ontarians identified by each
administrative database coding algorithm. ..................................................................... 125
Table 6-1. Databases and coding definitions for restriction criteria, baseline
characteristics and outcome measurements. ................................................................... 137
Table 6-2. Characteristics of the autosomal dominant polycystic kidney disease
(ADPKD) cohort and controls at the time of cohort entry before and after inverse
probability exposure weighting based on propensity scores and truncating extreme
weights. ........................................................................................................................... 150
Table 6-3. Comparison of the hazards of (i) time to first hospital encounter with stone,
and (ii) time to first stone intervention between patients with autosomal dominant
polycystic kidney disease cohort (ADPKD) and patients without ADPKD with similar
baseline health................................................................................................................. 156
Table 6-4 Hazard ratio of hospital encounter with upper urinary tract stone and stone
intervention among patients with autosomal dominant polycystic kidney disease versus
patients without ADPKD with similar indicators for baseline health in various subgroups.
......................................................................................................................................... 161

xvi

Table 6-5. Risk factors for hospital encounter with upper urinary tract stones and stone
interventions in patients with autosomal dominant polycystic kidney disease (ADPKD)
and patients without ADPKD with similar indicators for baseline health when each group
was analyzed separately. ................................................................................................. 163
Table 7-1. Database and coding definitions for restriction criteria, baseline characteristics
and outcome measurements. ........................................................................................... 178
Table 7-2. List of baseline characteristics that were present in one study group but not the
other group. ..................................................................................................................... 188
Table 7-4. Characteristics of patients with and without autosomal dominant polycystic
kidney disease at the time of cohort. ............................................................................... 193
Table 7-5. Unadjusted, and adjusted 30-days risk of ureteroscopic complications, hospital
presentation, hospital admission, and emergency department visits in patients with
compared to patients without autosomal dominant polycystic kidney disease (ADPKD).
......................................................................................................................................... 196

xvii

List of Figures
Figure 2-1. Study selection ............................................................................................... 26
Figure 2-2. Calculated unadjusted prevalence ratio of stones in patients with autosomal
dominant polycystic kidney disease compared to unaffected family members................ 54
Figure 3-1. Study selection. .............................................................................................. 78
Figure 5-1. Definition of positive predictive value used for the first (chart review) study.
......................................................................................................................................... 122
Figure 6-1. Total sample size required to detect a clinically significant difference with an
effect size (Hazard Ratio) varying between 1.5 to 5.0 when the prevalence of upper
urinary tract stone is 1%, 5%, 10%, 15%, and 20%. ...................................................... 134
Figure 6-2. Cohort selection of patients with autosomal dominant polycystic kidney
disease (ADPKD) using International Classification of Diseases codes for ADPKD. ... 148
Figure 6-3. Cohort selection of patients without autosomal dominant polycystic kidney
disease using International Classification of Diseases, 10th revision codes. .................. 149
Figure 6-4. Cumulative incidence function of (A) time to first hospital encounter with
upper urinary tract stone; and (B) time to first stone intervention. ................................. 155
Figure 6-5. Log-minus-log curve of the hospital encounter with upper urinary tract stone
outcome. .......................................................................................................................... 158
Figure 6-6. Log-minus-log curve of the hospital encounter with stone intervention
outcome ........................................................................................................................... 159
Figure 7-1. Cohort selection. .......................................................................................... 192

xviii

List of Appendices
APPENDIX A: Detailed descriptions of ICES data sources used in Chapters 5 to
7 ...................................................................................................................................... 216
APPENDIX B: Copyright information ........................................................................ 219

xix

Abbreviations
ACEi

angiotensin converting enzyme inhibitors

AKI

acute kidney injury

AMOSO

Academic Medical Organization of Southwestern Ontario

ARBs

angiotensin II receptor blockers

CCI

Canadian Classification of Health Intervention

CCI

Canadian Classification of Health Intervention

CI

confidence interval

CIHI

Canadian Institute for Health Information

CIHI-DAD

Canadian Institute for Health Information Discharge Abstract Database

CKD

chronic kidney disease

CT

computed tomography scan

ESKD

end-stage kidney disease

Fam Hx

family history

HR

hazards ratio

ICD-10

International Classification of Diseases, 10th revision

ICD-9

International Classification of Diseases, 9th revision

ID

identification number

IPDB

ICES Physician Database

IPTW

inverse probability treatment weighting

IQR

interquartile range

IV

intravenous

KUB

kidney, ureter, bladder

kV

kilovolts

LHIN

Local Health Integration Network
xx

LHRI

Lawson Health Research Institute

MOHLTC

Ministry of Health and Long-Term Care

N/A

not applicable

NACRS

National Ambulatory Care Reporting System

NR

not reported

NSAIDs

nonsteroidal anti-inflammatory drugs

OHIP

Ontario Health Insurance Plan

PCNL

percutaneous nephrolithotomy

PHIPA

Personal Health Information Protection Act

PKD

polycystic kidney disease

PRISMA

Preferred Reporting Items for Systematic Review and Meta-Analysis

RD

risk difference

RPDB

Registered Persons Database

RR

relative risk

SDS

same day surgery

SSMD

Schulich School of Medicine and Dentistry

SWL

shockwave lithotripsy

U/S

ultrasound

UTI

urinary tract infection

WHO

World Health Organization

xxi

1

Introduction
1.1 BURDEN OF UPPER URINARY TRACT STONES IN
THE GENERAL POPULATION
Upper urinary tract stones are a common occurrence in the general population
(prevalence ranging between 0.1% and 14.8% and the incidence ranging between 24.2
and 81.0 individuals per 100,000 person-years) with its prevalence increasing globally.1
The prevalence of upper urinary tract stones is higher in men than in women, with the
difference in stone prevalence between men and women decreasing overtime.2
Approximately half of the patients experience a recurrent upper urinary tract stone event
within seven years of the first stone occurrence, if left untreated. 3
Upper urinary tract stone events impose a significant burden on the healthcare system. 4 In
the United States in 2009, there were 1.3 million emergency department visits for upper
urinary tract stones, of which 20% resulted in a hospitalization.4 The number of
emergency department visits increased 20%, and the rate of hospitalization increased
14% between 2005 and 2009.4 This clinical demand translates to a significant economic
burden on the healthcare system, with annual estimates greater than $5 billion. 4 Upper
urinary tract stones impose both a direct cost and an indirect cost via lost work
productivity.4

1.2 AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY
DISEASE (ADPKD)
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder
with no cure.5,6 It has an estimated prevalence of 1 in 1000 to 1 in 400 worldwide, and is
characterized by focal cyst development in both kidneys. 7–11 It is primarily diagnosed
using ultrasound according to the Ravine criteria (Table 1-1) prior to 2009, and according
to the Pei criteria (Table 1-2) after 2009.12,13 In early stages of ADPKD, the cysts cause
structural deformation to the kidney and damage adjacent nephrons, but overall kidney
function is maintained by compensatory hyperfiltration of functioning nephrons.14,15 As
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the number and size of cysts increase progressively, more nephrons become damaged,
and overall kidney function starts to decline.16 The level of kidney function is indicated
by chronic kidney disease (CKD) stages in patients with ADPKD (Table 1-1).17 The
earlier stages of CKD are defined by kidney damage (determined by albuminuria
(albumin type proteins in the urine)), and mild-to-moderate reductions in how well the
kidney clears the blood of waste products, which is indicated by the estimated glomerular
filtration rate (eGFR).17,18 Further decrements in eGFR defines more advanced stages of
CKD.17,18 By the age of 55, about half of the patients with ADPKD reach end-stage
kidney disease (ESKD) and require kidney transplantation or dialysis to sustain life. 19,20
Currently, tolvaptan is the only drug approved to delay progression to ESKD, and much
of current research on patients with ADPKD is focused on identifying other therapeutic
agents. However, kidney failure is not the only manifestation of ADPKD; patients with
ADPKD are affected with other morbidities that warrant attention to prevent loss of
health-related quality of life.21 One such morbidity is upper urinary tract stones.22
Table 1-1. Ravine ultrasonographic criteria for diagnosing autosomal dominant
polycystic kidney disease
Age
< 30 years
30 to 60 years
> 60 years

Positive Family History

Negative Family history

2 cysts bilaterally or
unilaterally
4 cysts bilaterally
8 cysts bilaterally

5 cysts bilaterally
5 cysts bilaterally
8 cysts bilaterally

Table 1-2. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic
kidney disease (ADPKD) among patients with a positive family history
Age (years)
15 to 39
40 to 59
> 60

Diagnostic Criteria
At least 3 cysts (unilateral or bilateral)
2 cysts/kidney
4 or more cysts/kidney

*Note: Fewer than 2 cysts in individuals > 40 years old and are at risk of ADPKD is sufficient to rule out
the disease.
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Table 1-3. Chronic kidney disease stages categorized based on the classification system
established by the National Kidney Foundation outcome Quality initiative
Chronic Kidney Disease Stage
Stage 1

Clinical Characteristics
Persistent albuminuria & eGFR >
90 mL/min/1.73m2

Stage 2

Persistent albuminuria & 60 >
eGFR > 90 mL/min/1.73m2

Stage 3

30 > eGFR > 60 mL/min/1.73m2

Stage 4

15 > eGFR > 30 mL/min/1.73m2

Stage 5

eGFR < 15 mL/min/1.73m2

Abbreviations: eGFR, estimated glomerular filtration rates

1.3 UPPER URINARY TRACT STONES IN ADPKD
Many popular educational materials and clinical practice guidelines indicate patients with
ADPKD are at higher risk of upper urinary tract stones.23,24 Although the exact
mechanism underlying stone formation in patients with ADPKD is unknown, this makes
clinical sense based on our speculation of the pathophysiology of stone disease in patients
with ADPKD. In general, supersaturation of salts causes crystals to form in the urine
(crystallization).25 There are inhibitors to prevent crystallization in our urine (e.g.
citrate).25 However, as salts become more and more supersaturated, clusters of crystals
start to form (nuclei).25 Nucleation often needs a surface or a seed (e.g. epithelial lining,
other crystal, cell debris).25 Over time, these microscopic nuclei aggregate together to
form stones.25 In patients with ADPKD, the kidney cysts lead to urinary stasis, which
along with metabolic abnormalities, such as hyperoxaluria (high urinary excretion of
oxalate), hyperuricosuria (high uric acid level in urine), hypocitraturia (low citrate
concentration, an inhibitor of crystallization in urine), may promote stone formation. 26–28
The kidney cysts in these patients may also impede stone passage promoting stone
growth. Although the idea that the cystic burden in patients with ADPKD may make
them more susceptible to upper urinary tract stones makes clinical sense, a systematic
review has not been conducted to summarize the burden of stones in patients with
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ADPKD, and to give insight into whether patients with ADPKD have a higher risk of
upper urinary tract stones compared to non-ADPKD patients of similar baseline health.
Understanding the burden of upper urinary tract stones in patients with ADPKD would
inform future clinical practice guidelines and guide prognostication.
Upper urinary tract stones in patients with ADPKD are associated with significant pain
and morbidity.29 In the general CKD population, patients with stones are at higher risk of
ESKD compared to patients without stones, with the suggestion that this is also true in
patients with ADPKD.30,31 For these reasons, stones should be optimally managed in
patients with ADPKD. A clinical practice guideline on recommended upper urinary tract
stone management in patients with ADPKD states that similar approaches are being taken
to manage stones as the general population. The interventions appear safe and efficacious
based on limited evidence.24

1.4 UPPER URINARY TRACT STONE MANAGEMENT IN
THE GENERAL POPULATION
Most stones usually do not require a urological intervention, and will often pass within
four weeks upon presenting symptoms.32 Pain may be managed with narcotics or
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).32 However, urgent intervention is
often required in the presence of infection/urosepsis, intractable pain, vomiting,
impending acute renal failure, and/or obstruction.25 Prior to the 1980s, open stone surgery
or nephrectomy (i.e. partial or full removal of a kidney) was performed to remove stones
in anatomically abnormal kidneys.33,34 However, recently less invasive procedures are
used.35 These procedures are shock wave lithotripsy (SWL), ureteroscopy, and
percutaneous nephrolithotomy (PCNL).35

1.4.1

Shockwave lithotripsy (SWL) in the general population

SWL is the least invasive treatment option and is one of the recommended first-line
treatments for proximal ureteral or renal stones less than 1 cm.36,37 SWL emits
shockwaves from an external device, which propagates through the body and causes the
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stones to fragment by either exerting mechanical stress or by causing the cavitation
bubbles within the stones to collapse.32,38 SWL is non-invasive and associated with few
short-term or long-term complications; the rate of major (0.4%) and minor (5.8%)
complications for SWL is low in the general population. 36 Some SWL related
complications include transient hematuria, pain, perirenal hematoma, and acute kidney
injury.39 SWL is contraindicated for pregnant women and for patients with uncontrolled
hypertension, uncontrolled coagulopathy, or a distal urinary obstruction to where the
stone is located.36

1.4.2

Ureteroscopy in the general population

Ureteroscopy is an alternative first-line therapy for stones in the ureter or kidney
(generally < 2cm). It is performed by inserting a rigid, semi-rigid, or flexible
ureteroscope through the urethra, and by positioning it close to the stone.40,41 Various
instruments, such as a laser or a pneumatic intracorporeal lithotripter, are then used to
fragment the stones.42 Other instruments, such as stone baskets, can be used to remove
the stone fragments.43 Ureteral stents are often used with ureteroscopy to prevent
obstruction from ureteral oedema or residual stone fragments (especially in the presence
of ureteric injury, stricture, solitary kidney, CKD, or a large stone).43 Ureteral stents are
associated with patient discomfort.36 In the general population, the percentage of patients
that are stone free after ureteroscopy is approximately 90%. 36

1.4.3

Percutaneous nephrolithotomy (PCNL) in the general
population

PCNL is recommended for large stones (>2cm), or in cases where retrograde access to
the ureter or kidney is not possible. During PCNL, a renal calyx is punctured with the
guidance of fluoroscopy and/or ultrasound to gain access to the stone.42 Various
instruments, such as lasers, can then be introduced to fragment the stone, and instruments
such as suction, graspers, or baskets are introduced to remove the stones.23 Although this
procedure is relatively more invasive than the other procedures for stone removal, it is
still considered safe and efficacious to treat large, multiple, or complex stones in the
general population.23
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1.5 UPPER URINARY TRACT STONE MANAGEMENT IN
ADPKD
Optimal stone management requires proper access to upper urinary tract stones. The
structural kidney deformation in patients with ADPKD may make gaining optimal access
challenging leading to potentially lower stone free rates following SWL, ureteroscopy,
and PCNL. The kidney distortion may also increase complication rates in patients with
ADPKD. For example, the kidney distortion may impede passage of residual stones, and
may lead to urinary tract obstruction; this may cause an acute kidney injury (AKI) event.
Additionally, patients with ADPKD are more likely to develop a urinary tract infection
(UTI).45,46 During a UTI event, a coexisting stone may passively trap bacteria and
provide an environment that protects the bacteria from the host immune system and
antibiotics allowing it to grow easily.47,48 The passively trapped bacteria may be released
upon fragmentation resulting in a UTI event post-discharge.47 Preoperative obstruction
may limit drainage of the urine infected by the released bacteria and sepsis may also
result.48 Therefore, patients with ADPKD may also be at higher risk for sepsis postintervention. Overall, stone interventions may be associated with lower success rate (i.e.
lower stone free rate), and higher post-operative complication rate. However, a
systematic review on the outcomes of SWL, ureteroscopy, and PCNL to understand the
current state of knowledge and to identify knowledge gaps on this topic is lacking.

1.6 OVERALL AIMS
Understanding of the epidemiology of upper urinary tract stones and stone intervention
and the outcomes of stone interventions is limited. The overarching aim of this thesis is
to understand the epidemiology of upper urinary tract stones and stone interventions, and
consequences of upper urinary tract stone management, in patients with ADPKD. We
will address current knowledge gaps with the following five studies and their respective
objectives.
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1.7 STUDY OBJECTIVES
My thesis consists of five manuscripts, and the first two manuscripts are systematic
reviews of the literature. My five thesis manuscripts and their respective objectives are
outlined below:
STUDY 1 - Stone prevalence in patients with ADPKD: a systematic review and
meta-analysis
Objective 1: To review English-language studies reporting the incidence and
prevalence of stones and stone interventions in adults with ADPKD.
STUDY 2 – Efficacy and safety of surgical upper urinary tract stone interventions
in patients with ADPKD: a systematic review.
Objective 2: To systematically review studies describing being stone free after
the intervention and post-operative complications as reported by each study of the
three main stone interventions in adults with ADPKD: shockwave lithotripsy
(SWL), ureteroscopy, and percutaneous nephrolithotomy.
STUDY 3 – Positive predictive values of International Classification of Diseases, 10th
Revisions coding algorithms to identify patients with ADPKD
Objective 3: To determine whether different International Classification of
Diseases, 10th, revision coding algorithms in large healthcare databases identify
adult patients who meet strict clinical criteria for ADPKD as assessed through
medical chart review.
Secondary objective: To assess the number of patients identified with different
ADPKD coding algorithms in Ontario.
STUDY 4 – Risk of hospital encounters with upper urinary tract stones in patients
with ADPKD: a cohort study
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Objective 4: To describe the rate of hospital encounters (emergency department
visits or hospital admissions) with upper urinary tract stones, and the rate and type
of stone intervention in patients with ADPKD.
Secondary objectives:
a) To compare the rate of hospital encounters (emergency department visits or
hospital admission) with stones in patients with and without ADPKD with
otherwise similar indicators for baseline health.
b) To determine whether the association between ADPKD (yes, no) and the
outcomes are modified by age, sex, and hospital encounters with stones or
stone interventions in the prior five years.
c) To identify risk factors for hospital encounters with stones and stone
interventions in patients with ADPKD. To also do the same in patients
without ADPKD with otherwise similar baseline health as those with
ADPKD.
STUDY 5 – Complications in patients with ADPKD undergoing ureteroscopy
Objective 5: To describe the 30-day cumulative incidence of ureteroscopic
complications, (composite of urinary tract infection, acute kidney injury, and
sepsis), all-cause hospital presentation (either an emergency room visit or hospital
admission), all-cause hospital admission, and all-cause emergency department
visit following ureteroscopy in patients with ADPKD compared to patients
without ADPKD.

1.8 STRUCTURE OF THESIS
An integrated manuscript-based format will be used to present the work of this thesis in a
series of five manuscripts, each of which is presented as a chapter.
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Chapter 2 addresses objective 1 of the thesis, and it identifies knowledge gaps and
summarizes the prevalence and incidence of upper urinary tract stone and stone
intervention reported in the literature. This chapter contains a part of the literature review,
and a version of this chapter has been published the Canadian Journal of Kidney Health
and Diseases as the first manuscript: “Stone prevalence in autosomal dominant
polycystic kidney disease: a systematic review and meta-analysis.”
Chapter 3 addresses objective 2 of the thesis, and it summarizes the outcomes of the three
commonly used stone interventions (SWL, ureteroscopy, and PCNL) in patients with
ADPKD. This chapter contains the second part of the literature review and a version of
this chapter has been published the Canadian Journal of Kidney Health and Diseases as
the second manuscript: “Efficacy and safety of surgical upper urinary tract stone
interventions in autosomal dominant polycystic kidney disease: a systematic review.”
Chapter 4 discusses the limitations of the existing literature based on results from
Chapters 2 and 3.
Chapter 5 addresses objective 3 of the thesis, and provides insight into whether patients
with hospital encounter codes related to ADPKD truly have ADPKD. A version of this
chapter has been published in the Canadian Journal of Kidney Health and Diseases:
“Positive predictive values of International Classification of Diseases, 10 th Revision
coding algorithms to identify patients with autosomal dominant polycystic kidney
disease.”
Chapter 6 addresses objective 4 of the thesis, and it describes the rate of upper urinary
tract stones and rate of stone interventions compared to non-ADPKD patients with
similar indicators for baseline health. A version of this chapter has been submitted for
publication as the fourth manuscript: “Risk of hospital encounters with upper urinary
tract stones in autosomal dominant polycystic kidney disease: a cohort study”.
Chapter 7 addresses objective 5 of the thesis, and it provides an interim perspective on
whether ADPKD is associated with an increased risk of post-operative outcomes
following ureteroscopy. A version of this chapter has been submitted for publication as
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the fifth manuscript: “Ureteroscopic complications in patients with autosomal dominant
polycystic kidney disease”
The last chapter (Chapter 8) of this thesis is the discussion. This chapter summarizes the
major findings of this thesis, links all the chapters of the thesis together, states strengths
and limitations of the thesis, and discusses future directions.
Additional details on the healthcare administrative databases used for my thesis are
provided in Appendix A. Appendix B provides copyright information.
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2.1 INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly
inherited kidney disease and is characterized by focal cyst development in both kidneys.1
In early stages of ADPKD, the cysts cause structural deformation to the kidney and
damage adjacent nephrons, but overall kidney function is maintained by compensatory
hyperfiltration of functioning nephrons.2,3 As the number and size of cysts increase
progressively, more nephrons become damaged, and overall kidney function starts to
decline.4 By the age of 55, about half of the patients reach end-stage kidney disease
(ESKD) and require kidney transplantation or dialysis to sustain life.5,6
ESKD is not the only kidney manifestation of ADPKD. Previous studies suggest that
upper urinary tract stones are more prevalent in patients with ADPKD compared to the
general population; however, there remains uncertainty about the incidence and
prevalence of upper urinary tract stone in patients with ADPKD.7–12 Upper urinary tract
stones in patients with ADPKD are associated with significant morbidity. For example,
stones are a significant determinant of pain, and may accelerate disease progression to
ESKD in patients with ADPKD.13,14
We conducted this systematic review to critically appraise and summarize studies which
reported the incidence and prevalence of upper urinary tract stones and stone
interventions in patients with ADPKD. This encompassed studies which also included
patients without ADPKD as a comparator.

2.2 METHODS
2.2.1

Design and study selection

We conducted this systematic review using a pre-specified protocol not previously
published but detailed below, and report this review according to the Preferred Reporting
Items for Systematic Review and Meta-Analysis (PRISMA) statement.15
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The following studies met our eligibility criteria for review: a) published English full-text
articles and conference proceedings; b) any study design (for example, cross-sectional, or
cohort study); c) mean age of studies population 18 years or older; d) study populations
not solely restricted to patients with ESKD; e) reported prevalence or incidence of stones;
and f) studies published any time after 1970 (the resolution of imaging modalities in older
studies would be different from current ones). In some studies, patients without ADPKD
were included as a comparator to patients with ADPKD, and in such cases we abstracted
information on both groups of patients.

2.2.2

Identifying relevant articles

We performed a comprehensive search of bibliographic databases from 1970 to February
2019 (MEDLINE, EMBASE, Web of Science, BIOSIS Preview, and CINAHL) to
identify all relevant journal articles and conference proceedings (detailed in Table 2-1).
To identify further relevant articles, we also used the ‘cited by’ function on Web of
Science and Google Scholar, and ‘related article’ function on Google Scholar and
‘similar article’ function on PubMed to identify other relevant articles. We also reviewed
the reference lists of all relevant articles.
Two reviewers (VK and GG) independently removed duplicates and rated the title and
abstract of each citation as “relevant”, “possibly relevant” or “not relevant”. We then
retrieved the full-text of “relevant” and “possibly relevant” articles to assess study
eligibility. The two reviewers resolved any disagreement through discussion and
consensus.
Table 2-1. Search strategy used to identify relevant articles.
Database
1.
MEDLINE
2.

3.
4.

Search Strategy
Polycystic Kidney Diseases/ or Polycystic Kidney,
Autosomal Dominant/
(((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or
adpkd).mp.
1 or 2
exp Urolithiasis/
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EMBASE

CINAHL

Web of Science
&
BIOSIS
Preview

5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt
or urolyts or ((kidney* or renal or urin* or ureter*) adj3
(calculus or calculi or stone*))).mp.
6. 4 or 5
7. 3 and 6
1. kidney polycystic disease/
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or
adpkd).mp.
3. 1 or 2
4. urolithiasis/ or calcium oxalate stone/ or calcium stone/ or
nephrolithiasis/ or staghorn stone/ or uric acid stone/ or
ureter stone/
5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt
or urolyts or ((kidney* or renal or urin* or ureter*) adj3
(calculus or calculi or stone*))).mp.
6. 4 or 5
7. 3 and 6
1. (MH "Kidney, Cystic") OR (MH "Polycystic Kidney,
Autosomal Dominant")
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) N3 (kidney* or renal)) or
adpkd)
3. S1 OR S2
4. (MH "Urolithiasis+")
5. (nephrolith* or urolith* or ureterolith* or lithias* or urolyt
or urolyts or ((kidney* or renal or urin* or ureter*) N3
(calculus or calculi or stone*)))
6. S4 OR S5
7. S3 AND S6
(((((((((polycystic OR "type 2") OR "type II") OR "type 1") OR
"type I") OR "autosomal dominant") OR pkd) NEAR (kidney* OR
renal)) OR adpkd) AND (((((((((nephrolith* OR urolith*) OR
ureterolith*) OR lithias*) OR uralyt) OR uroliths) OR ((((kidney*
OR renal) OR urin*) OR ureter*) NEAR ((calculus OR calculi) OR
stone*))) OR ((((ESWL OR eswls) OR SWL) OR lithotrips*) OR
litholapax*)) OR ((((ureteroscop* OR ureterorenoscop*) OR RIRS)
OR retrograde intrarenal surgery) OR FURS)) OR ((PCNL OR
mpnl) OR (percutaneous NEAR (nephrostom* OR
nephrolithotom*)))))
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2.2.3

Data abstraction

Two reviewers (VK and GG) independently abstracted data from all included articles,
recorded the data on the standardized abstraction form (Table 2-2), and resolved any
disagreements through discussion, or with the help of a third reviewer (DMN). We
collected data on study characteristics, patient characteristics, incidence or prevalence of
stones, and stone characteristics. We abstracted the prevalence of stone intervention from
the included studies that reported it.
We assessed the methodological quality of included studies using a modified Downs and
Black checklist (Table 2-3). We assigned all included studies a score between 0 and 22
based on our modified checklist with a higher score indicating a greater quality.16
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Table 2-2. Data abstraction form
Study Characteristics

ID

Author (Year)
Country

Study
design

No. of
centers

Inclusion criteria

Recruitment
period

Mean
(standard
deviation)
follow-up

ADPKD
sample
size

ADPKD case
definition

1

Imaging
modality used
for ADPKD
diagnosis

Control
population

Control
sample size

Quality
score

Stone
type

Setting

Patient Characteristics

Author (Year)
ID
Country

1

Mean age
No.
No. of
(standard
of
patients on
deviation) males
dialysis (%)
(years)
(%)

No. of
transplant
recipients
(%)

No. of
patients
who had
ESKD
(%)

No. of
hypertensive
patients (%)

No. of
patients
with UTI
(%)

Serum
creatinine
(µmol/L)
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Prevalence and Characteristics of Stones

Author (Year)
ID
Country

No. of
unique
patients
with stones

Prevalence
of stone
(%)

Stone
definition

Modality
used to
diagnosis
stone

Symptoms

Location

1

Composition

No. of patients
that
underwent
stone
intervention

% of patients with
stone that underwent
intervention

% of ADPKD
patients who
underwent
intervention

Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; end-stage kidney disease, ESKD; urinary tract infection, UTI
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Table 2-3. Modified Downs and Black Checklist for observational studies
Description of Criteria

Probable
Answers

1 Is the hypothesis/aim/objective of the study clearly described?

1-Yes; 0-No

2 Are the main outcomes to be measured clearly described in the
Introduction or Methods section?

1-Yes; 0-No

3 Are the inclusion and exclusion criteria of the populations
clearly described?

1-Yes; 0-No

4 Is the case definition for ADPKD clearly described?

1-Yes; 0-No

5 Is the ADPKD case definition valid or reliable? After 2009, Pei
criteria; between 1994 and 2009 Ravine criteria; before 1994 other
definitions that sounds reasonable

1-Yes; 0-No

6 Is the distribution of age, sex, and baseline kidney function in
each group of subjects to be compared clearly described?

1-Yes; 0-No

7 Are the main findings of the study clearly described? Simple
data (including denominators and numerators) should be reported
for all major findings so that the reader can check the major
analyses and conclusions.

1-Yes; 0-No

8 Does the study provide estimate of the random variability in the 1-Yes; 0-No
data for the main outcome? In non-normally distributed data, the
inter-quartile range of results should be reported. In normally
distributed data the standard error, standard deviation, or
confidence intervals should be reported. If the distribution of the
data is not described, it must be assumed that the estimate used
were appropriate and the question should be answered yes.
9 Have the characteristics of patients lost to follow-up been
described? This should be answered YES where there were no
losses to follow-up or where losses to follow-up were so small that
findings would be unaffected by their inclusion. This should be
answered nowhere a study does not report the number of patients
lost to follow-up. If LOF <15% then NO.

1-Yes; 0No; 0-N/A

10 Have actual probability values been reported (e.g. 0.035 rather
than <0.05) for the main outcomes except where the probability
value is less than 0.001?

1-Yes; 0No; 0-N/A
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11 Were the subjects asked to participate in the study
representative of the entire population from which they were
recruited?

1-Yes; 0No; 0-UTD

12 Were those subjects who were prepared to participate
representative of the entire population from which they were
recruited? The proportion of those asked who agreed should be
stated. Validation that the sample was representative would include
demonstrating that the distribution of the main confounding factors
was the same in the study sample and the source population.

1-Yes; 0No; 0-UTD

13 Was the prevalence of stone estimated at a place or facility that
is representative of where most of the source population would
attend? If recruited from tertiary care center, then NO. If recruited
from outpatient clinic, then YES.

1-Yes; 0No; 0-UTD

14 There are no unplanned retrospective analyses performed (i.e.
data dredging)? Any analyses that had not been planned at the
outset of the study should be clearly indicated. If no retrospective
unplanned subgroup analyses were reported, then answer yes. If
authors report any outcomes/clinical characteristics that were not
explicitly referenced in the intro/method section, then my answer to
this question is NO; If methods section too brief/not detailed
enough, then UTD)

1-Yes; 0No; 0-UTD

15 In cohort studies, do the analyses adjust for different length of
1-Yes; 0follow-up of patients, or in case-control studies is the time
No; 0-UTD;
period between the intervention and outcome the same for cases 0-N/A
and controls? Where follow-up was the same for all study patients,
the answer should be yes. If different lengths of follow-up were
adjusted for by, for example, survival analysis the answer should be
yes. Studies where differences in follow-up are ignored should be
answered no.
16 Were the statistical tests used to assess the main outcome
appropriate? The statistical techniques used must be appropriate
to the data. For example, non-parametric methods should be used
for small sample sizes. Where little statistical analysis has been
undertaken but where there is no evidence of bias, the question
should be answered yes. If the distribution of data (normal or not)
is not described it must be assumed that the estimates used were
appropriate and the question should be answered yes.

1-Yes; 0No; 0-UTD;
0-N/A

17 Reported a case definition for stone?

1-Yes; 0No; 0-UTD
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18 Was the case definition for stones accurate and reliable? For
studies where the outcome measures are clearly described, the
question should be answered yes. For studies which refer to other
work or that demonstrate the outcome measure are accurate, the
question should be answered as yes. If authors reference a
validation study for their stone definition, or comment on the
sensitivity/specificity of the method they used to identify stone, then
answer yes

1-Yes; 0No; 0-UTD

19 Were the ADPKD population and controls recruited from the
same population?

1-Yes; 0No; 0-UTD;
0-N/A

20 Were the ADPKD population and the controls recruited from
the same time period? For a study which does not specify the time
period over which patient were recruited, the question should be
answered as unable to determine.

1-Yes; 0No; 0-UTD;
0-N/A

21 Was there adequate adjustment for confounding in the analyses
from which the main finding was drawn? Should be answered
no if: 1) the distribution of known confounders in the different
treatment group was not described;or 2) the distribution of known
confounders differed between the two groups but was not taken into
account in the analysis.

1-Yes; 0No; 0-UTD;
0-N/A

22 Were losses of patients to follow-up taken into account? If the
number of patients lost to follow-up are not reported, the question
should be answered as unable to determine. If the proportion lost to
follow-up was too small to affect the main findings, the question
should be answered yes.

1-Yes; 0No; 0-UTD;
0-N/A

Abbreviations: not applicable, N/A; unable to determine, UTD
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2.2.4

Data analysis

We used a Fischer Exact test for studies with controls that did not statistically compare
the prevalence of stones between patients with ADPKD and controls. We also calculated
the prevalence ratio of upper urinary tract stones for each of the studies with controls
using Cochrane Review Manager 5.3. We assessed for heterogeneity across all studies
using the I2 test. I2 values of 25%, 50%, and 75% corresponds to low, moderate and high
levels of heterogeneity, respectively.17 We conducted a meta-analysis to combine the
results if I2 was less than 75%. We calculated the meta-analyzed prevalence ratio
estimates for upper urinary tract stones using a random effects model and Cochrane
Review Manager 5.3.

2.3 RESULTS
2.3.1

Study selection

A schematic diagram of the study selection process is presented in Figure 2-1. Our search
yielded 1812 citations, and we identified 29 eligible articles that met our eligibility
criteria. We identified an additional 20 eligible articles through our further search
strategy described above, which resulted in a total of 49 eligible articles (a total of 9,396
patients with ADPKD) 7–12,14,18–59. The chance corrected agreement between two
independent reviewers for full-text eligibility was excellent (κ = 0.86).
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Figure 2-1. Study selection

2.3.2

Description of included studies

The characteristics of included studies are summarized in Table 2-1. The 49 eligible
studies were published between 1977 and 2019, and the studies were conducted in
Turkey (7 studies) followed by the United States (6 studies), Albania (5 studies), Brazil
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(3 studies), India (3 studies), Spain (3 studies), Canada (2 studies), Italy (2 studies), and
Japan (2 studies). A single study was conducted in Bulgaria, China, Cyprus, Greece,
Ireland, Korea, Pakistan, Philippines, Republic of Macedonia, Saudi Arabia, Senegal,
Taiwan, Tunisia, and the United Kingdom, and one was a multi-national study. The
country where the study was conducted was unknown for one study. The number of
centres participating in a study was unclear in 19 of 49 studies; of the remainder, 21
studies were single center, and 9 were multi-center. Among the 49 included studies, 12
were cohort studies, 33 were cross-sectional studies, and the study design was unclear for
4 studies.

28

Table 2-4. Study Characteristics
Author (Year)
Country

No. of
Centers

Control
population
(sample
size)

Quality
Scoreɶ

1. 5+ renal cysts
distributed between
both kidneys
(U/S, intravenous
pyelogram, or CT)
NR
(NR)

None

4

None

6

Ravine criteria
(x-ray or U/S)
1. Ravine criteria;
OR
2. No fam hx +
bilateral kidney
enlargement + at
least 10 cysts in each
kidney
(U/S)
Ravine criteria
(U/S)

None

9

None

9

None

12

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Cross-sectional Studies
Al-Muhanna
(1995)
Saudi

1

ADPKD

NR

N/A

30

Baishya (2012)
India

Unclear

ADPKD

Since 1992

N/A

452

Bajrami (2016)
Albania
Chang (2013)
Taiwan

Unclear

ADPKD

2011 to 2014

N/A

100

1

ADPKD

October 2008
to May 2011

N/A

46

Corradi (2009)
Italy

Multicenter
(unclear)

ADPKD

Since April
2007

N/A

100

29

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

N/A

106

NR

N/A

180

1. 1+ cyst in
one kidney for
patients aged 5
to 14 years;
2. 2+ unilateral
cysts or one in
each kidney for
patients aged
15 to 19;
3. 3+ cysts in
both kidneys
combined for
patients aged
20 to 29; 4. 2+
cysts in each
kidney for
patients aged
30 to 59; AND
5. 4+ cysts in
each kidney for
patients aged
60 or over
(U/S)
Unclear
(NR)

ADPKD

1995 to 2014

N/A

144

1. Genkyst study
participants
2. 18+ years old
3. Mutation in
PKD2 gene

January 2010
to March 2016

N/A

293

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

Demitriou
(2000)
Cyprus

1

1. Alive
2. Has an
affected family
member with a
PKD2 mutation

up to August
1998

Duli (2013)
Albania

Unclear

ADPKD

Ekin (2014)
Turkey

1

Gall (2017)
France
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Control
population
(sample
size)
unaffected
family
members
(105)

Quality
Scoreɶ
11

None

7

1. 5+ renal cysts in
both kidneys
(NR)

None

9

1. Pei criteria; OR
2. 10+ cysts in both
kidneys combined +
no fam hx
(NR)

None

10

30

Control
population
(sample
size)
None

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Galliani (2015)
Italy
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ADPKD

February 2013
to April 2014

N/A

462

NR
(NR)

Gonzalo (1995)
Spain

Unclear

1. At-risk of
ADPKD
2. Asymptomatic
3. 13+ years old

June 1993 to
December
1994

N/A

65

1. 1+ cysts in each
kidney; OR
2. 2+ cysts in one
kidney (U/S)

unaffected
family
members
(60)

13

Grampsas
(2000)
United States

1

NR

N/A

48

NR
(NR)

None

7

Ishibashi
(1981)
Japan
Ka (2010)
Senegal

1

1. ADPKD
2. Part of The
University of
Colorado Health
Sciences Center’s
Research Study
Group database
ADPKD

May 1972 to
September
1980
January 1,
1995 to
December 31,
2005

N/A

118

NR
(U/S or CT)

None

3

N/A

53

Ravine criteria
(U/S)

None

5

1

1. ADPKD
2. Black
3. 16+ years
4. Without
acquired simple
cyst,
angiomyolipoma,
tuberous
sclerosis, cyst
calcification, any
alterations

Quality
Scoreɶ
2

31

Author (Year)
Country

No. of
Centers

Kaygis (2018)
Turkey

1

Kazancioglu
(2011)
Turkey

12

Kim (NR)
Korea

9

Eligibility
Criteria
suggestive of
malignancy
1. Referred and
diagnosed with
ADPKD at a
tertiary care
center
2. Not on dialysis
3. eGFR >30
mL/min
ADPKD

1. Korean
2. ADPKD and
CKD
3. Pre-dialysis
4. Part of
KNOW-CKD
cohort
5. Provided
written consent
6. Not a
transplant
recipient
7. Without heart
failure, liver
cirrhosis, or
current or past
history of cancer
8. Not pregnant
9. No single
kidney due to
trauma or kidney
donation

Control
population
(sample
size)

Quality
Scoreɶ

Pei criteria
(U/S)

None

11

5+ cysts distributed
between both
kidneys
(NR)
Pei criteria
(U/S)

None

11

None

11

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

2010 to 2016

N/A

118

January 2003
to December
2009

1139
N/A

April 2011 to
February 2016

N/A

364

32

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Kumar (2012)
India

1

ADPKD

N/A

41

Memili (2007)
Turkey

1

N/A

136

Unclear
(U/S, intravenous
pyelogram, CT)
NR
(NR)

Meng (2018)
China

1

January 2012
to December
2016

N/A

167

Milutinovic
(1984)
United States

Unclear

1. ADPKD
2. Referred to
nephrology
outpatient clinic
1. ADPKD
2. Inpatient
3. Complete
medical records
At-risk of
ADPKD

November
2011 to
October 2012
January 2003
to December
2006

NR

N/A

140

Milutinovic
(1990)
United States

Unclear

1. Fam hx of
ADPKD
2. 50+ years old

NR

N/A

32

1. Bilateral renal
cysts + fam hx
(Unclear)

Nikolov (2012)
Unclear
Nishiura (2009)
Brazil

1

1998 to 2008

N/A

208

NR

N/A

125

NR
(NR)
Ravine criteria
(U/S or CT)

Parfrey (1990)
Canada

NR

ADPKD referred
to center
1. Referred to
PKD unit due to
presence of
affected
progenitor/sibling
with ADPKD
2. ADPKD
confirmed using
U/S
Family members
of index ADPKD
cases

NR

N/A

Unclear

1

Japanese criteria for
patients with
unknown genotype
(NR)
1. Fam hx + multiple
bilateral cysts
(Unclear)

1. Reported on
autopsy report,
surgical report or of
a death due to CKD
with an ADPKD
diagnosis;

Control
population
(sample
size)
None

Quality
Scoreɶ
7

None

8

None

10

unaffected
family
members
(119)
unaffected
family
members
(25)
None

12

None

14

Unaffected
family
members
(Unclear)

12

12

4
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Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)
2. 1+ in each kidney;
OR
3. 1+ in one kidney
(excretory
urography, CT, U/S)
1. Ravine criteria;
OR
2. Fam hx + hepatic
cyst
(U/S)
NR
(NR)

Control
population
(sample
size)

Quality
Scoreɶ

None

9

None

9

Romao (2006)
Brazil

1

ADPKD

January 1985
to December
2003

N/A

92

Roscoe (1993)‡
Canada

Unclear

ADPKD

NR

N/A

80

Segal (1977)
United States

2

ADPKD

NR

N/A

100

NR
(NR)

None

3

Strakosha
(2006)
Albania

NR

ADPKD

NR

N/A

180

NR
(NR)

None

5

Torra (1996)
Spain

Unclear

ADPKD or atrisk of ADPKD

NR

N/A

PKD1:
146
PKD2:
20
All: 166

Ravine criteria
(U/S)

Unaffected
Family
members
(150)

13

34

Control
population
(sample
size)
None

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Torres (1988)
United States

1

1. ADPKD
2. Without any
cyst wall
calcification, or
with poorly
localized
parenchymal
calcification

1976 to 1986

N/A

751

1. Bilateral
polycystic kidneys +
fam hx; OR
2. No fam hx +
bilaterally enlarged
and polycystic
kidneys + exclusion
of other disorders
associated with renal
cysts
(NR)

Vikrant (2017)
India

1

1. ADPKD
2. Attending renal
clinic

April 2009 to
March 2015

N/A

208

None

13

Yildz (2016)
Turkey

Unclear

1. ADPKD
2. Not on renal
replacement
therapy
3. eGFR >
30mL/min
4. in the Turkish
Nephrology
Society Cystic
Kidney Disease
Working Group
online database

NR

N/A

93

1. Pei criteria; OR
2. Fam hx + hepatic
cyst
(U/S)
NR
(NR)

None

3

1

ADPKD

June 1977 to
June 1988

6 years 3
months (NR)

107

1. 3+ cysts in each
kidney + fam hx
(excretory
urography or U/S)

None

Cohort Study
Gonzalo (1990)
Spain

Quality
Scoreɶ
10

35

Control
population
(sample
size)
None

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Hajji (2019)
Tunisia

Multicenter
(Unclear)
7

ADPKD

1969 to 2016

NR

569

NR
(NR)

ADPKD

NR

NR

624

1. Ravine criteria;
2. DNA linkage test;
OR
3. Report of ADPKD
on medical records
(U/S)

None

14

Unclear

ADPKD

NR

NR

180

None

10

1

ADPKD

100 (38)
months

323

None

13

Papadopoulou
(1999)
Greece

Unclear

At-risk of
ADPKD

January 2000
to January
2012
NR

NR
(NR)
Pei criteria
(U/S)

NR

85

None

10

Rabbani (2008)
Pakistan

1

ADPKD

January 1997
to December
2003

7.6 (4.2) years

56

1. 2+ cysts in one
kidney and one cyst
in the other kidney+
fam hx
(U/S)
1. Fam hx + 2+ cysts
in either kidney +
hypertension or renal
insufficiency;
2. Bilateral cysts +
no fam hx; OR
3. Unilateral
polycystic kidney +
liver cyst, berry
aneurysm, arteriovenous malformation
or evidence of prior
cerebrovascular
accident on
MRI/MRA
(U/S)

None

9

Hateboer
(1999)
The
Netherlands,
Spain, Bulgaria,
and the United
Kingdom
Idrizi (2009)
Albania
Ozkok (2013)
Turkey

Quality
Scoreɶ
10

36

Control
population
(sample
size)
None

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Ritovska
(2014)
Republic of
Macedonia
Senal (2016)
Turkey

Unclear

ADPKD

NR

3 (NR) years

60

Unclear
(echosonography or
CT)

Unclear

ADPKD

NR

300

NR
(NR)

None

6

Tantoco (1986)
Philippines

1

ADPKD

January 1990
to January
2015
May 1973 to
January 1986

3 (NR) years

60

None

3

Thong (2013) ‡
United Kingdom

Unclear

1978 to 2012

11.3 (5.5)
years

210

None

8

Wright (1993)
Ireland

Unclear

1. ADPKD
2. In research
database
3. Have at least
five years of renal
function tests at
the time of
analysis
Belonging to
PKD1 family

1. Signs and
symptoms + fam hx
+ imaging
(intravenous
pyelogram, infusion
intravenous
pyelogram with
tomogram, U/S or
CT)
NR
(NR)

NR

NR

PKD1:
49
NonPKD1:
17
All: 66

ADPKD
documented the
following ways: 1)
by post-mortem
examination;
2) by report of a
death due to chronic
renal failure with a
clinical diagnosis of
ADPKD;

None

10

Quality
Scoreɶ
5

37

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Control
population
(sample
size)

Quality
Scoreɶ

3) by operative
report during
abdominal surgery;
4) by excretory
urography or CT
scan;
5) by unequivocal
findings on
ultrasonography; OR
6) 1+ cyst in in at
least one kidney
(diagnostic data files
or ultrasound)

Study Design Unclear
Delaney (1985)
United States

1

symptomatic
ADPKD

1947 to 1980

12 (NR) years

53

1. History and
physical
examination; OR
2. Diagnosis
confirmed with
imaging or autopsy
(intravenous
pyelogram with
tomograms,
sonography, CT with
contrast,
arteriography,
laparotomy)

None

4

Dimitrakov
(1994)
Bulgaria

Unclear

ADPKD

NR

N/A

82

Unclear
(echography, venous
urography, or CT)

None

5

38

Author (Year)
Country

No. of
Centers

Eligibility
Criteria

Recruitment
Period

Mean (SD)
Follow-up

ADPKD
sample
size

ADPKD Case
Definition (imaging
modality)

Higashira
(1992) Japan

38

ADPKD

January 1988
to December
1988
2002 to 2009

N/A

316

NR
(U/S or CT)

Control
population
(sample
size)
None

Quality
Scoreɶ
11

Idrizi (2011)
Unclear
ADPKD
N/A
200
Ravine criteria
None
7
Albania
(U/S)
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; computed tomography, CT; family history, Fam Hx; intravenous, IV; not
applicable, N/A; not reported, NR; standard deviation, SD; ultrasound, U/S
‡
Data was abstracted and methodological quality was assessed for the portion of the multi-component study that reported the prevalence of stones
ɶ
A modified Downs and Black checklist was used to assess the methodological quality of each included study. The methods quality score ranged
between 0 and 22 with higher scores indicating higher quality.
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2.3.3

Patient population

The sample size of patients with ADPKD ranged from 30 to 1139 (Table 2-4). The mean
age of patients with ADPKD ranged from 26 to 61 years, 35% to 71% of the patients with
ADPKD were male, up to 51% developed ESKD, 5% to 88% were hypertensive, and 1%
to 73% experienced at least one prior urinary tract infection (UTI) (Table 2-5).
Six studies compared the prevalence of stones in patients with ADPKD to
unaffected family members as controls.7–12 The mean age of controls ranged from 35 to
60 years, 36% to 48% of the controls were male, 4% to 36% were hypertensive, and 2%
to 36% experienced a prior UTI (Table 2-5).
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Table 2-5. Patient characteristics
Author (Year)
Country
Al-Muhanna
(1995)
Saudi
Baishya
(2012)
India
Bajrami
(2016)
Albania
Chang (2013)
Taiwan
Corradi
(2009)
Italy
Demitriou
(2000)
Cyprus
Duli (2013)
Albania
Ekin (2014)
Turkey
Gall (2017)
France
Galliani
(2015)
Italy
Gonzalo
(1995)
Spain

Mean Age
(standard
deviation)
(years)

No. of Male
(%)

No. of
Patients on
Dialysis (%)

No. of
Transplant
Recipient
(%)

No. of
patients
who had
ESRD (%)

No. of
Hypertensive
Patients (%)

No. of
Patients with
UTI (%)

Serum
Creatinine
(µmol/L)

45 (10)

13 (43)

2 (7)

2 (7)

4 (13)

17 (57)

22 (73)

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

42 (42)

NR

NR

NR

NR

NR

NR

48 (13)

24 (52)

NR

NR

NR

31 (67)

17 (37)

NR

48 (NR)

58 (58)

NR

6 (6)

29 (29)

75 (75)

NR

NR

ADPKD: 38
(NR)
CONTROL:
NR (NR)

NR

ADPKD: 0
(0)
CONTROL:
NR (NR)

ADPKD: 1
(1)
CONTROL:
NR (NR)

NR

ADPKD: 24
(23)
CONTROL: 4
(4)

ADPKD: 24
(23)
CONTROL:
12 (11)

NR

NR

NR

NR

NR

NR

NR

NR

NR

45 (NR)

61 (42)

NR (11)

NR

NR (11)

117 (82)

14 (2)*

168 (186)

61 (NR)

123 (42)

NR

NR

Unclear

221 (75)

NR

NR

NR

194 (42)

NR

NR

NR

NR (60)

NR (28)

NR

ADPKD: 33
(NR)
CONTROL:
NR (NR)

ADPKD: 26
(40)
CONTROL:
28 (47)

NR

ADPKD: 19
(29)
CONTROL: 3
(5)

ADPKD: 4 (6)
CONTROL: 1
(2)

NR

NR

NR
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Author (Year)
Country
Grampsas
(2000)
United States
Ishibashi
(1981)
Japan
Ka (2010)
Senegal
Kaygis (2018)
Bursa
Kazancioglu
(2011)
Turkey
Kim (NR)
Korea
Kumar (2012)
India
Memili (2007)
Turkey
Meng (2018)
China
Milutinovic
(1984)
United States
Milutinovic
(1990)
United States
Nikolov
(2012)
Unclear
Nishiura
(2009)
Brazil

Mean Age
(standard
deviation)
(years)

No. of Male
(%)

No. of
Patients on
Dialysis (%)

No. of
Transplant
Recipient
(%)

No. of
patients
who had
ESRD (%)

No. of
Hypertensive
Patients (%)

No. of
Patients with
UTI (%)

Serum
Creatinine
(µmol/L)

NR

17 (35)

NR

NR

NR

23 (48)

NR

NR

44 (NR)

54 (46)

NR

NR

NR

NR

57 (54)*

NR

47 (5)

30 (57)

10 (19)

NR

27 (51)

36 (68)

7 (13)

NR

NR

54 (46)

0 (0)

NR

0 (0)

72 (61)

29 (25)

NR

NR

548 (48)

108 (11)

8 (1)

NR

828 (73)

228 (23)*

194 (194)

47 (11)

184 (51)

0 (0)

0 (0)

NR

319 (88)

8 (2)

119 (79)

NR

29 (71)

NR

NR

13 (32)

27 (66)

6 (40)

398 (283)

47 (16)

65 (48)

16 (12)

1 (1)

NR

98 (72)

22 (16)

NR

49 (NR)

72 (43)

NR

NR

NR

84 (50)

41 (25)

309 (290)

ADPKD: 37
(14)
CONTROL:
35 (16)
ADPKD: 58
(7)
CONTROL:
60 (7)

ADPKD: 64
(46)
CONTROL:
NR (NR)
ADPKD: 15
(47)
CONTROL:
9 (36)

ADPKD: 25
(18)
CONTROLS
: 0 (0)

NR

NR

NR

ADPKD: 28
(20)
CONTROL:
0 (0)
ADPKD: 15
(47)
CONTROL:
0 (0)

ADPKD: 73
(52)
CONTROLS:
13 (11)
ADPKD: 22
(69)
CONTROL:N
R (36)

ADPKD: 64
(46)
CONTROLS:
33 (28)
ADPKD: 13
(41)
CONTROL:
NR (36)

NR

NR

NR

NR

NR

NR

NR

NR

NR

45 (36)

NR

NR

NR

59 (47)

4 (3)

NR

NR

NR
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Author (Year)
Country
Parfrey
(1990)
Canada
Romao (2006)
Brazil
Roscoe (1993)
‡

Canada
Segal (1977)
United States
Strakosha
(2006)
Albania
Torra (1996)
Spain
Torres (1988)
United States
Vikrant
(2017)
India
Yildz (2016)
Turkey
Gonzalo
(1990)
Spain
Hajji (2019)
Tunisia
Hateboer
(1999)
The
Netherlands,
Spain,
Bulgaria, and

Mean Age
(standard
deviation)
(years)

No. of Male
(%)

No. of
Patients on
Dialysis (%)

No. of
Transplant
Recipient
(%)

No. of
patients
who had
ESRD (%)

No. of
Hypertensive
Patients (%)

No. of
Patients with
UTI (%)

Serum
Creatinine
(µmol/L)

ADPKD: 24
(22)*
CONTROL:
35 (17)*

NR

NR

NR

NR

NR

NR

ADPKD: 118
(36)
CONTROL:
238 (16)

35 (15)

34 (37)

NR

NR

27 (29)

61 (63)

33 (36)

212 (247)

NR

NR

NR

NR

22 (28)

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

ADPKD: 72
(43)
CONTROL:
72 (48)

NR

NR

ADPKD: 42
(25)
CONTROL:
NR (NR)

ADPKD: 76
(46)
CONTROL:
23 (15)

ADPKD: 57
(34)*
CONTROL:
26 (17)

NR

NR

393 (52)

NR

NR

NR

NR

NR

NR

46 (15)

126 (61)

5 (2)

NR

20 (10)

145 (70)

81 (39)

292 (318)

41 (13)

49 (53)

0 (0)

0 (0)

0 (0)

NR (72)

NR

NR

46 (14)

58 (54)

NR

NR

NR

73 (68)*

33 (31)*

NR

49 (14)

297 (52)

298 (52)

13 (2)

NR

321 (59)

NR (24)

459 (NR)

NR

308 (49)

NR

NR

NR

227 (50)*

119 (28)*

NR
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Author (Year)
Country
the United
Kingdom
Idrizi (2011)
Albania
Ozkok (2013)
Turkey
Papadopoulou
(1999)
Greece
Rabbani
(2008)
Pakistan
Ritovska
(2014)
Republic of
Macedonia
Senal (2016)
Turkey
Tantoco
(1986)
Philippines
Thong (2013)

Mean Age
(standard
deviation)
(years)

No. of Male
(%)

No. of
Patients on
Dialysis (%)

No. of
Transplant
Recipient
(%)

No. of
patients
who had
ESRD (%)

No. of
Hypertensive
Patients (%)

No. of
Patients with
UTI (%)

Serum
Creatinine
(µmol/L)

NR

97 (49)

NR

NR

NR

NR

108 (54)

NR

53 (15)

149 (46)

46 (14)

NR

48 (14)

255 (79)*

64 (21)*

NR

26 (12)

44 (52)

NR

NR

NR

ADPKD: 4
(5)

ADPKD: 1 (1)

NR

NR

40 (71)

NR

NR

7 (13)

38 (68)

NR

398 (282)

43 (13)

NR

NR

NR

NR

NR

NR

NR

NR

143 (48)

NR

NR

NR

231 (83)*

52 (19)*

203 (221)

44 (NR)

30 (50)

NR

NR

17 (28)

40 (67)

17 (28)

NR

46 (16)

102 (49)

NR

NR

NR

147 (70)

57 (27.2)

NR

NR

NR

NR

NR

12 (18)

16 (24)

5 (8)

NR

NR

21 (40)

9 (17)

NR

NR

11 (21)

10 (19)

NR

NR

34 (41)

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

108 (60)

NR

‡

United
Kingdom
Wright (1993)
Ireland
Delaney
(1985)
United States
Dimitrakov
(1994)
Bulgaria
Idrizi (2009)
Albania
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Author (Year)
Country

Mean Age
(standard
deviation)
(years)

No. of Male
(%)

No. of
Patients on
Dialysis (%)

No. of
Transplant
Recipient
(%)

No. of
patients
who had
ESRD (%)

No. of
Hypertensive
Patients (%)

No. of
Patients with
UTI (%)

Serum
Creatinine
(µmol/L)

Higashira
(1992)
51 (13)
167 (53)
72 (23)
NR
72 (23)
201 (64)*
NR
354 (380)
Japan
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; not reported, NR; standard deviation, SD; urinary tract infection, UTI
‡
Data was abstracted for the portion of the multi-component study that reported the prevalence of stones.
*
Denominator includes a subset of the population.
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2.3.4

Quality assessment of studies

The methodological quality of the studies was limited as the methods quality score
ranged from 2 to 14 out of 22 (where higher scores indicates higher methodological
quality).
The internal validity of studies’ results is affected by the definition of the exposure being
investigated and the outcome of interest. Of the 49 studies, 29 specified the definition for
ADPKD. Patients with ADPKD were identified using the Ravine’s criteria in 6 studies,
Ravine’s criteria or another additional criterion such as family history and liver cysts in 3
studies, Pei’s criteria in 3 studies, Pei’s criteria and an additional criterion in 2 studies, at
least 5 cysts in each kidney in 3 studies, and other criteria in the remaining 13 studies; the
definition for ADPKD was unclear or not reported in the remaining 19 studies. Ravine
and Pei criteria to diagnose ADPKD are summarized in Table 2-6 and Table 2-7,
respectively.61,62 Some studies used a definition different from the most accepted
diagnostic criteria at the time the study was published. For example, Ekin et al. (2014)
and Kazancioglu et al. (2011) defined patients with at least five cysts in each kidney as
patients with ADPKD, although Pei’s criteria were the most commonly used diagnostic
criteria for ADPKD during the time period in which the studies were conducted. 29,46
Table 2-6. Ravine ultrasonographic criteria for diagnosing autosomal dominant
polycystic kidney disease
Age
< 30 years
30 to 60 years
> 60 years

Positive Family History

Negative Family history

2 cysts bilaterally or
unilaterally
4 cysts bilaterally
8 cysts bilaterally

5 cysts bilaterally
5 cysts bilaterally
8 cysts bilaterally
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Table 2-7. Pei ultrasonographic criteria for diagnosing autosomal dominant polycystic
kidney disease (ADPKD)
Age (years)

Diagnostic Criteria

15 to 39

At least 3 cysts (unilateral or bilateral)

40 to 59

2 cysts/kidney

> 60

4 or more cysts/kidney

*Note: Fewer than 2 cysts in individuals > 40 years old and are at risk of ADPKD is sufficient to rule out
the disease.

Thirty of the 49 studies described how they identified patients with stones, while the
remaining 19 studies did not. Among the 30 studies that specified how the stones were
detected, 3 studies relied on patient self-report of a history of stones, 14 solely relied on
radiological evidence of stone, and 13 studies relied on combination of radiological
evidence of stone and at least one other criterion (i.e. stone passage and recovery,
surgical removal of stone and self-report of stone). Among the 27 of the 30 studies that
used radiological evidence of stones as one of their diagnostic criteria, 9 reviewed
historic imaging, 10 reviewed recent imaging, and the nature of considered imaging was
unclear in 8 studies. Eight of the 27 studies thoroughly described what they were looking
for on the radiological image to identify stones. Amongst the five studies that reported
asymptomatic stones, the percentage of patients ranged between 1% and 68%. 18,19,22,38,49
The setting and source population from which the samples are recruited affects the study
generalizability. For 21 of the studies, the setting or population from which the sample
was recruited from was unclear or not reported. Patients were recruited from hospitals in
18 studies, outpatient clinics in 7 studies, solely from an inpatient setting in 1 study, an
outpatient ADPKD specialty clinic in 1 study, and from both an inpatient and outpatient
setting for 1 study. It is unclear if patients were recruited from an inpatient or outpatient
setting for 20 studies and setting was not reported for one study.
Six of the 49 studies compared the prevalence of stones in patients with ADPKD to
controls, which were unaffected family members. All of these studies were cross-
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sectional. Only two of the six studies statistically compared the prevalence of stones in
patients with ADPKD to controls. Both of these studies used univariate analyses and did
not adjust for any confounders.

2.3.5

Prevalence and characteristics of stones and prevalence of
stone intervention

In patients with ADPKD, the prevalence of stones ranged between 3% and 59% (Table 28). Of those patients with stones, 2% to 47% underwent at least one stone intervention.
UTI and flank pain were the predominant precursor to diagnosis of stones in patients with
ADPKD.18,22,25,38,41,49 In most patients, stones were solely located in the renal calyces
18,19

. Most stones were composed of uric acid according to six studies7,19,21,22,38,49, and

oxalate according to two studies (Table 2-9).23,27
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Table 2-8. Prevalence of stones and stone intervention in patients with autosomal dominant polycystic kidney disease and
controls
Author (Year) Country

Stone Definition (Modality)

Al-Muhanna (1995)
Saudi
Baishya (2012)
India

NR
(Unclear)
NR
(NR)
Echogenic focus with posterior acoustic shadowing within
the kidney Ɍ
(U/S; or plain abdominal KUB film, intravenous
pyelography and non-contrast helical CT in cases where
stones were not observed on U/S or KUB film)
NR
(NR)
NR
(NR)
Passage of stone or presence of stone on a plain KUB film or
U/S 𝜓
(Plain KUB film or U/S)
Image of stone within the urinary collecting system Ɍ
(U/S, renal radiography, CT)
Presence and absence of stone on U/S 𝜓 and/or history of
passing stone
(U/S)
NR
(NR)
NR
(NR)
Hyperechogenic image with posterior shadowing Ɍ
(U/S or plain roentgenogram with tomograms)
Echogenic focus with posterior acoustic shadowing within
the kidney but outside an identifiable cyst Ɍ + with or
without a clinical history of stone
(U/S)

Bajrami (2016)
Albania
Chang (2013)
Taiwan
Corradi (2009)
Italy
Demitriou (2000)
Cyprus
Duli (2013)
Albania
Ekin (2014)
Turkey
Gall (2017)
France
Galliani (2015)
Italy
Gonzalo (1995)
Spain
Grampsas (2000)
United States

No. of unique
patients with stones
(%)

No. of unique patients
who underwent stone
intervention (%)

5 (17)

NR

19 (4)

9 (2)

58 (58)

NR

19 (41)

NR

24 (24)

NR

ADPKD: 21 (20)
CONTROL: 4 (4)

NR

106 (59)

NR

24 (17)

NR

57 (20)

NR

102 (22)

NR

ADPKD: 7 (11)
CONTROL: 2 (3)

NR

15 (31)

NR
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Author (Year) Country

Stone Definition (Modality)

Ishibashi (1981)
Japan
Ka (2010)
Senegal
Kaygis (2018)
Bursa

NR
(NR)
NR
(NR)
History of stone or positive imaging Ɍ
(U/S, non-contrast CT)
Presence or absence of urinary tract stones on U/S Ɏ and/or
history of passing stone
(U/S)
NR
(NR)
NR
(NR)
Presence and absence of upper urinary tract stone 𝜓
(U/S)
NR
(NR)
Stones apparent on radiogram Ɏ or passed in urine
(radiogram)
Stone apparent on radiograms Ɍ or were found in urine
(radiogram)
NR
(NR)
Image of stone within the renal collection systemɌ
(U/S and CT)
Self-report history of upper urinary tract stones during
interview
(NR)
NR
(NR)
Acoustic shadowing on radiologic imaging 𝜓
(NR)
NR
(NR)

Kazancioglu (2011)
Turkey
Kim (NR)
Korea
Kumar (2012)
India
Memili (2007)
Turkey
Meng (2018)
China
Milutinovic (1984)
United States
Milutinovic (1990)
United States
Nikolov (2012)
Unclear
Nishiura (2009)
Brazil
Parfrey (1990)
Canada
Romao (2006)

Brazil

Roscoe (1993) ‡
Canada
Segal (1977)
United States

No. of unique
patients with stones
(%)

No. of unique patients
who underwent stone
intervention (%)

10 (13)

NR

6 (11)

NR

28 (24)

10 (8)

278 (27)*

NR

92 (29)*

NR

6(15)

NR

39 (29)

NR

65 (39)

NR

ADPKD: 16 (11)
CONTROL: 5 (4)
ADPKD: 5 (17)
CONTROL: 3 (12)

NR
NR

29 (14)

NR

35 (28)

NR

ADPKD: 16 (15) *
CONTROL: 20 (10)
*

NR

15 (16)

NR

8 (10)

NR

20 (20)

NR
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Author (Year) Country

Stone Definition (Modality)

Strakosha (2006)
Albania

Presence on imaging Ɍ
(ultrasound or abdominal x-ray)
Passage of stone with recovery of stone or evidence of stone
within the collecting system as reported by the radiologist 𝜓
(unclear)
Historical evidence of passage, recovery, surgical removal of
stone, evidence of stone within the collecting system, or
renal papillary tips as reported by radiologist 𝜓
(excretory urogram for a subset [79 patients]; unclear for
remaining patients)
History of stone passage, removal of stone or calcific
foci/nephrocalcinosis seen on imaging 𝜓
(unclear)
Self-reported history of stone
(NR)
Passage or surgical removal of stones or presence of radioopaque deposits on x-ray Ɏ
(x-ray)
NR
(NR)

Torra (1996)
Spain

Torres (1988)
United States

Vikrant (2017)
India
Yildz (2016)
Turkey
Gonzalo (1990)
Spain
Hajji (2019)
Tunisia
Hateboer (1999)
The Netherlands, Spain,
Bulgaria, and the United
Kingdom
Idrizi (2009)

Albania

Ozkok (2013)
Turkey
Papadopoulou (1999)
Greece
Rabbani (2008)
Pakistan

Radiological evidence of upper urinary tract stone Ɏ
(U/S, plain radiographs, intravenous pyelograms, CT)
An echogenic focus with posterior acoustic shadowing
within the kidney but outside an identifiable cyst and with or
without clinical history of stone Ɍ
(U/S and X-ray)
Self-reported hx of passing stone or presence or absence of
upper urinary tract stone on ultrasound 𝜓
(U/S)
Self-reported history of stone during interview
(NR)
Presentation on imaging 𝜓
(NR)

No. of unique
patients with stones
(%)

No. of unique patients
who underwent stone
intervention (%)

81 (45)

2 (1)

ADPKD: 29 (18)
CONTROL: 15 (10)*

NR

151 (20)

31 (4)

81 (39)

NR

23 (25)

NR

32 (30) ʌ

NR

28 (5) ʌ

NR

42 (10)* κ

NR

76 (42) ɶ

2 (1)

101 (33) ɶ

NR

3 (4) ɶ

NR

6 (11) ɶ

NR
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Author (Year) Country

Stone Definition (Modality)

Ritovska (2014)
Republic of Macedonia
Senal (2016)
Turkey
Tantoco (1986)
Philippines
Thong (2013) ‡
United Kingdom
Wright (1993)
Ireland

Evidence on imaging Ɍ
(echosonography and CT scan)
NR
(NR)
Presence of radiopaque stone on radiographic ultrasound Ɏ
(radiograph or U/S)
NR
(NR)
NR
(NR)
Passage of stone or surgical removal of stones from urinary
tract or presence of radio-opaque deposits on x-ray Ɏ
(x-ray)
Presence or absence of upper urinary tract stone on imaging

Delaney (1985)
United States
Dimitrakov (1994)
Bulgaria

Ɏ

No. of unique
patients with stones
(%)

No. of unique patients
who underwent stone
intervention (%)

22 (37) ɶ

NR

68 (28)* ɶ

NR

18 (30) ʌ

NR

16 (8) ɶ

NR

2 (3) ɶ

NR

18 (34)

1 (2)

23 (28)
NR
(echography, venous urography, CT)
Higashira (1992)
NR
53 (18)*
NR
Japan
(NR)
Echogenic focus with posterior acoustic shadowing within
the kidney Ɏ
Idrizi (2011)
Albania
116 (58)
4 (2)
(U/S; or plain abdominal KUB film, intravenous
pyelography and non-contrast helical CT in cases where
stones were not observed on U/S or KUB film)
Abbreviations: computed tomography scan, CT; kidney, ureter, bladder, KUB; not reported, NR; ultrasound, U/S
* The denominator only includes a subset of the study population
‡
Data was abstracted for the portion of the multi-component study that reported the prevalence of stones
Ɍ
Patients underwent prospective abdominal imaging.
𝜓 Authors reviewed historic images to ascertain stone event.
Ɏ
Unclear whether investigators prospectively imaged abdomen or reviewed past abdominal images or imaging report to identify stone event.
ɶ
Stone event was ascertained at baseline; therefore, the percentage is a prevalence estimate.
κ
Stone was ascertained at baseline and during follow-up; therefore, the percentage is a prevalence estimate.
ʌ
Unclear whether stone event was ascertained at baseline or during follow-up; therefore, unknown whether the reported percentage was a prevalence or
incidence estimate.
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Table 2-9. Symptoms and characteristics of stones
Author (Year)
Country

Symptoms

Location

Composition

Baishya (2012)
India

• Anorexia: 3 (16%)
• Fever: 1 (5%)
• Fluid Overload: 2 (11%)
• Hematuria: 5 (26%)
• Pain: 6 (32%)
• Vomiting: 3 (16%)
• Weakness: 2 (11%)

NR

Bajrami (2016)
Albania

NR

Location of stones in the 23 kidneys with
stones among 19 patients (denominator is
23):
• Renal calyces: 10 (28%)
• Renal pelvis: 2 (9%)
• Both renal pelvis and calyces: 5 (22%)
• Ureter: 5 (22%)
• Staghorn: 1 (4%)
NR

Demitriou (2000)
Cyprus
Kaygis (2018)
Bursa
Nishiura (2009)
Brazil
Strakosha (2006)
Albania

NR

NR

• Calcium oxalate: NR (39%)
• Urate: NR (47%)
• Other compounds: NR (14%)
Majority were uric acid

Lower back pain: 10 (36%)

NR

NR

Low back pain

NR

NR

• 40% of patients with stone associated
with a history of UTI and flank pain

NR

Torres (1988)
United States

NR

Among the 71 patients where details
about stone location is available:
• Only renal calyces: 63 (89%)
• Renal pelvis/Staghorn: 4 (6%)
• Ureter: 4 (6%)

Idrizi (2009)
Albania

History of UTI and flank pain: NR (40%)

NR

Idrizi (2011)
Albania

• UTI and Flank pain: 70 (60%)
• Gross Hematuria: 65 (56%)

NR

• Calcium oxalate: NR (39%)
• Urate: NR (47%)
• Other Compounds: NR (14%)
Composition examined in 30 patients:
• Calcium carbonate: 3 (10%)
• Calcium oxalate: 14 (47%)
• Calcium phosphate: 6 (20%)
• Struvite: 3 (10%)
• Uric Acid: 17 (57%)
• Calcium oxalate: NR (39%)
• Urate: NR (47%)
• Other compounds: NR (14%)
Among the 63 patients with information
on stone composition:
• Calcium oxalate: 25 (39%)
• Uric acid: 30 (47%)
• Other compounds: 8 (14%)
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Author (Year)
Country
Delaney (1985)
United States

Symptoms

Location

Composition

NR

NR

• Calcium oxalate: 3 (50%)
• Uric Acid stones: 1 (17%)
• Calcium oxalate stones in one occasion
and uric acid or calcium phosphate stones
on the other occasion: 2 (33%)
• Oxalate: 12 (52%)
• Urate: 6 (26%)
• Mixed composition: 5 (22%)

Dimitrakov
NR
(1994)
Bulgaria
Abbreviation: not reported, NR; urinary tract infection, UTI
* The denominator only includes a subset of the study pop8ulation

NR

54

The prevalence of stones ranged from 3% to 12% in family members confirmed not to be
affected with ADPKD (Table 2-3). None of the studies described the characteristics of
stones in unaffected family members. All six studies that compared the prevalence of
stones in patients with and without ADPKD reported stones were more prevalent in
patients with ADPKD; however, four studies did not statistically analyze the prevalence
of stones between the two groups, and the remaining two studies found no statistical
difference. When we statistically compared the prevalence of stones in patients with
ADPKD to unaffected family members in the four studies that did not conduct any
statistical analyses, we found that only one out of the four studies found a significant
difference. Meta-analysis of the calculated prevalence ratios across six cross-sectional
studies show that patients with ADPKD had a higher prevalence of upper urinary tract
stones compared to unaffected family members (unadjusted prevalence ratio: 1.8, 95%
confidence interval: 1.3 to 2.6, p=0.0007; test for heterogeneity: I 2 = 0%, p=0.8) (Figure
2-2).

Figure 2-2. Calculated unadjusted prevalence ratio of stones in patients with autosomal
dominant polycystic kidney disease compared to unaffected family members
Note: The prevalence ratios were calculated using prevalence estimates obtained from studies and
Cochrane Review Manager 5.3.
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Six studies reported the prevalence of stone intervention in patients with ADPKD, which
ranged between 1% and 8% (Table 2-8). None of the studies with controls reported the
prevalence of stone intervention in unaffected family members.

2.3.6

Stone incidence

No study clearly reported the incidence of upper urinary tract stones and the incidence of
stone intervention in patients with ADPKD. Most cohort studies included in this review
assessed upper urinary tract stones at cohort entry and not during follow-up. Whether the
reported percentage was a prevalence or incidence estimate was unclear for three of the
included cohort studies.

2.4 DISCUSSION
Many popular educational materials and clinical practice guidelines state that upper
urinary tract stones are common in patients with ADPKD, and its prevalence may be five
to ten times higher than the general population.63,64 This makes clinical sense based on
our knowledge of the pathophysiology of ADPKD; the kidney cysts in patients with
ADPKD leads to urinary stasis which promotes stone formation. 24 Our review of the
literature, however, indicates that the evidence to support these assertions is weak, and
illuminates several knowledge gaps about the clinical epidemiology of stones in ADPKD.
No study has clearly reported the incidence of stones in ADPKD. Prevalence estimates in
ADPKD varied widely ranging from 3% to 59% for upper urinary tract stones, and from
1% to 8% for stone interventions. UTI and flank pain were the predominant precursors to
diagnosis of stones; however, UTI and flank pain are not specific to stones and are also
manifestations of ADPKD independent of stones. It is likely that UTI and flank pain was
associated with ADPKD itself rather than stones because most of the stones in ADPKD
were located in the renal calyces where they would be less likely to be symptomatic. Uric
acid stones are the most prevalent stone composition in patients with ADPKD. The wideranging prevalence estimates along with the discovery that no published studies clearly
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reported stone incidence, confirms that how often patients with ADPKD develop upper
urinary tract stones remains uncertain.
There are several reasons why prevalence estimates of stones varied drastically across
studies. These include inconsistent stone definitions, different distributions of stone risk
factors, potential recall bias in studies that relied on patient self-report to identify stone
events, and relying on past imaging reports done for reasons other than stone
identification. Self-report is particularly problematic because the symptoms of flank pain
and hematuria are common with ADPKD in the absence of stone disease. Patients with
ADPKD may be more likely to undergo renal imaging, which would lead to overdetection of potentially clinically insignificant stones which may also exist undetected in
the general population. The variability in imaging modalities used across studies and
even between patients in the same study may also explain the variable prevalence
estimates across studies. For example, computed tomography (CT) is a more sensitive
method of stone detection than ultrasound and would provide a more accurate estimate of
stone prevalence.65,66 Most of the studies published to date on stones in ADPKD were
conducted in a single-center, and are of poor methodological quality. Additionally, only
six studies compared the prevalence of stones in patients with ADPKD to controls.7–12
Among these six studies, only two statistically compared the prevalence of stones
between the two groups,9,10 and none of these studies adjusted for confounders.7–12
Additionally, not all patients with ADPKD were hospitalized; as a result, prevalence
estimates obtained from patients recruited from an inpatient setting must be generalized
to the broader ADPKD population with caution. Similarly, the prevalence estimates
obtained from patients recruited from an outpatient specialty clinic must also be
generalize to the broader ADPKD population with caution due to increased surveillance.
Also, only 8 of 49 of the included studies described the composition of stones in patients
with ADPKD; none of the eight studies compared the composition of stones in patients
with ADPKD to patients without ADPKD.
This review serves as a call to action for better research in this field. We recommend
conducting large, multi-center studies that compare the risk of stones and risk of stone
intervention between a representative population of ADPKD and controls to better
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characterize the magnitude of upper urinary tract stone and stone intervention risk in
patients with ADPKD. We also recommend such studies adjust for important
confounders, such as hypertension, to better characterize the true association between
ADPKD and upper urinary tract stones and stone intervention. Imaging tests are much
more advanced, widespread, and frequent over time; this may lead to the possibility of
detecting stones in ADPKD that may not be clinically relevant. Examining risk of upper
urinary tract stone diagnosis and upper urinary tract stones that require intervention
separately would provide insight into whether there is a potentially higher burden of
asymptomatic stone that were detected incidentally on imaging. More reliable estimates
of the magnitude of risk of stones and stone intervention would provide insight into
clinical management practices and help patients with ADPKD and their physicians better
prognosticate. If patients with ADPKD are truly at higher risk for upper urinary tract
stones, then nephrologists may want to consider preventative measures for upper urinary
tract stones. For example, if patients with ADPKD are at higher risk of upper urinary
tract stones and hypocitraturia, then nephrologists may want to screen for hypocitraturia
and treat patients with potassium citrate. Nephrologists may also want to consider
treating large cysts that obstruct the urinary system and cause urinary stasis. Preventing
stone formation would alleviate pain due to upper urinary tract stones and potentially
slow down disease progression in patients with ADPKD. We also recommend comparing
the composition of stones observed in patients with ADPKD compared to patients
without ADPKD. New medications used in ADPKD, such as vasopressin receptor 2
antagonists, may alter the urine composition and change the types of renal stones that
these patients get. Future ADPKD-specific risk factors, such as mutation type, of upper
urinary tract stone studies may help identify patients at high-risk for stones and provide
further insight into the pathophysiology of upper urinary tract stones in patients with
ADPKD.
Our study is the first to systematically review and summarize the prevalence of stones in
patients with ADPKD. Unlike past narrative reviews, we used a comprehensive search
strategy across five different databases, and two reviewers independently screened all
citations retrieved from the search strategy to identify all relevant articles. We also
conducted this review in accordance with an a priori protocol and published guidelines
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for systematic reviews. Two independent reviewers abstracted the data to minimize
human error and bias.
There are some limitations inherent in our systematic review. First, we only included
original journal articles and conference proceedings published in English. However,
studies show that language-restricted meta-analysis does not lead to biased estimates.67
Second, the definitions for ADPKD and stones varied across studies; therefore, the
pooled estimate must be interpreted with caution.

2.5 CONCLUSION
Our systematic review highlights that there is poor consensus on the prevalence of stones
in patients with ADPKD. A more methodologically robust study is needed to better
characterize the magnitude of risk of stones and stone intervention in patients with
ADPKD. This information can help patients with ADPKD and physicians with their
prognostication, and might inform the use of interventions to reduce the risk of stones.

2.6 ADDENDUM
There has been quite some time between when we initially searched for relevant studies
(February 2019) and when we completed the thesis (July 2020). Since the time from the
last search (February 2019), an additional conference proceeding of 241 patients with
ADPKD was published which described disease progression and renal and extrarenal
manifestations.68 135 of the 241 (56%) of the patients with ADPKD experienced a upper
urinary tract stone over a span of 18 years, and the methods quality score for this
conference proceeding was 8.68 Findings from this study does not change the conclusion
of this chapter review that there is poor consensus on the prevalence of stones in patients
with ADPKD.
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3.1 INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder
with no cure.1,2 It is characterized by focal cyst development leading to a progressive
enlargement of both kidneys and kidney failure.3,4 The prevalence of stones in patients
with ADPKD ranges from 3 to 59%. The wide range of upper urinary tract stone
prevalence reported in the literature can be explained by several factors including
inconsistent stone definitions, different distributions of stone risk factors, potential recall
bias in studies that relied on patient self-reported data to identify stone events, and
relying on past imaging reports for reasons other than stone identification.5 Upper urinary
tract stones in patients with ADPKD are associated with significant morbidity. For
example, stones are a major determinant of pain and may accelerate chronic kidney
disease progression.6,7 For these reasons, effective stone management is important in
patients with ADPKD. However, the distorted kidneys and the reduced kidney function in
patients with ADPKD may make active stone removal more challenging. For example,
the cysts in patients with ADPKD may hinder optimal stone access and hence the success
rate of stone interventions.
A published clinical practice guideline states that stone management in patients with
ADPKD should not differ from the general population, and recommends that if necessary
that stone interventions be considered.8 The guideline authors also indicated that their
recommendation was based on limited evidence.
Irrespective of whether a patient has ADPKD or not, urgent intervention is often required
in the presence of infection/urosepsis, intractable pain, vomiting, impending acute renal
failure, and/or obstruction.9 Currently, shock wave lithotripsy (SWL), ureteroscopy, and
percutaneous nephrolithotomy (PCNL) are commonly used procedures to remove stones.8
The choice of stone intervention to treat stone is primarily dependent on stone
characteristics such as, stone location and size, and availability of equipment. In some
instances, a combination of interventions may be required to remove stones. SWL emits
shockwaves from an external device, which then propagate through the body and cause
the stones to fragment.10,11 The fragmented stones then pass on their own in the
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subsequent weeks. SWL is least invasive stone intervention, and is not recommended for
pregnant women, and for patients with uncontrolled hypertension, uncontrolled
coagulopathy, or a distal urinary obstruction to where stone is located.12 Ureteroscopy is
performed by inserting a rigid, semi-rigid, or flexible ureteroscope through the urethra
and into the ureter, and positioning it close to the stone.13,14 Instruments, such as laser, are
used to fragment the stones, and these stone fragments can be left to pass or can be
removed using instruments such as stone baskets or graspers.15 During PCNL, a renal
calyx is punctured percutaneously with fluoroscopy and/or ultrasound guidance to gain a
access to the stone.16 Stones are then fragmented using instruments, such as lasers or
pneumatic lithotripters, and removed using tools such as graspers or suction devices.9
PCNL is relatively the most invasive stone intervention.9
We undertook this systematic review to critically appraise and summarize the results of
studies which described the efficacy and safety outcomes of the three main stone
interventions (SWL, ureteroscopy, and PCNL) in adults with ADPKD. The outcomes of
interest were the proportion of patients who were stone-free after the intervention, and the
proportion who experienced at least one post-operative complication.

3.2 METHODS
3.2.1

Design and study selection

We conducted this systematic review using an internal pre-specified protocol and
reported this review according to the Preferred Reporting Items for Systematic Review
and Meta-Analysis (PRISMA) statement.17
We included studies that met the following eligibility criteria: (1) published English
language full-text articles and conference proceedings; (2) any study design; (3) at least
two patients with ADPKD included in the study; (4) with and without a comparator
group; and (5) described any efficacy or safety outcome following at least any one of
SWL, ureteroscopy, and/or PCNL in adults with ADPKD and upper urinary tract stones.
If multiple publications reported outcomes on similar groups of patients, then we
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abstracted data on the study published more recently. We only included studies with
comparators if outcomes of a stone intervention were compared between ADPKD and
non-ADPKD populations who underwent the same stone intervention; we did not include
studies if outcomes of two different interventions were compared in patients with
ADPKD.

3.2.2

Identifying relevant articles

With an experienced librarian, we developed a comprehensive search strategy (Table 3-1)
to identify eligible published, original journal articles and conference proceedings on
upper urinary tract stone interventions performed in adults with ADPKD. We retrieved
all citations using MEDLINE (1947 to February 2019), EMBASE (1947 to February
2019), Web of Science, BIOSIS Preview (1955 to February 2019), and CINAHL.
Two reviewers (VK and RJ) removed duplicates and rated the remaining title and
abstracts obtained from the search syntax. We retrieved the full text of all “relevant” and
“potentially relevant” articles to further assess study eligibility. To identify additional
eligible articles, we also manually searched the reference list of all included articles, used
the “cited by” function in Google Scholar and Web of Science, and the “similar article”
feature of PubMed. The two reviewers resolved any disagreement by consensus.

3.2.3

Data abstraction

One author (VK) developed a standardized form to abstract data from each study
including information on study, patient and stone characteristics, interventions, and
outcomes. Two authors (VK and RJ) pilot-tested and improved the form by
independently extracting data from five eligible articles. Using the final data abstraction
form (see Table 3-2), two abstractors independently extracted data from remaining
studies, recorded the data, and resolved any disagreement by consensus.
Two authors (VK and GG) assessed the methodological quality of each of the included
studies using a modified Down’s and Black checklist (Table 3-3). We assigned a score
between 0 and 22 for all included studies, with a higher score indicating better
methodological quality.
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3.2.4

Data analysis

Results were described qualitatively. The heterogeneity of included studies precluded a
formal meta-analysis.
Table 3-1. Search strategy used to identify relevant articles related to thesis
DATABASE
MEDLINE

EMBASE

SEARCH STRATEGY
1. Polycystic Kidney Diseases/ or Polycystic Kidney,
Autosomal Dominant/
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or
adpkd)
3. 1 or 2
4. lithotripsy/ or lithotripsy, laser/
5. (ESWL or ESWLs or SWL or lithotrips* or litholapax*)
6. 4 or 5
7. 3 and 6
8. Ureteroscopy/
9. (ureteroscop* or ureterorenoscop* or RIRS or retrograde
intrarenal surgery or FURS)
10. 8 or 9
11. 3 and 10
12. Nephrostomy, Percutaneous/
13. (PCNL or mPCNL or (percutaneous adj3 (nephrostom* or
nephrolithotom*)))
14. 12 or 13
15. 3 and 14
16. 7 or 11 or 15
1. kidney polycystic disease/
2. (((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) adj3 (kidney* or renal)) or
adpkd)
3. 1 or 2
4. extracorporeal lithotripsy/
5. (ESWL or ESWLs or SWLs or lithotrips* or litholapax*)
6. 8 and 9
7. 3 and 6
8. ureteroscopy/
9. (ureteroscop* or ureterorenoscop* or RIRS or retrograde
intrarenal surgery or FURS)
10. 8 or 9
11. 3 and 10
12. percutaneous nephrolithotomy/
13. (PCNL or mPCNL or (percutaneous adj3 (nephrostom* or
nephrolithotom*)))
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Web of Science
&
BIOSIS
Preview

CINAHL

14. 12 or 13
15. 3 and 14
16. 7 or 11 or 15
1. (((((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) NEAR/3 (kidney* or
renal)) or adpkd)))
2. (ESWL or ESWLs or SWL or lithotrips* or litholapax*))
3. ((ureteroscop* or ureterorenoscop* or RIRS or retrograde
intrarenal surgery or FURS))
4. ((PCNL or mPCNL or (percutaneous NEAR/3 (nephrostom*
or nephrolithotom*))))
5. #4 OR #3 OR #2
6. #5 AND #1
7. (MH "Kidney, Cystic") OR (MH "Polycystic Kidney,
Autosomal Dominant")
8. (((polycystic or "type 2" or "type II" or "type 1" or "type I"
or "autosomal dominant" or pkd) N3 (kidney* or renal)) or
adpkd)
9. S1 OR S2
10. (MH "Lithotripsy+")
11. (ESWL or ESWLs or SWL or lithotrips* or litholapax*)
12. S4 OR S5
13. S3 AND S6
14. (MH "Ureteroscopy")
15. (ureteroscop* or ureterorenoscop* or RIRS or retrograde
intrarenal surgery or FURS)
16. S8 OR S9
17. S3 AND S10
18. (MH "Nephrostomy, Percutaneous")
19. (PCNL or mPCNL or (percutaneous adj3 (nephrostom* or
nephrolithotom*)))
20. S12 OR S13
21. S3 AND S14
22. S7 OR S11 OR S15
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Table 3-2. Data abstraction form

UID

Author

Sample size

ADPKD
Population

No. of affected
kidneys

Recruitment
Period

Stone Free Status
(SFS) Definition

No. (%) of patient stone
free after all sessions

Study
No.

Title

Type of Stone
Intervention

Mean (SD)
Length of Followup

Modality Used
to Assess SFS

No. (%) of kidney units
stone free after one session

Country

% of patients lost
to follow-up

Time since treatment
to assess SFS

No. (%) of kidney unit stone
free after all session

Study Design

No. of
Male (%)

Centre

Mean
(SD) Age

No. (%) of patients
stone free after one
session

No. (%) of patients that
underwent ancillary
procedures
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Ancillary
Procedure Details

Pre-operative
Serum
Creatinine

No. (%) of patients
undergoing a followup procedure

Post-operative
Serum Creatinine

Follow-up
procedure Details

Operative Time

Time since first
treatment

Intraoperative
Complications

Post-Operative
Complications

No. (%) of patients who had
stent placed after procedure

PCNL
Modality used to guide
PCNL

Type of Lithotripter

Dilator

Type of
Nephroscope

No. of Shockwaves
[Mean (SD; range)]

Instrument Used to
Fragment Stone

Voltage of Shockwaves
(kV)

Instrument Used to
Remove Stone

Type of Ureteroscopy

No. (%) of patients
with multiple
access tract

Instrument Used to
Fragment Stone
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Abbreviation: kilovolts, kV; percutaneous nephrolithotomy, PCNL; standard deviation, SD; stone free status, SFS; unique identification number, UID
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Table 3-3. Modified Downs and Black checklist
Description of Criteria
1 Is the hypothesis/aim/objective of the study clearly
described?
2 Are the main outcomes to be measured clearly described in
the Introduction or Methods section?
If assessing being stone-free or any complication are first
mentioned in the Results section, the question should be
answered NO.
3 Are the inclusion and exclusion criteria of the populations
clearly described?
4 Is the case definition for ADPKD clearly described?
5

6
7

8

9

10

Probable
Answers
1-Yes;
0-No
1-Yes;
0-No

1-Yes;
0-No
1-Yes;
0-No
Is the ADPKD case definition valid or reliable?
1-Yes;
If the case definition of ADPKD was not reported, then UTD.
0-No;
After 2009, Pei criteria; between 1994 and 2009 Ravine criteria; 0-UTD
before 1994 other definitions that sounds reasonable
Is the distribution of age, sex, and baseline kidney function in 1-Yes;
each group of subjects to be compared clearly described?
0-No
Are the main findings of the study clearly described?
1-Yes;
Simple data (including denominators and numerators) should be 0-No
reported for all major findings so that the reader can check the
major analyses and conclusions.
Does the study provide estimate of the random variability in 1-Yes;
the data?
0-No
In non-normally distributed data, the inter-quartile range of
results should be reported. In normally distributed data the
standard error, standard deviation, or confidence intervals
should be reported. If the distribution of the data is not
described, it must be assumed that the estimate used were
appropriate and the question should be answered yes.
Have any post-operative adverse events of the intervention
1-Yes;
been reported?
0-No
If study reports no patient experience of any complications, or
list any post-operative adverse events, then YES; if the results do
not mention anything about complications, then answer NO.
Have the characteristics of patients lost to follow-up been
1-Yes;
described?
0-No;
If no loss to follow-up, then YES. If authors describe any
0-N/A
characteristics of those loss to follow-up then answer YES. If
authors do not describe any characteristics and just state
number of follow-up, then NO. If author does not mention
number of patients lost to follow-up but reported the main
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11

12

13

14

15

16

17

outcome for all patients, then YES. If the author does not report
number of patients’ loss to follow-up, but only report outcome in
a subset of the patients, then NO.
Have actual probability values been reported (e.g. 0.035
rather than <0.05) for the main outcomes except where the
probability value is less than 0.001?
If statistical analysis was not conducted, then N/A.
Were the subjects asked to participate in the study
representative of the entire population from which they were
recruited? (i.e. did they recruit all or a consecutive patient or a
random sample?)
Were those subjects who were prepared to participate
representative of the entire population from which they were
recruited?
The proportion of those asked who agreed should be stated.
Validation that the sample was representative would include
demonstrating that the distribution of the main confounding
factors was the same in the study sample and the source
population.
Were the staff, places, and facilities where the patient was
treated, representative of the treatment most patients
receive?
There are no unplanned retrospective analyses performed
(i.e. data dredging)?
Any analyses that had not been planned at the outset of the study
should be clearly indicated. If no retrospective unplanned
subgroup analyses were reported, then answer yes. If authors
report any outcomes/clinical characteristics that were not
explicitly referenced in the intro/method section, then my answer
to this question is NO; If methods section too brief/not detailed
enough, then UTD)
In cohort studies, do the analyses adjust for different length
of follow-up of patients, or in case-control studies is the time
period between the intervention and outcome the same for
cases and controls?
If length of follow-up was the same for all study patients, the
answer should be YES. If different lengths of follow-up were
account for by, survival analysis for example, the answer should
be yes. Studies where differences in follow-up are ignored
should be answered NO.
Reported case definition of stone free status?

1-Yes;
0-No;
0-UTD;
0-N/A
1-Yes;
0-No;
0-UTD
1-Yes;
0-No;
0-UTD

1-Yes;
0-No;
0-UTD
1-Yes;
0-No;
0-UTD;
0-N/A

1-Yes;
0-No;
0-UTD;
0-N/A

1-Yes;
0-No;
0-UTD;
0-N/A
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18 Were the ADPKD population and controls recruited from
the same population?
N/A for all case series
19 Were the ADPKD population and the controls recruited
from the same time period?
For a study which does not specify the time period over which
patient were recruited, the question should be answered as
unable to determine. N/A for all case series
20 Was there adequate adjustment for confounding in the
analyses from which the main finding was drawn?
If the distribution of known confounders in the different
treatment group was not described or the distribution of known
confounders differed between the two groups but was not
considered in the analysis, then NO. If effect of the main
confounders was not investigated or confounding was
demonstrated but no adjustment was made in the final analyses
the questions should be answered as NO. N/A for case series.
21 Were losses of patients to follow-up considered?
If the number of patients lost to follow-up are not reported, the
question should be answered as unable to determine. If the
proportion lost to follow-up was too small to affect the main
findings, the question should be answered YES.

1-Yes;
0-No;
0-UTD;
0-N/A
1-Yes;
0-No;
0-UTD;
0-N/A
1-Yes;
0-No;
0-UTD;
0-N/A

1-Yes;
0-No;
0-UTD;
0-N/A

Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; not applicable, N/A; unable to
determine, UTD
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3.3 RESULTS
Figure 3-1 summarizes the study selection process. Our search strategy yielded 221
citations that we reviewed and identified 24 eligible articles. We identified an additional
article when manually searching the reference lists of the study conducted by Delakas et
al. (1997).18 This yielded a total of 25 relevant articles (311 patients with ADPKD)
published between 1993 and 2019. Studies were conducted in India (n=7), United States
(n=6), China (n=3), Greece (n=2), and Kuwait (n=2). One study was conducted in each of
the following countries: Azerbaijan, Denmark, Iran, Romania, and Taiwan. Of the 25
included articles, 24 studies were case series (96%), and one (4%) was a cohort study.
Sixteen (64%) of these were full-text journal articles, and nine (36%) were conference
proceedings.
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Figure 3-1. Study selection.
The number of patients in each study ranged from 2 to 29 cases (2 to 30 kidneys), and the
mean age of the patients ranged from 32 to 61 years. The stone interventions were
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performed between October 1981 and January 2017. It was unclear whether the
interventions were emergent or elective in all included studies. The study and patient
characteristics of each included study are summarized in Table 3-4, and overall outcomes
of stone interventions are listed in Table 3-5.
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Table 3-4. Study and patient characteristics of included studies.
Author (Year)
Country (Citation)

No. of Cases
(No. of
Kidneys)

No. of
Centres

Recruitment
Period

Length of
Follow-up,
Mean (SD)

Mean Age
(SD), years

No. of Male
(%)

Quality
Score±

Shockwave Lithotripsy - Case Series
Baishya (2012) *
India 14
Cass (1995) *
United States 30
Chen (1993) *
Taiwan 31
Delakas (1997)
Greece 18
Deliveliotis (2002) *
Greece 26
Ng (2000) *
United States 32
Singh (2019) *
India 24

3 (3)

Unclear

Since 1992

1.5 (1.3) years

NR

NR

9

4 (NR)

1

NR

3 months‡

61 (12)

2 (50)

7

2 (2)

1

NR

NR

NR

9

13 (16)

1

7 (54)

9

Unclear

5.6 (NR)
months
1 month‡

55 (NR)

4 (Unclear)

June 1986 to
December 1989
April 1990 to
October 1994
NR

49 (NR)

3 (75)

8

3 (3)

1

Since 1993

NR

NR

NR

9

3 (3)

1

January 1990 to
July 2014

NR

NR

NR

12

2 (3)

Unclear

Since 1992

NR

NR

9

9 (NR)

1

NR

7.3 (1.2)
months
NR

NR

NR

7

11 (Unclear)

1

January 2007 to
January 2017

NR

61 (NR)

NR

8

2 (3)

1

Since 1993

NR

NR

NR

9

5 (6)

1

NR

NR

NR

12

13 (15)

1

January 1990 to
July 2014
2005 to 2010

3 (NR)

35 (NR)

9 (69)

11

Ureteroscopy - Case Series
Baishya (2012) *
India 14
Franke (2010) *
Denmark 33
Geavlete (2017) *
Romania 28
Ng (2000) *
United States 32
Singh (2019) *
India 24
Yili (2012)
China 13

Percutaneous Nephrolithotomy - Cohort
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Author (Year)
Country (Citation)
Khorrami (2012)
Iran 29

No. of Cases
(No. of
Kidneys)
• ADPKD: 8
(NR)
• CONTROL:
100 (NR)

No. of
Centres

Recruitment
Period

1

2003 to 2011

Length of
Follow-up,
Mean (SD)
NR

Mean Age
(SD), years

No. of Male
(%)

Quality
Score±

• ADPKD:
45 (5)
•
CONTROL:
47 (4)

• ADPKD:
7 (88)
•
CONTROL:
NR

4

Percutaneous Nephrolithotomy - Case Series
Al-Kandari (2009)
Kuwait 23
Al-Kandari (2008)
United States 34
Baishya (2012) *
India 14
Bendigeri (2016)
India 35
Boaz (2016)
India 36
Enganti (2017)
India 37
Ismayil (2014) *
Azerbaijan 38
Khadgi (2016)
Kuwait 25
Lei (2014)
China 19
Sabnis (2016)
United States 22
Singh (2013)
India 39
Singh (2019) *
India 24
Srivastava (2012)
India 40

19 (20)

2

1995 to 2007

NR

42 (9)

12 (63)

11

29 (30)

2

NR

NR

NR

21 (72)

4

3 (3)

Unclear

Since 1992

2.2 (0.8) years

NR

NR

9

13 (17)

NR

NR

NR

NR

10 (77)

8

19 (23)

Unclear

NR

NR

NR

6

22 (Unclear)

Unclear

NR

42 (NR)

NR

4

3 (NR)

NR

January 2003 to
July 2015
January 2014 to
April 2016
2004 to 2014

NR

NR

NR

6

7 (NR)

NR

NR

42 (8)

3 (43)

12

23 (23)

Unclear

NR

43 (11)

17 (74)

12

10 (NR)

NR

March 2010 to
September 2012
January 2007 to
December 2012
NR

NR

NR

8 (80)

7

22 (26)

1

2002 to 2011

38 (NR)

NR

8

6 (6)

1

NR

NR

12

22 (25)

1

January 1990 to
July 2014
January 2000 to
January 2010

35 (NR)
months
NR
NR

40 (14)

18 (82)

10
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Author (Year)
Country (Citation)
Umbreit (2010)
United States 21
Wang (2017)
United States 41
Zhang (2014)
China 27

No. of Cases
(No. of
Kidneys)
9 (11)

No. of
Centres

Recruitment
Period

1

October 1981 to
February 2009
Since 2010

11 (13)

Unclear

11 (12)

1

January 2002 to
December 2012

Length of
Follow-up,
Mean (SD)
2.7 (NR)
years
NR
36 months‡

Mean Age
(SD), years

No. of Male
(%)

Quality
Score±

32 (NR)

7 (78)

9

50 (13)

8 (73)

7

42 (11)

7 (64)

11

Abbreviations: not reported, NR; standard deviations, SD
*The described cases are a subset of a larger case series.
‡
The reported length of follow-up is not the average but rather constant for all included patients.
±
A modified Downs and Black checklist was used to assess the methodological quality of each included study. The methods quality score ranged
between 0 and 22 with higher scores indicating higher quality.
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Table 3-5. Outcomes of stone interventions.

Author (Year)
Country

No. of
Patients
Stone Free
after One
Session
(%)

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)

Shockwave Lithotripsy - Case Series
Baishya (2012)
India

0 (0)

2 (67)

NR

NR

NR

NR

Cass (1995)
United States
Chen (1993)
Taiwan

2 (50)

Unclear

NR

None

NR

NR

0 (0)

NR

NR

None

NR

NR

Delakas (1997)
Greece

9 (69)

2 (15)

None

• At least one complication:
Unclear
• Colic pain that improved
with oral analgesics: 3 (23)
• Transient Gross Hematuria:
8 (62)

NR

NR

Deliveliotis
(2002)
Greece
Ng (2000)
United States
Singh (2019)
India

1 (25)

NR

NR

None

NR

NR

NR

1 (33)

NR

None

NR

1 (33)

NR

• At least one complication: 2
(33)
• Fever: 2 (33)

76.6 (10.2;
70.7 to 88.4)
NR

79.6 (25.0;
61.9 to 97.2)
NR

2 (100)

0 (0)

NR

None

NR

NR

9 (100)

0 (0)

NR

None

NR

NR

Ureteroscopy - Case Series
Baishya (2012)
India
Franke (2010)
Denmark
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8 (73)

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)
Unclear

Ng (2000)
United States

NR

0 (0)

NR

None

Singh (2019)
India

NR

0 (0)

NR

• At least one complication: 1
(20)
• Fever: 1 (20)

11 (85)

2 (15)

None

• At least one complication: 3
(23)
• Low-grade fever: 1 (8)
• Flank pain: 1 (8)
• Moderate stent pain: 1 (8)

NR (NR; 70.7
to 291.7)

NR

• ADPKD: None
• CONTROL: None

• Urinary leakage from
nephrostomy tube was longer
in patients with ADPKD (31 +
4 hours) vs. controls (6 + 1.5
hours)

NR

NR

Author (Year)
Country

Geavlete (2017)
Romania

Yili (2012)
China

No. of
Patients
Stone Free
after One
Session
(%)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

NR

• At least one complication: 3
(27)
• Fever: 1 (9)
• Hematuria: 1 (9)
• Renal colic: 1 (9)

NR

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
NR

556.9 (399.6;
274.0 to
839.8)
NR

300.6 (75.0;
247.5 to
353.6)
NR

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)

Percutaneous Nephrolithotomy - Cohort
Khorrami (2012)
Iran

• ADPKD:
7 (88)
•
CONTROL:
91 (91)

NR

Percutaneous Nephrolithotomy - Case Series
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16 (84)

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)
3 (16)

NR

2 (7)

•At least one complication: 3
(10)
• Renal Pelvic Tear: 2 (7)
• Intraoperative bleeding: 1
(3)

None

NR

NR

2 (67)

1 (33)

NR

• At least one complication: 2
(67)
• Post-operative fever: 1 (33)
• Pain in operating site: 1 (33)

NR

NR

Bendigeri (2016)
India

NR

3 (23)

NR

• At least one complication:
Unclear
• Fever: 3 (23)
• Blood transfusion: 1 (8)

NR

NR

Boaz (2016)
India

NR

4 (21)

• At least one complication:
1 (5)
• Blood transfusion: 1 (5)

• At least one complication: 4
(21)
• Fever: 4 (21)
• Sepsis: 1 (5)

179.5 (84.2;
97.2 to 389.0)

175.9 (71.6;
97.2 to
309.4)

Author (Year)
Country

Al-Kandari
(2009)
Kuwait

Al-Kandari
(2008)
United States

Baishya (2012)
India

No. of
Patients
Stone Free
after One
Session
(%)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

Unclear

• At least one complication: 3
(15)
• Mild hematuria with lowgrade fever: 1 (5)
• Bleeding through
nephrostomy tube after
declamping: 1 (5)
• Low grade fever: 1 (5)

150.3 (70.7;
NR)

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
132.6 (70.7;
NR)

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
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Enganti (2017)
India

NR

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)
NR

Ismayil (2014)
Azerbaijan

2 (67)

1 (33)

NR

• At least one complication: 3
(100)
• Blood transfusion: 3 (100)

NR

NR

Khadgi (2016)
Kuwait

7 (100)

0 (0)

NR

• At least one complication: 3
(43)
• Fever: 1 (14)
• Urinary tract infection: 1
(14)
• Bleeding: 1 (14)

NR

NR

Lei (2014)
China

16 (70)

6 (26)

NR

• At least one complication:
Unclear
• Fever: 4 (17)
• Urinary tract infection: 3
(13)
• Blood transfusion: 2 (9)
• Selective renal artery
embolization: 1 (4)

148.2 (110.1;
77.0 to 568.0)

•
Immediately
after: 149.2
(86.2; 72.0
to 475.0)
• One-month
follow-up:
136.2 (86.7;
53.0 to
441.0)45455
54444

Author (Year)
Country

No. of
Patients
Stone Free
after One
Session
(%)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

NR

• At least one complication: 5
(23)
• Renal pelvic perforation: 1
(5)
• Hematuria requiring blood
transfusion: 2 (9)
• Perirenal fluid collection: 2
(9)

NR

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
NR

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
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Sabnis (2016)
United States

NR

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)
0 (0)

Singh (2013)
India

12 (55)

10 (45)

• At least one complication:
4 (18)
• Hypotension requiring
resuscitation but did not
require termination of
procedure: 4 (18)

• At least one complication:
Unclear
• Blood transfusion: 9 (32)
• Fever due to cyst infection: 4
(18)
• Perirenal hematoma
collection: 4 (18)
• Renal failure that worsened:
3 (14)
• Hydrothorax: 2 (9)
• Hemothorax: 1 (5)
• Pneumothorax: 1 (5)
• Paralytic ileus: 3 (14)

NR

NR

Singh (2019)
India

NR

Unclear

NR

• At least one complication:
Unclear
• Fever: 2 (33)
• Urinary tract infection: 1
(17)

NR

NR

Author (Year)
Country

No. of
Patients
Stone Free
after One
Session
(%)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

NR

• At least one complication: 2
(20)
• Fever: 2 (20)

NR

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
NR

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
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Unclear

No. of
Patients
who
Underwent
Follow-up
Procedures
(%)
3 (14)

Umbreit (2010)
United States

NR

2 (18)

None

None

123.8 (NR;
79.6 to 238.7)

Wang (2017)
United States

NR

7 (64)

NR

• At least one complication:
Unclear
• Severe hematuria: 1 (9)
• Fever: 5 (45)
• Paralytic ileus: 1 (9)
• Urinary tract infection: 3
(27)

89.3 (15.9;
NR)

Zhang (2014)
China

5 (45)

4 (36)

NR

• At least one complication:
Unclear
• Bleeding: 3 (27)
• Fever: 4 (36)
• Blood transfusion: 2 (18)
• Infection: 1 (9)

1337.5 (291.7;
875.2 to
1780.4)

Author (Year)
Country

Srivastava (2012)
India

No. of
Patients
Stone Free
after One
Session
(%)

Abbreviations: not reported, NR; standard deviation, SD

Pre-operative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)

Intraoperative
Complications, No. of
Patients (%)

Post-operative
Complications, No. of
Patient (%)

NR

• At least one complication:
Unclear
• Fever: 4 (18)
• Blood transfusion: 3 (14)
• More than one transfusion: 1
(5)
• Positive fungal culture with
antibiotic treatment for 3
months: 1 (5)

NR

Postoperative
Serum
Creatinine
[mean (SD;
range)]
(µmol/L)
NR

123.8 (NR;
70.7 to
247.5)
90.5 (18.6;
NR)

1262.4
(198.0;
951.2 to
1527.6)
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3.3.1

Quality assessment of studies

The methods quality score was highly variable and ranged between 4 to 12 out of 22
(where higher scores indicates studies of higher methodological quality).
The ADPKD and outcome definitions affect the internal validity of a study. Only one
study reported the case definition of ADPKD, which defined ADPKD using the
validated, Ravine ultrasonographic criteria.19,20
The definition of stone free status post-intervention was highly variable across studies.
Seven of the 25 studies specified and defined stone free status as complete clearance or
residual fragments less than a prespecified size. The prespecified size for an acceptable
residual fragment was less than four millimeters for five studies, less than two
millimeters for one study, and less than one millimeter for one study.
The sampling strategy and the source population influenced the generalizability of the
findings to the broader ADPKD population who underwent stone intervention. Seven of
the 25 studies specified how cases were recruited, and all seven studies included
consecutive or all patients within a specified time frame.13,14,21–25 One study recruited
patients from an outpatient setting26, and four studies recruited patients from a hospital
setting.18,19,27,28 For the latter, it was unclear whether the cases were recruited from a same
day surgery setting, emergency department, inpatient, or an outpatient hospital-based
clinic.
One conference proceeding described the efficacy outcomes of PCNL performed in
patients with ADPKD compared to non-ADPKD controls, without adjustment for any
covariates.29

3.3.2

Shockwave lithotripsy

We identified seven case series describing the outcomes and experience of treating stones
in patients with ADPKD with SWL (in total 32 patients).14,18,24,26,30–32 The characteristics
of SWL for each study is summarized in Table 3-6.
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Table 3-6. Characteristics of shockwave lithotripsy (SWL).
Author (Year)
Country
Baishya (2012)
India
Cass (1995)
United States
Chen (1993)
Taiwan
Delakas (1997)
Greece
Deliveliotis (2002)
Greece
Ng (2000)
United States

Type of Lithotripter

# of
Shockwaves
[Mean (SD;
range)]

Voltage of
Shockwave
(kV)

Dornier Compact Delta

<1500

<13

Medstone STS Lithotripter

24

Dornier HM-4 Lithotripter

2050 (700;
1000 to 2400)
2500 (NR;
2000 to 3000)
1800 (NR;
1400 to 2500)
Unclear

Dornier HM-3 or MFL 5000
Lithotripter

4333 (3402;
1800 to 8200)

Dornier HM-3 Lithotripter
Dornier HM-4 Lithotripter

20
15 to 21
23
NR

Modality used to assess
stone free status

Operative
Time
(minutes)

X-ray, U/S of the KUB
region
Plain radiograph

NR

KUB x-ray and
excretory urography
Plain x-ray film and U/S

NR

Plain KUB x-ray film
and U/S
Plain x-ray film and
kidney U/S or noncontrast CT

NR

NR (35 to
88)
NR
NR

NR
< 1500
< 13
U/S or KUB x-ray
100 (80 to
Singh (2019)
120)
India
Abbreviations: computed tomography, CT; kidney, ureter, bladder, KUB; kilovolts, kV; standard deviation; SD; ultrasound, U/S
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None to 69% of the patients were stone free after a single SWL session, and 15% to 67%
of the patients received additional follow-up procedures to achieve stone-free
status.14,18,24,26,30–32 In four of the six case series that examined at least one post-operative
SWL complication, no patients experienced any complications post-operatively.26,30–32
The percentage of patients that experienced at least one complication was unclear in one
study18, and 33% of the patients described by Singh (2019) experienced fever postoperatively.24 The reported post-operative complications of SWL in patients with
ADPKD included colic pain and fever.18,24 Delakas and colleagues specified that none of
the patients experienced any post-operative complications18, whereas the remaining six
case series did not report any intraoperative complications.14,24,26,30–32

3.3.3

Ureteroscopy

We identified six case series reporting stone treatment in patients with ADPKD using
ureteroscopy (in total 42 patients) 13,14,24,28,32,33. The characteristics of ureteroscopy are
detailed in Table 3-7.
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Table 3-7. Characteristics of ureteroscopy.
Author (Year)
Country
Baishya (2012)
India
Franke (2011)
Denmark
Geavlete (2017)
Romania
Ng (2000)
United States
Singh (2019)
India
Yili (2012)
China

Operative
Time
(minutes)
Mean
(Range)
NR

Type of
Ureteroscope

Instrument used to
Fragment Stones

Modality used to Assess
Stone Free Status

NR

NR

Flexible
ureteroscope
Flexible
ureteroscope

NR

X-ray, U/S of the KUB
region at one month
CT

Laser lithotripsy

NR

NR

NR

Laser for 1 of 2 patients

NR

Semirigid and
flexible
ureteroscope

Holium YAG laser

Plain x-ray film and renal
U/S or non-contrast CT
Plain x-ray KUB and U/S
KUB

7.2 flexible
ureteroscope

Holium YAG laser lithotripsy
performed via 200um
(Dornier Lightguide Super
200) core-sized fiber until
only very small pieces
(<1mm) remained.

U/S

Abbreviations: computed tomography, CT; kidney, ureter, bladder, KUB; not reported, NR; ultrasound, U/S

NR

60 (30- 90)

46 (36-60)
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After a single session, 73% to 100% of the patients were stone-free.13,28,33 In four case
series, no patients required a second procedure to facilitate complete stone
removal,14,24,32,33 whereas another case series reported 15% undergoing a second
ureteroscopy one week following the first procedure.13 The percentage of patients that
underwent a second procedure was unclear or not reported in one case series.28 Three case
series reported that none of the patients experienced any post-operative
complications.14,32,33 About 20% to 27% of the patients experienced at least one postoperative complication, such as fever, hematuria, and pain in the remaining three case
series.13,24,28 One case series reported that not a single patient experienced any
intraoperative outcomes during ureteroscopy13, whereas the remaining five case series did
not report about any intraoperative outcomes.14,24,28,32,33

3.3.4

Percutaneous nephrolithotomy (PCNL)

Sixteen case series14,19,21–25,27,34–41 and one cohort study29 reported the use of PCNL for
stone removal in adults with ADPKD, with 3 to 29 patients per series (3 to 30 kidneys)
(in total 237 patients). PCNL-specific characteristics of each study is detailed in Table 38.
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Table 3-8. Characteristics of percutaneous nephrolithotomy (PCNL).

Author (Year)
Country

Khorrami (2012)
Iran
Al-Kandari
(2009)
Kuwait

Al-Kandari
(2008)
United States
Baishya (2012)
India

% of
Affected
Kidneys
with
Multiple
Access Tract
NR

Modality
Used to
Guide
Procedure

Dilator

Type of
Nephroscope

Instrument
Used to
Fragment
Stones

Instrument
Used to
Remove
Stones

Modality Used to
Assess Stone Free
Status

Operative
Time
(Minutes)
Mean
(SD;
Range)
NR

Fluroscopy

Metal
telescoping
dilator

NR

NR

NR

NR

5

Fluoroscopy

Amplatz
sequential
facial dilator
in 14
procedures
and
Nephromax
balloons in
remaining 6
procedures

26F rigid
nephroscope

U/S and/or
pneumatic
disintegration
were used
together

NR

• Day of
procedure: plain
abdominal x-ray
and intraoperative
nephrostography
• At time of
nephrostomy tube
removal (2 to 4
days postoperatively): plain
abdominal x-ray
for radiopaque
stone;
nephrostomy or
non-spiral CT for
radiolucent stones

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

• U/S (67%)
•
Fluroscopy
(33%)

NR

NR

NR

NR

X-ray,
ultrasonography of
the KUB region at
one month

Unclear
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% of
Affected
Kidneys
with
Multiple
Access Tract
NR

Modality
Used to
Guide
Procedure

Dilator

Type of
Nephroscope

Instrument
Used to
Fragment
Stones

Instrument
Used to
Remove
Stones

Modality Used to
Assess Stone Free
Status

NR

NR

NR

NR

NR

NR

Operative
Time
(Minutes)
Mean
(SD;
Range)
NR

NR

NR

NR

NR

NR

NR

NR

85

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

CT

NR

0

Fluroscopy

fascial dilator

Semi-rigid
ureteroscope
(8.5/11.5 Fr)

1.5 mm
pneumatic
lithotripsy probe

A pulsatile
pressurized
irrigation
pump;
occasionally
cleared by
forceps

• 1-day postoperatively: KUB
and U/S
• 12-weeks postoperatively: noncontrast CT

54.9 (6.9;
45-60)

Lei (2014)
China

13

•
Fluroscopy
(91%)
• U/S (9%)

fascial dilator

8/9.8F semirigid
ureteroscope

Pneumatic
lithotripsy or
holmium laser

Forceps and
small
fragments
flushed out
with an
endoscopic
pulsed
perfusion
pump

Plain KUB
radiography, U/S,
and CT

95.2 (14.0;
NR)

Sabnis (2016)
United States
Singh (2013)
India

NR

U/S or
Fluroscopy
Fluroscopy

NR

NR

NR

NR

NR

NR

Alkene
metallic
dilator up to
26F/28F

26F (Richard
Wolf)
nephroscope

Pneumatic
lithoclast (Swiss
Lithoclast)

NR

X-ray KUB and
renal U/S

90
(NR;70120)

Author (Year)
Country

Bendigeri (2016)
India
Boaz (2016)
India
Enganti (2017)
India
Ismayil (2014)
Azerbaijan
Khadgi (2016)
Kuwait

31

96

Modality
Used to
Guide
Procedure

Dilator

Type of
Nephroscope

Instrument
Used to
Fragment
Stones

Instrument
Used to
Remove
Stones

Modality Used to
Assess Stone Free
Status

U/S and
fluoroscopy

Serial Dilator

Unclear

laser or
pneumatic
lithoclast

NR

Plain x-ray KUB
and U/S KUB

Operative
Time
(Minutes)
Mean
(SD;
Range)
112 (NR;
70-145)

Unclear

NR

Amplatz
sequential
facial dilators

28Fr
nephroscope;
Flexible
nephroscope
in some cases

Pneumatic
lithotripter;
holmium laser
with flexible
nephroscope in 3
patients where
forceps
extraction was
not possible

Forceps

Non-contrast CT

NR

Umbreit (2010)
United States

45

Fluroscopy

Amplatz
fascial dilators

Rigid
nephroscope;
two patients
also required
a flexible
nephroscope

• Ultrasonic
lithotripsy: 10
(91%)
•Electrohydraulic
lithotripsy: 2
(9%)

• Basket: 2
(9%)

• Immediately
after: endoscopy
nephrostogram
• One day after:
Antegrade
nephrostogram

•
Unilateral
PCNL =
66 (NR;
47-82)
• Bilateral
PCNL =
127 (NR;
121-132)

Wang (2017)
United States

18

U/S

Amplatz
fascial dilators

Rigid

Pneumatic and
U/S
disintegration

NR

NR

NR

Author (Year)
Country

Singh (2019)
India
Srivastava (2012)
India

% of
Affected
Kidneys
with
Multiple
Access Tract
NR
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Author (Year)
Country

Zhang (2014)
China

% of
Affected
Kidneys
with
Multiple
Access Tract
NR

Modality
Used to
Guide
Procedure

Dilator

Type of
Nephroscope

Instrument
Used to
Fragment
Stones

Instrument
Used to
Remove
Stones

Modality Used to
Assess Stone Free
Status

U/S

6F plastic
dilator then
metal coaxial
metal dilators
(second step)

Rigid
nephroscope

U/S and
pneumatic
disintegration

Graspers

Ultrasound/ KUB
film

Abbreviations: computed tomography, CT; kidney, ureter, and bladder, KUB; not reported, NR; ultrasound, U/S

Operative
Time
(Minutes)
Mean
(SD;
Range)
77 (23.5;
45- 128)
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The stone-free status of patients after a single session ranged from 45% to 100%, and 0%
to 64% of the patients required a follow-up procedure for residual stones among the 12
studies that reported it.14,19,21–23,25,27,34–36,38–41 Two studies reported no patients
experiencing any post-operative complications21,34, seven case series did not report the
percentage of patients with complications19,24,27,35,39–41, and 15% to 100% of patients
experienced at least one complication among the remaining seven case series.14,23–25,36–38
The post-operative complications of PCNL included fever, pain, hematuria, bleeding,
urinary tract infection, cyst infection, perirenal hematoma collection, hydrothorax,
hemothorax, pneumothorax, paralytic ileus, worsening of pre-existing renal failure, blood
transfusion, renal pelvic perforation, urinary leakage from nephrostomy tube, and
sepsis.14,19,22–25,27,35–41 None of the patients described by Umbreit et al. experienced any
intraoperative complications.21 In three other case series, at least one patient experienced
an intraoperative complication, including bleeding, renal pelvic tear and
hypotension34,36,39; the remaining studies did not clearly report any intraoperative
complications. 14,19,22–25,27,35,37,38,40,41
Khorrami et al. conducted a cohort study of patients undergoing PCNL, comparing eight
patients with ADPKD to 100 patients without ADPKD.29 There were no significant
between-group differences in stone-free status, the rise in the concentration of serum
creatinine after the procedure, or the decline in concentration of hemoglobin after the
procedure.29 However, urinary leakage lasted significantly longer in patients with
ADPKD compared to patients without ADPKD.29

3.4 DISCUSSION
We conducted a systematic review of 25 studies describing at least one post-operative
outcome of SWL, ureteroscopy, and PCNL in patients with ADPKD to summarize the
literature and to identify knowledge gaps. The estimates are limited by small sample sizes
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and between study variability in patient characteristics, stone characteristics, and
treatment protocol. This concern notwithstanding, based on the literature published to
date, the percentage of patients who were stone free after one session ranged from none
to 69% for SWL, 73% to 100% for ureteroscopy, and 45% to 100% for PCNL. The
overall complication rate ranged from none to 33% for SWL, none to 27% for
ureteroscopy, and none to 100% for PCNL. Post-operative complications experienced by
patients with ADPKD after any intervention included residual stones, pain, and fever.
Post-operative hematuria was observed after ureteroscopy and PCNL. Other PCNL
complications included urinary leakage, bleeding, renal pelvic perforation, perirenal fluid
collection, urinary tract infection, cyst infection, worsening renal failure, hydrothorax,
hemothorax, pneumothorax, and paralytic ileus.
The post-operative complication and stone free rates of all three stone interventions were
highly variable. The variability in post-operative complication and stone free rates can be
explained by between-study variability in the definitions used for stone free status,
sample size, treatment protocol, timing when imaging was performed post-intervention,
and the type of imaging performed to assess stone free status post-intervention. For
example, among all imaging modalities used to assess stone free status, computed
tomography (CT) is the most sensitive modality to detect residual stones.42,43 Ultrasound
and kidney, ureter, and bladder (KUB) radiograph cannot detect radiolucent stones, such
as uric acid stones, and the ultrasound performance is poor for patients who are obese and
patients with residual fragments less than 5 millimeters42,43, and would be expected to be
less sensitive in the setting of ADPKD. As a result, studies that use CT post-operatively
would report a lower stone free rate compared to studies that use ultrasound or KUB.
Patient and stone characteristics, including ADPKD-specific characteristics such as
residual renal function and cyst volume and location, influence intervention choice and
subsequent success and complication rates. In general, symptomatic stones that are
between one to two centimeters would be treated with either SWL or ureteroscopy, and
PCNL would be reserved for stones greater than two centimeters, or in patients where
retrograde access is not possible. The success rate of all three intervention is dependent
on gaining optimal access to stones.44 Therefore, variability in patient and stone
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characteristics across studies also explain the variability in reported success and
complication rate.
It is difficult to determine whether SWL, ureteroscopy, and PCNL are truly efficacious
and safe in patients with ADPKD because the variability described above also limits
indirect comparison of stone interventions success and complication rates between that
reported in patients with ADPKD and the general population. Furthermore, the ADPKD
cases described in the studies were likely more selected than the general population
because of their complex kidney anatomy. Future randomized controlled trials or
observational studies that use a representative sample of patients with ADPKD and
address potential confounding factors are required to elucidate whether ADPKD is truly
associated with poor outcomes following SWL, ureteroscopy, and PCNL.
Our findings must be interpreted with caution due to several limitations. First, except for
one cohort study, all studies were clinical case series. Although case series give some
insight into the outcomes of stone interventions, and are useful for generating new
hypotheses, the observations are not necessarily generalizable to the broader ADPKD
population. Based on our systematic, comprehensive search, the conference proceeding
published by Khorrami et al. (2009) is the only cohort study in the literature.39 Although
they compared the outcomes of PCNL in patients with ADPKD to patients without
ADPKD, they did not adjust for any covariates. Second, the sample size of all included
studies, including the cohort study was small so the reported estimates were imprecise.
Third, most of the data were retrospectively collected. As a result, the conclusions were
highly dependent on the accuracy of medical records. Fourth, the inclusion and exclusion
criteria were not explicitly reported in all identified studies. Lastly, all studies published
to date did not describe the cystic volume in patients with ADPKD. As a result, it was
difficult to elucidate whether and how cystic volume influences post-operative
complication and success rates.
Aside from inherent limitations of the information in the primary studies, with respect to
the quality of this review, we used a very comprehensive search strategy to identify
relevant literature. Data were carefully abstracted using a robust form. Our study is the
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first systematic review to summarize the outcomes of stone interventions in adults with
ADKPD.

3.5 CONCLUSION
Our systematic review shows that empirical evidence on the efficacy and safety of SWL,
ureteroscopy, and PCNL in ADPKD is limited. Our findings corroborate Mallett et al’s
suggestion to undertake methodologically rigorous studies to understand the
consequences of these procedures in patients with ADPKD.8

3.6 ADDENDUM
We updated our search to identify whether additional studies were published between
February 2019 (when the initial search was conducted) and July 2020. We identified one
additional study that described 21 patients with ADPKD who underwent ureteroscopy,
and 11 patients with ADPKD who underwent PCNL.46 The methods quality score of the
additional study was 12. The percentage of patients who were stone free after one session
was 85.9% for patients who underwent ureteroscopy, and 90.9% for those who
underwent PCNL. 46 The percentage of patients who experienced one complication was
28.6% for patients who underwent ureteroscopy, and 45.5% for patients who underwent
PCNL. 46 The percentage of patients who experienced at least one post-operative
complication following ureteroscopy now ranges from 0% to 29% instead of 0% to 27%
according to all studies published in the literature; however, the findings from this study
do not change the conclusion of this chapter that empirical evidence on the efficacy and
safety of SWL, ureteroscopy, and PCNL in ADPKD is limited.
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4.1 Limitations of the existing literature
We conducted two systematic reviews to identify knowledge gaps, and to gain a current
state of knowledge on the prevalence and incidence of upper urinary tract stones and
stone interventions, and on the safety and efficacy of SWL, ureteroscopy, and PCNL in
patients with ADPKD.
Our first systematic review revealed that there is still poor consensus on the prevalence of
upper urinary tract stones and stone interventions in patients with ADPKD. Most studies
published to date on stones in ADPKD were conducted in a single center, and are of poor
methodological quality. The ADPKD and stone definitions were variable across studies.
Additionally, only six studies compared the prevalence of stones in patients with ADPKD
to controls.1–6 Among the six studies, two statistically compared the prevalence of stones
between the two group, and none of these studies adjusted for confounders.3,4
Our second systematic review showed that empirical evidence of the efficacy and safety
of SWL, ureteroscopy, and PCNL in ADPKD is limited. Except for one cohort study, all
studies were clinical case series. Although case series give some insight into the
outcomes of stone interventions, and are useful for generating new hypotheses, the
observations are not necessarily generalizable to the broader ADPKD population. Based
on our systematic, comprehensive search, the conference proceeding published by
Khorrami et al. (2009) is the only cohort study in the literature.7 Although they compared
the outcomes of PCNL in patients with ADPKD to patients without ADPKD, they did not
adjust for any covariates. The sample size of all included studies, including the cohort
study, was small so the reported estimates were imprecise. Most of the data were
retrospectively collected. As a result, the conclusions were highly dependent on the
accuracy of medical records. Lastly, the inclusion and exclusion criteria were not
explicitly reported in all identified studies.
Our systematic reviews show that the epidemiological data to support the assertion that
patients with ADPKD are at higher risk of upper urinary tract stones is weak.
Additionally, there is limited evidence on how stones are currently managed in patients
with ADPKD and we are unsure how frequently patients with ADPKD receive stone
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interventions, such as lithotripsy, for their upper urinary tract stones. We also do not
know if patients with ADPKD who underwent stone interventions experience a higher
risk of post-operative outcomes. More methodologically robust studies are needed to
better characterize the association between ADPKD and upper urinary tract stones, and
between stone interventions and post-operative outcomes. This information will help
patients with ADPKD and physicians guide prognostication, and might inform the use of
interventions; it will also help inform future clinical practice guidelines.
Conducting a retrospective cohort study using healthcare administrative databases would
allow us to conduct large studies and give us insight into rate of hospital encounters with
upper urinary tract stones and stone interventions in patients with ADPKD, and into the
risk of post-operative outcomes of stone intervention in patients with ADPKD. However,
we must first ensure that we can reliably identify patients with ADPKD using
administrative codes. Patients with ADPKD can be identified using Ontario Health
Insurance Plan (OHIP) diagnosis codes, codes submitted by physicians for the services
they provide, or by using the International Classification of Diseases, 9 th revision (ICD-9)
codes, and International Classification of Diseases, 10th, revision (ICD-10) codes
(healthcare encounter codes). Healthcare encounter codes are assigned per the ICD-9
(used in Canada prior to 2002) and ICD-10 (used in Canada in 2002 onwards)
classification system by highly trained coders.9 These data are collected for
administrative purposes rather than research purposes.10 Physician misdiagnosis,
incomplete documentation in medical records, or errors by personnel who assign the
administrative codes to each hospital encounter can potentially lead to misclassification. 9
Thus, patients who truly have ADPKD may not be assigned the code and patients with
ICD-9 or ICD-10 codes related to ADPKD may not truly have ADPKD. Based on a
comprehensive literature search of bibliographic databases, there is only a single study
which validated an administrative code related to ADPKD.11 Blanchette et al. validated
the ICD-9 code for unspecified PKD (753.12) by using medical chart review as the
reference standard.11 The positive predictive value of the ICD-9 code 753.12 was 94.7%,
indicating it identified patients who truly had ADPKD.11 No study, to date, has formally
validated the more recent ICD-10 code. Additionally, coding practices differ by
countries, and even by different provinces. No study, to date, validated administrative
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codes related to ADPKD in Ontario. Validating administrative codes related to ADPKD
will provide assurance of the robustness of our cohort and the internal validity of our
studies.
I will address the limitations in the current literature by conducting one validation study,
and two cohort studies using healthcare administrative databases.
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5.1 INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic condition
characterized by focal cyst development leading to bilateral enlargement of both
kidneys.1 Approximately, half of these patients will require end-stage kidney disease care
by the age of 50.2 ADPKD has an estimated prevalence of 1 in 1000 to 1 in 400 (0.1 to
0.25%) persons worldwide.3 Since ADPKD is a relatively uncommon disease, using large
healthcare administrative databases may allow a large number of patients with ADPKD
to be identified and studied in a time-efficient and cost-effective manner. 4 However, this
approach requires assurances that ADPKD is coded accurately in these data sources, and
an appreciation of the number of patients with ADPKD who had at least one hospital
encounter can be accurately identified in this way. This is because information available
from administrative databases are collected primarily to monitor healthcare use and to
assess healthcare needs, without the same rigour used in clinical research studies to assess
conditions of interest.5 Physician misdiagnoses, incomplete documentation in medical
records, or errors by personnel who assign codes to each hospital encounter can all
potentially lead to misclassification of a condition. 6
We conducted a comprehensive search of bibliographic databases (search last updated to
December 2015), and found only a single study in the United States that described any
aspect of the accuracy of healthcare administrative database codes for ADPKD.
Blanchette and colleagues assessed the positive predictive value of a single International
Classification of Disease, 9th revision (ICD-9) code for any kind of polycystic kidney
disease (PKD) (753.12), where a medical chart review was used to ascertain whether
PKD was truly present or not.7 In this study, the clinical criterion used to define PKD in
the medical chart was not defined. In addition, despite knowing that the population
comprised of members of commercial health plans, it was not clear whether the charts
were from an outpatient and/or hospital-based setting.7 In 132 patients, the positive
predictive value of ICD-9 code 753.12 was 95%, indicating that most patients identified
with the ICD-9 code 753.12 had ADPKD according to their medical chart review. 7
We undertook two studies. Frist, we determined if different coding algorithms containing
International Classification of Disease, 10th revision (ICD-10) codes for ADPKD
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assigned during hospital encounters (emergency room visits or hospital admissions) can
be used to identify adult patients who meet the clinical criteria for ADPKD in the
province of Ontario, Canada. This was done to estimate the positive predictive value of
various coding algorithms considering the manual chart review and a rigorous definition
of ADPKD as the reference standard. Second, we used Ontario-wide healthcare databases
to assess the number of patients identified with different sets of ADPKD codes to
determine the proportion of the general public identified with ADPKD with each of the
coding algorithms (where an expected prevalence is 0.1 to 0.25%).

5.2 METHODS
5.2.1

Study design

We completed two studies to evaluate the performance of ICD-10 coding algorithms for
the identification of ADPKD patients and to understand the frequency of ICD-10 coding
algorithms. For our first study, we manually reviewed inpatient and outpatient medical
records (including both electronic medical records and paper charts) to assess the positive
predictive values of different ICD-10 coding algorithms for ADPKD. For our second
study, we conducted analyses of large healthcare databases housed at ICES, to understand
the frequency of ICD-10 coding algorithm use in the province of Ontario, Canada.8

5.2.2

Ethics approval and consent to participate

The institutional review board at Western University, London, Ontario, Canada approved
the chart abstraction study, and the one at Sunnybrook Health Sciences Centre, Toronto,
Ontario, Canada approved the second study using the healthcare administrative data
housed at the ICES. The institutional review boards waived the need for patient consent.
The Institute for Clinical Evaluative Sciences is a designated prescribed entity under
Section 45 of the Personal Health Information Protection Act (PHIPA), and as such the
need for patient consent is waived (as confirmed by the institutional review board that
approved this study).
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5.2.3

Data sources and database algorithms

The World Health Organization (WHO) developed the ICD-10 codes collaboratively with
ten international centres to promote comparability in mortality data across countries. In
Canada, the National Implementation Advisory Committee (established by the Canadian
Institute for Health Information, CIHI) modified and enhanced some of the ICD-10 codes
developed by WHO to better accommodate Canadians’ administrative, epidemiological,
and public health research needs prior to implementation. ICD-10-CA is the Canadian
modification of the ICD-10 codes. The ICD-10 codes related to ADPKD used in Canada
were not modified and are identical to those developed by the WHO.
ICD-10 and ICD-10-CA codes are used in Canadian administrative databases such as the
CIHI Discharge Abstract Database (CIHI-DAD) and the CIHI National Ambulatory Care
Reporting System (CIHI-NACRS). The CIHI-DAD houses administrative, demographic
and clinical information on hospital discharge and day surgery procedures, and the CIHINACRS database contains information on all emergency room visits. 12 Neither CIHIDAD nor CIHI-NACRS houses information on outpatient physician office visits. Trained
personnel at each hospital in Ontario review the medical charts of all patients with
healthcare encounters. Based on rules and guidelines provided by CIHI, these trained
personnel code all diagnoses and procedures using the ICD-10 coding system, and then
enter these codes into the CIHI-DAD and CIHI-NACRS databases.6 These trained
personnel only consider physician-recorded diagnoses in a patient’s medical chart when
assigning the codes, and do not review or interpret diagnostic imaging reports, laboratory
values, family history, or signs and symptoms of ADPKD.
In our two studies, we compiled a list of relevant ICD-10 codes for ADPKD (Table 5-1)
and developed nine unique algorithms using two databases (CIHI-DAD and CIHINACRS) and two ICD-10 codes, Q61.2 (polycystic kidney disease, autosomal dominant)
and Q61.3 (polycystic kidney disease, unspecified) (Table 5-2).
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Table 5-1. International classification of diseases, 10th revision codes relevant for
autosomal dominant polycystic kidney disease.
Database
CIHI-DAD
CIHI-DAD
CIHI-NACRS
CIHI-NACRS

Code
Q61.3
Q61.2
Q61.3
Q61.2

Description
polycystic kidney disease - unspecified
polycystic kidney disease - autosomal dominant
polycystic kidney disease - unspecified
polycystic kidney disease - autosomal dominant

Abbreviations: Canadian Institute of Health Information Discharge Abstract Database, CIHI-DAD;
Canadian Institute of Health Information National Ambulatory Care Reporting System, CIHI-NACRS

Table 5-2. Combination of International Classification of Diseases, 10th revision of the
nine administrative coding algorithms evaluated to identify patients with autosomal
dominant polycystic kidney disease.
Administrative Code Algorithms
1
2
3
4
5
6
7
8
9

Q61.2 in CIHI-DAD
Q61.3 in CIHI-DAD
Q61.2 in CIHI-NACRS
Q61.3 in CIHI-NACRS
Q6.2 or Q61.3 in CIHI-DAD
Q61.2 or Q61.3 in CIHI-NACRS
Q61.2 in either CIHI-DAD or CIHI-NACRS
Q61.3 in either CIHI-DAD or CIHI-NACRS
Q61.2 or Q61.3 in either CIHI-DAD or CIHI-NACRS

Abbreviations: Canadian Institute of Health Information Discharge Abstract Database, CIHI-DAD;
Canadian Institute of Health Information National Ambulatory Care Reporting System, CIHI-NACRS

5.3 METHODS SPECIFIC TO CHART ABSTRACTION
STUDY
5.3.1

Patient selection

For the chart abstraction study, we compiled a list of adult patients (age > 18 years) with
emergency department visits and/or hospital admissions (CIHI-DAD or CIHI-NACRS)
and the presence of one or more ICD-10 code Q61.2, Q61.3 between April 1st, 2002 and
March 31st, 2014 at two major teaching hospitals in London, Ontario (Victoria Hospital
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and University Hospital). ICD-10 codes are only available after April 1st, 2002, and thus
defined our accrual start date. The main purpose of this study was to determine whether
we could confidently use the ICD-10 codes related to ADPKD to identify patients with
ADPKD using ICES data. The data was only available until March 31st, 2014 at the time
the study was conducted, and thus defined our accrual end date. We assigned a unique
Subject identification number (ID) to each patient, and saved a list of all patients’
medical record numbers and Subject IDs in a password protected Microsoft Excel file,
which was stored on a secure hospital network, as prescribed by our REB. If a patient had
more than one code or more than one hospital and/or ambulatory care encounter, we
assigned the unique subject ID to the first hospital or ambulatory care encounter because
that was the first time the individual was recognized as affected with ADPKD during our
study period. We included all patients with an ICD-10 code Q61.2. For the observations
with ICD-10 code Q61.3, we stratified all patients by database (CIHI-DAD or NACRS)
and by year of hospital encounter, and randomly sampled within strata to review the
medical records of a total of 201 patients from a list of 305 patient charts eligible for
review.

5.3.2

Data collection

We manually reviewed the medical records of the 201 patients. We abstracted
information on physician report of ADPKD, family history of ADPKD, indication of
ADPKD from surgical pathology reports or autopsy reports, and information from
imaging reports (reason for examination, number of cysts in each kidney, and dimensions
of each kidney). Certain imaging reports did not specify the exact number of cysts. In
these instances, we interpreted “multiple cysts bilaterally” as at least three cysts in each
of the two kidneys, and “innumerable cysts bilaterally” as at least four cysts in each of
the two kidneys after consultation with an experienced nephrologist and radiologist.
Sensitivity analysis were performed to determine whether interpreting “multiple cysts
bilaterally” as at least four cysts in each kidney meaningfully changed the results. If
information was missing in an electronic medical record, we obtained the paper in-patient
chart. If information was still missing after reviewing the paper chart, we reviewed the
nephrology outpatient chart when available. Subsequently, a senior radiology resident
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(M.R.) retrieved and reviewed available diagnostic images for patients with missing or
ambiguous information. We recorded all abstracted information onto a detailed data
abstraction form (Table 5-3).
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Table 5-3. Data abstraction form to collect relevant clinical information required to elucidate whether patients have ADPKD or not
according to the reference standard.

Subject
ID

Type of
Polycystic
Kidney Disease
Diagnosis

ICD-10
Code

Current
Age

Weight

Height

Death
Summary

Family

Renal Family

Indication of

Specify how

Physician

Report

Physician

Physician

PKD

it is indicated

Diagnosis

Date

Sex

Last
Serum
Creatinine
Value

Date of
Physician
Diagnosis

Date of
Last
Serum
Creatinine
Value

Imaging

Year of

Modality

Birth
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Type of
Age at

Date of

U/S

Imaging

U/S
imaging
(e.g. renal

Reason

U/S indicates

for Exam

ADPKD

Radiologist
report
ADPKD

Right Kidney
Dimension

RK

Left Kidney
Dimension

U/S)

Number
LK

of renal
cysts

Onset
Date

Mutation

Presence Document
of

that

Genetic

Family

indicates

Screening?

History

Fam Hx

Notes

detected

Met

in

diagnostic

genetic

criteria?

screening

Indication of PKD
Pathology/Autopsy
report

Date

in
pathology/autopsy
report
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Abbreviations: family history, Fam Hx; International Classification of Diseases,
10th revision, ICD-10; left kidney, LK; polycystic kidney disease, PKD; right
kidney, RK; ultrasound, U/S
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5.3.3

Clinical definition of ADPKD

In the chart abstraction study, two reviewers (V.K. and R.M.) independently determined
whether each of the 201 patients had ADPKD or not using strict criteria (described in
next paragraph). These criteria were developed in consultation with two experienced
nephrologists (A.G. and Y.P.). To determine final ADPKD status, any disagreements
between the two reviewers were resolved by consensus. Having two reviewers helped to
reduce human error and personal bias.
A reference standard is a method used to diagnose a disease with the most acceptable
accuracy and provides a standard to which new screening or diagnostic test can be
compared. Currently, physicians use the ultrasound diagnostic criteria developed by Pei
et al. to diagnose patients with ADPKD.13 This criteria requires the presence of a positive
family history of ADPKD, and evidence of the following number of cysts on a
conventional kidney ultrasound: i) at least three cysts when counting the total number of
cysts in both kidneys combined for patients 15 to 39 years old; ii) at least two cysts in
each kidney for patients 40 to 59 years old; and iii) at least four cysts in each kidney for
patients 60 years of age or older.13 We used this internationally accepted diagnostic
criteria as our primary clinical definition for ADPKD. One of the disadvantages of
retrospectively collecting data for the reference standard is that some information
required to elucidate ADPKD status based on our primary definition may have been
missing. To reduce the number of patients with indeterminant ADPKD status, we
developed less stringent criteria to identify patients with ADPKD. First, we classified
patients with a negative or indeterminate family history of ADPKD as affected if they
had innumerable cysts in both kidneys with each kidney greater than 13 cm in length.
Median (10th and 90th percentile) is 11.2 (10.1 to 12.3) cm for the left kidney and is 10.9
(9.6 to 12.2) cm for the right kidney; hence, we chose 13 cm as a cutoff point to consider
a kidney as enlarged.14 Second, we classified all patients who had a nephrectomy
performed and with a diagnosis of ADPKD in a surgical pathology or autopsy report as
affected irrespective of their ADPKD family history status. Finally, we classified patients
with missing imaging reports as affected with ADPKD if they had a family history of
ADPKD and a clear physician reported diagnosis of ADPKD. When ADPKD status was
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still ambiguous, an experienced nephrologist (A.G.) reviewed all medical records to make
a determination of whether ADPKD was present or not according to clinical criteria.
When there was insufficient information to make a determination of whether ADPKD
was present or not, patients were excluded from analysis. Sensitivity analyses were
performed to determine if classifying the excluded patients as having ADPKD, or as not
having ADPKD, meaningfully changed the results.

5.3.4

Data analysis

For the chart abstraction study, we expressed continuous variables as median and
interquartile ranges (IQR) and binary variables as percentages. We calculated the positive
predictive value for each of the nine coding algorithms and calculated their respective
95% confidence intervals using the Wilson Score method (Figure 5-1).15 Given the way
the study was designed, we only had data from patients with hospital encounter with
ICD-10 codes for ADPKD. We did not have data from patients without the codes; as a
result, we could only calculate positive predictive value and could not calculate other
measures of validity, such as sensitivity, specificity, and negative predictive value.
Reference Standard: ADPKD
defined by the clinical definition
specified in Section D.3.3

ADPKD defined ADPKD
by
Code(s)
administrative
Present
algorithm
ADPKD
Code(s)

ADPKD

Non-ADPKD

Total

TP (a)

FP (b)

TP + FP

FN (c)

TN (d)

FN+TN

TP+FN

FP+TN

N

Absent
Total

Figure 5-1. Definition of positive predictive value used for the first (chart review) study.
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Note: Positive Predictive Value = TP/(TP+FP). Positive predictive value is defined as the percentage of
patients who truly have ADPKD according to our clinical definition of ADPKD detailed in Section D.3.3
among everyone with at least one administrative code related to ADPKD. The cells highlighted in dark
grey are data that was not available.

5.4 METHODS SPECIFIC TO ICES STUDY
5.4.1

Patient Selection

We linked and analyzed CIHI-DAD and CIHI-NACRS using unique encoded identifiers
at ICES. We identified all patients over the age of 18 years who were assigned either an
ICD-10 Q61.2 code or Q61.3 code during an emergency department visit or hospital
admission between April 1st, 2002 and March 31st, 2014. As with our first study, we only
considered the first encounter for patients with more than one hospital encounter.

5.4.2

Data analysis

We estimated the number of patients with ADPKD in Ontario by calculating the
percentage of the adult Ontario population with the different coding algorithms in CIHIDAD and CIHI-NACRS described in Table D-1. We conducted all statistical analyses
using SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).

5.5 RESULTS
5.5.1

Chart abstract study sample

We obtained a list of unique patients with ICD-10 codes Q61.3 and Q61.2 using the
CIHI-DAD and CIHI-NACRS database. We then included all patients with the ICD-10
code Q61.2, and stratified random sampled patients with ICD-10 code Q61.3 to sample a
total of 201 patients. We abstracted information using electronic medical records for all
201 patients, inpatient charts for 117 patients, and nephrology outpatient charts for 52
patients. A senior radiology resident (M.R.) reviewed the images of 65 patients with
ADPKD because imaging reports did not clearly provide all the required information.
After excluding 14 patients because of insufficient information to determine ADPKD
status, our final cohort consisted of 187 patients.
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5.5.2

Chart abstraction patient characteristics

Among the 187 patients identified in our cohort through database codes, median
(interquartile) patient age was 61 (53 to 70), and 95 (50%) were men. Family history of
ADPKD was positive in 116 (62%) patients, negative in 42 (22%) patients, and was
missing or indeterminate in 29 (16%) patients. A total of 158 (85%) patients met the
clinical criteria of ADPKD. The number and percent of patients that satisfied each
ADPKD criteria is presented in Table 5-4.
Table 5-4. Number and percentage of patients that satisfied each criterion for autosomal
dominant polycystic kidney disease.
Autosomal Dominant Polycystic Kidney Disease Criteria
Current Ultrasonographic Diagnostic Criteria: Family
History and age-dependent, ultrasonographic diagnostic
criteria:
a) Ages 15 to 39: at least 3 cysts in one or both kidneys
b) Ages 40 to 59: at least 2 cysts in each kidney
c) Ages 60 and over: at least 4 cysts in each kidney
No family history, both kidneys > 13 cm and age-dependent
minimal number of cysts:
a) Ages 15 to 39: at least 3 cysts in one or both kidneys
b) Ages 40 to 59: at least 2 cysts in each kidney
c) Ages 60 and over: at least 4 cysts in each kidney
Indication of ADPKD in surgical pathology report or
autopsy report
Physician report of ADPKD and family history of ADPKD
or patient has ADPKD based on nephrologist adjudication
Did not meet any criteria
Excluded from the study given a lack of information to make
a determination of whether ADPKD was present or not

Number of Patients
(%)

108 (53.73)

37 (18.41)

7 (3.48)
6 (2.98)
29 (14.43)
14 (6.97)

*Note: These data were obtained from chart review. In accordance with privacy regulations, cell sizes
less than or equal to five cannot be reported.
Abbreviations: autosomal dominant polycystic kidney disease, ADPKD
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5.5.3

Coding algorithm positive predictive value and frequency

The positive predictive values, their respective 95% confidence intervals (from our chart
abstraction study), and the number of Ontarians with the 9 different coding algorithms
(from our ICES study) are presented in Table 5-5. The presence of either ICD-10 code
Q61.2 or Q61.3 in either the CIHI-DAD or CIHI-NACRS database had a positive
predictive value of 85% (95% CI 79% to 89%) and identified 2981 adults in Ontario
(0.02% of the Ontario adult population). The presence of ICD-10 code Q61.2 in either the
CIHI-DAD or CIHI-NACRS database had a positive predictive value of 97% (95% CI
86% to 100%) and identified 394 adults in Ontario (0.003% of the Ontario adult
population). Sensitivity analyses did not meaningfully change the results.
Table 5-5. Positive predictive values and the number of Ontarians identified by each
administrative database coding algorithm.

Code Algorithm
CIHI-DAD Q61.2
CIHI-DAD Q61.3
CIHI-NACRS Q61.2
CIHI-NACRS Q61.3
CIHI-DAD Q61.2 or Q61.3
CIHI-NACRS Q61.2 or
Q61.3
Q61.2 in either CIHI-DAD
or CIHI NACRS
Q61.3 in either CIHI-DAD
or CIHI-NACRS
Q61.2 or Q61.3 in either
CIHI-DAD or CIHI-NACRS

96.97% [84.68, 99.46]
80.00% [71.35, 86.53]
100.00% [43.85, 100.00]
84.78% [71.78, 92.43]
84.06% [77.04, 89.23]

Estimated
# of
Ontarians
*
342
1901
52
686
2243

Percentage of
adult Ontario
population*
(%)
0.0028
0.0154
0.0004
0.0056
0.0182

85.71% [73.33, 92.90]

738

0.0060

97.22% [85.83, 99.51]

394

0.0032

81.46% [74.51, 86.85]

2587

0.0210

84.49% [78.62, 88.98]

2981

0.0242

Positive Predictive
Value [95%CI]

Abbreviations: Canadian Institute for Health Information Discharge Abstract Database, CIHI-DAD;
National Ambulatory Care Reporting System, NACRS

5.6 DISCUSSION
Although past studies have assessed the positive predictive value of different ICD-10
codes or coding algorithms for other diseases or conditions, there is a lack of information
on the positive predictive value of ICD-10 coding algorithms for ADPKD. The positive
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predictive value is reported as a number from 0 to 100%, where a high value indicates
that individuals who are identified with the coding algorithm truly have the condition.
We manually reviewed a random sample of medical charts from two tertiary care
hospitals in London, Ontario where the medical coders in routine care had assigned a
code for polycystic kidney disease. Using rigorous clinical criteria, we then determined
whether ADPKD was present or not. We found that the presence of the ICD-10 code
Q61.2 in hospital admissions or emergency visits had an excellent positive predictive
value of 97% (95% CI: 86% to 100%). The positive predictive value of the presence of
either the ICD-10 code Q61.2 or Q61.3 in either hospital admissions or emergency visit
was also good at 85% (95% CI: 79% to 89%). Therefore, our study shows that
administrative coding algorithms for ADPKD successfully identifies patients who truly
have ADPKD, which is consistent with the findings from a study conducted by
Blanchette and colleagues.7 These values in the ADPKD setting are similar or better than
the positive predictive value of ICD-10 codes or ICD-10 coding algorithms for shock
(86%; 95% CI: 80% to 91%), infant respiratory distress syndrome (81%; 95% CI: 73% to
80%), and heart failure (84%; 95% CI: 81% to 87%).16–18 While our study has several
strengths, results of this study must be interpreted with caution given the limitations.
First, since we only reviewed the medical charts of patients with assigned ICD-10
database codes for ADPKD, we cannot estimate other measures of validity such as
negative predictive value, sensitivity, and specificity. We expect the sensitivity of the
ICD-10 codes for ADPKD to be low. Since the prevalence of ADPKD is estimated to be
1 in 1000 to 1 in 400, we would expect 13,000 to 32,500 Ontarians to be affected with
ADPKD 1. However, the expansive coding algorithm (any of the two ICD-10 codes in
CIHI-DAD or CIHI-NACRS) only identified approximately 3000 patients. Thus,
although the two ICD-10 codes appear to have a high positive predictive value, it is
possible only 9% to 23% of the patients with ADPKD in the province were captured with
the algorithm.
Second, by its design, we would expect the ICD-10 coding algorithm would
preferentially identify a spectrum of ADPKD patients with moderate to advanced disease
requiring hospital encounters, rather than ADPKD patients managed in the community
that did not have hospital encounters. The code sets may also identify some mild cases,
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such as patients with ADPKD admitted for uncomplicated pregnancy. Therefore, these
algorithms should only be used to assemble and study cohorts of adult patients with
ADPKD and hospital encounters, rather than all patients in the province with ADPKD.
Unfortunately, there are no relevant codes that can be used to identify the presence of
ADPKD in the Ontario outpatient billing system.
Third, we reviewed medical charts from two hospitals at the London Health Sciences
Centre. While coding practices are standardized across hospitals, any differences in
coding between these two hospitals and other hospitals would influence generalizability
of our study results.
Fourth, there were no reports from genetic testing in any of the patient charts, which
could have helped further ascertain the presence of ADPKD in cases when a family
history is absent or not available.19
Fifth, we are not sure that all imaging or other ancillary information for a given patient
was found. For example, a patient may have had an ultrasound performed in an outpatient
lab, and the nephrologist may not have a record of it. Therefore, the positive predictive
value may be underestimated. Additionally, this also may explain why the percentage of
our cohort is lower than the estimates reported in the published literature.
Finally, our adjudicators were aware that all reviewed records had ICD-10 codes assigned
for polycystic kidney disease in the healthcare database records. While this may have
influenced their adjudication of the records, we minimized the risk of information bias
through the use of pre-defined diagnostic criteria for ADPKD, where two reviewers
independently adjudicated each case.

5.7 CONCLUSION
In conclusion, the positive predictive value of the various coding algorithms for ADPKD
is moderately high. These codes can be used to assemble and study cohorts of adult
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patients with ADPKD and hospital encounters, but are expected to miss the majority of
the milder forms of ADPKD where patients are healthy without hospital encounters.

5.8 ADDENDUM
5.8.1

Rationale for sampling 201 patients

At the time the study was conducted, we sampled 201 patients from 305 eligible charts
for review. This was done for convenience. If we were to redo the study, we would have
reviewed the charts of all 305 charts. The positive predictive value (95% CI) of the
algorithm Q61.2 and Q61.3 using both databases (CIHI-DAD and NACRS) was 84.49%
(78.62 to 88.98). Assuming the point estimate would remain unchanged, the
corresponding number would be 84.49% (79.98 to 88.13) with 305 patients charts. In
other words, reviewing all 305 charts would have not have materially improved the
precision of the estimate.

5.8.2

Recommended algorithm for future studies

Although the Q61.2 code and the emergency department visit database has a perfect
positive predictive value, I used a combination of the Q61.2 and Q61.3 codes and both
databases (CIHI-DAD and NACRS) to assemble a robust ADPKD cohort for my cohort
studies (Chapter 6 and 7). The latter coding algorithm identifies the most patients
compared to the other eight coding algorithms examined and still has a positive
predictive value of 84%; therefore, more patients would be identified and the internal
validity of the study due to the exposure definition would not be compromised.
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6.1 INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the most commonly
inherited kidney disease and is characterized by focal cyst development. 1 In ADPKD,
cysts develop in the kidney that increase in size and number over time. 2 This causes
structural deformation of the kidney, which, along with metabolic abnormalities, is
believed to predispose patients with ADPKD to upper urinary tract stones.3 Specifically,
the structural damage to the kidney results in more urinary stasis, which favors urinary
crystals to form and stagnate.4,5 Prior cross-sectional studies suggest upper urinary tract
stones are more prevalent in patients with ADPKD compared to unaffected family
members. However, none of the between-group comparisons in prior studies were
statistically different.6–11 Additionally, no prior study adjusted for important covariates,
or longitudinally compared the risk of stones in patients with ADPKD to patients without
ADPKD.6–11 Finally, most inferences about the difference in stone risk in patients with
ADPKD were indirect comparisons with the general population.
Upper urinary tract stones in patients with ADPKD are associated with significant pain
and morbidity.12 In the chronic kidney disease population, patients with stones are at
higher risk of end-stage kidney disease compared to patients without stones, with the
suggestion that this is also true in patients with ADPKD. 13,14 For these reasons, stones
should be optimally managed in patients with ADPKD. However, the structural kidney
deformation in ADPKD may make optimal stone management challenging. There is
limited evidence on how stones are currently managed in patients with ADPKD and we
are unsure how frequently patients with ADPKD receive stone interventions such as
shockwave lithotripsy (SWL), ureteroscopy, and percutaneous nephrolithotomy (PCNL).
In this study, we used large healthcare databases to describe the rate of hospital
encounters (emergency department visits or hospital admissions) with upper urinary tract
stones in patients with ADPKD, and the rate and type of upper urinary tract stone
interventions. To put these rates into context we studied a group of patients without
ADPKD. We also assessed whether risk factors for hospital encounters with upper
urinary tract stones and stone interventions were similar in patients with and without
ADPKD.
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6.2 MATERIALS AND METHODS
6.2.1

Designs and setting

The prevalence of ADPKD is between 1 in 1000 and 1 in 400.15–17 In chapter 2 of this
study, we showed that the prevalence of stone ranges between 3% and 59% 8,10,11,18–61, and
the prevalence of stone intervention ranges between 1% and 8% 19,30,41,43,48,54,57. Since the
prevalence of ADPKD is lower than the prevalence of upper urinary tract stones and
stone intervention, a retrospective cohort study would allow us to accrue an adequate
number of patients with ADPKD and allow enough events to accumulate for a wellpowered study. As a result, we conducted a retrospective cohort study using Ontario’s
healthcare administrative databases held at ICES (a not-for-profit research institute).
Healthcare services in Ontario are funded through the Ontario Health Insurance Plan
(OHIP) program; with the exception of outpatient medications, which are only funded for
segments of the population including those 65 years and older. Healthcare encounters are
recorded in administrative databases, which are linked using unique encoded identifiers
and analyzed at ICES. The use of ICES data in this project was authorized under section
45 of Ontario’s Personal Health Information Protection Act, and did not require review
by a Research Ethics Board. No informed consent from patients was required. We
reported this study following guidelines for observational studies conducted using
routinely-collected data.62,63

6.2.2

Sample size calculations

The reported life time prevalence of upper urinary tract stone varies between 1% and
20%.64 We used the cox proportional hazard model sample size formula, to determine the
minimum total sample size that would be required to have a statistical power of 80% to
detect a clinically significant difference between the two groups at a significance level of
5%.65 Since the effect size is unknown, we determined the sample size by using common
effect sizes (Hazard Ratio ranging from 1.5 to 5.0). We also explored a range of values
for the baseline prevalence of upper urinary tract stones (1, 5, 10, 15 and 20%). Sample
size is inversely proportional to prevalence of event, and to be conservative in our sample
size calculation, we assumed the overall probability of event occurring during follow-up
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is 1%.We would need a total sample size of 19,097 to detect even a Hazard Ratio of 1.5
at a power of 80% and α=0.05 if the prevalence of event is 1% (Figure 6-1). Since our
total sample size exceeds 19,097, our study was well-powered for this and other potential
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Figure 6-1. Total sample size required to detect a clinically significant difference with an
effect size (Hazard Ratio) varying between 1.5 to 5.0 when the prevalence of upper
urinary tract stone is 1%, 5%, 10%, 15%, and 20%.

6.2.3

Data sources

We linked seven databases to create the study cohort, describe baseline characteristics,
and ascertain outcomes. The Canadian Institute for Health Information Discharge
Abstract Database, Same Day Surgery, and the National Ambulatory Care Reporting
System (NACRS) databases contain diagnostic and clinical information on hospital
admissions, same day surgery, and all emergency department visits in Ontario,
respectively. The OHIP database captures physician-billing claims for all hospital and
outpatient services for patients covered in Ontario. The Registered Persons Database
(RPDB) includes reliable demographic information and vital statistics. The ICES
Physician Database contains physician demographic and practice information. The
Canadian Organ Replacement Register (CORR) contains information on all patients
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receiving chronic dialysis and kidney transplants. A detailed description of each of the
Ontario healthcare administrative databases is described in Table A-1. All variables were
complete in this study except for average neighbourhood income (<1% missing) and
urban or rural residency (<1% missing). For patients with missing average
neighbourhood income quintile and urban or rural residency status, we assigned an
average neighbourhood income quintile value of 3 and urban residency, respectively.

6.2.4

Population and timeline

Our study cohort included Ontarians who had a hospital encounter with ADPKD (i.e.
admitted to the emergency department or hospital), identified using ICD-10 codes
between April 1st, 2002 and March 31st, 2016. We used the coding algorithm with the
highest positive predictive value (ICD-10 codes Q612 and Q613 validated details in
Chapter 3) to ensure that the internal validity of our study was not compromised.66 The
positive predictive value (95% confidence interval [CI]) of the coding algorithm that we
used was 84.1% (77.0% to 89.2%). A follow-up validation study conducted by our team
also showed that this coding algorithm differentiates patients with ADPKD from patients
with very similar conditions (specificity=86.2%; 95% CI 75.7% to 92.5%), but it only
identified a small subset of the broader ADPKD population (sensitivity=33.7%; 95% CI
30.1% to 37.7%). ICD-10 codes are only available after April 1st, 2002, and thus defined
our accrual start date. An accrual end date of March 31st, 2016 ensures that each patient
had the potential for at least one year of follow-up (March 31st, 2017 was the date of last
available data at the time that the study was conducted). We excluded the following
patients:
(1) Patients aged 18 and under. Autosomal recessive polycystic kidney disease
(ARPKD) displays very similar clinical characteristics as ADPKD; both patients
have multiple cysts in their kidneys. However, ARPKD primarily manifests
during birth or childhood, while ADPKD, although is a congenital condition,
primarily manifests during adulthood. By excluding patients under 18 years of
age, we can exclude patients with ARPKD who may have been misclassified as
ADPKD.
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(2) Patients with missing demographic or linkage data, or those who died on or before
the cohort entry date for data cleaning reasons.
(3) Non-Ontario residents who received care from a healthcare facility in Ontario to
limit our study population to Ontarians. We would not have follow-up data on
Non-Ontario residents who received care from a healthcare facility in Ontario.
(4) Patients with a history of end-stage kidney disease, as many have no urine output
making the presence of upper urinary tract stones less relevant.
Patients with prior upper urinary tract stones and treatments for upper urinary tract stones
were eligible for study participation; this was treated as an important baseline
characteristic that was included in the propensity score model and was also considered in
subgroup analysis. We selected the first hospital encounter during the accrual period for
patients with more than one hospital encounter.
We compared the rate of upper urinary tract stones and rate of stone intervention in
patients with ADPKD to patients without ADPKD with otherwise similar baseline health
to provide context. Our study population would primarily consist of patients with more
advanced ADPKD with few milder cases of ADPKD since our study included patients
who were admitted to the emergency department or who were admitted to the hospital
with ADPKD. To ensure our control group was as similar as possible to our study
population, we included patients with at least one hospital admission or emergency
department visit for any reason between April 1st, 2002 and March 31st, 2016 who were
not in the ADPKD cohort. For all patients with more than one hospital encounter, we
selected the first encounter. We applied the same exclusion criteria as we did for the
ADPKD cohort. In addition, we excluded patients with OHIP diagnosis codes for other
cystic diseases (OHIP diagnosis code 593) and congenital anomalies of the urinary
system (OHIP diagnosis code 753), as these codes can occasionally capture patients with
ADPKD. We then randomly selected 50,000 controls (versus the entire Ontario
population with hospital encounter) for reasons of computing efficiency.
The date of discharge for patients identified with hospital admission records and the date
of registration for patients identified from the emergency department records served as
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the date of cohort entry. We followed each patient until March 31st, 2017 (administrative
censoring), and censored the observational period at time of death or emigration from the
province.

6.2.5

Outcomes

The two outcomes were (a) time to first hospital encounter with upper urinary tract stone;
and (b) time to first stone intervention, which was a composite outcome of the three
common stone interventions: shock wave lithotripsy (SWL), ureteroscopy, and
percutaneous nephrolithotomy (PCNL). The administrative codes used to identify
outcomes are detailed in Table 6-1. In a validation study, codes similar to the ones we
used to identify stones had a positive predictive value of 96% compared to chart
review.67,68 We identified stone intervention events using OHIP fee codes and Canadian
Classification of Health Intervention (CCI) codes. Although the OHIP fee codes for stone
intervention have not been formally validated, we expect these codes to have excellent
validity similar to other fee for service codes.69 Further, the same coding algorithm used
to identify stone interventions has been used in past studies. 70,71 Any stone-related
database codes that appeared within 90 days of each other were considered the same
event, which has been done in past ICES studies.70 For stone intervention, we did not
restrict to individuals with hospital encounters for upper urinary tract stones (outcome a),
because we wanted to capture stone interventions in both the inpatient and outpatient
settings.
Table 6-1. Databases and coding definitions for restriction criteria, baseline
characteristics and outcome measurements.
Variable

Database & Administrative Codes

Study Population Inclusion Criteria
ADPKD

CIHI-DAD & NACRS ICD-10 codes: Q612, Q613

Control Population Inclusion Criteria
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Ontarians with hospital
encounter without
ADPKD

CIHI-DAD & NACRS

Exclusion Criteria
Chronic dialysis

CIHI-DAD CCP codes: 5195, 6698
CIHI-DAD CCI codes: 1PZ21
OHIP Fee: R849, G323, G325, G326, G860, G862, G865,
G863, G866, G330, G331, G333, G861, G082, G083,
G085, G090, G091, G092, G093, G094, G095, G096,
G294, G295, G864, H540, H740
CORR
RECIPIENT_TREATMENT dataset: select all chronic
dialysis patients using [Treatment_Code not equal to 171,
181] in the prior one year.

Kidney transplantation

CIHI-DAD CCP codes: 6759
CIHI –DAD CCI codes: 1PC85
OHIP fee codes: S435, S434

CORR
RECIPIENT_TREATMENT dataset: select all renal
transplant patients using [Treatment_Code equal to 171]
and [Transplanted_Organ_Type_Code (1-3) equal to 10,
11, 12, 18, 19] in the prior five year

Other cystic diseases and
congenital anomalies of
the urinary system (only
for control group

CIHI-DAD & NACRS ICD-9 codes: 7531
CIHI-DAD & NACRS ICD-10 codes: Q611, Q612,
Q613
OHIP Dx codes: 753, 593

Outcomes
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Urological Intervention

CIHI-DAD, NACRS, & OHIP: composite of shockwave
lithotripsy, ureteroscopy, and percutaneous
nephrolithotomy (refer to codes below)

Shockwave lithotripsy

CIHI-DAD & NACRS CCI: 1PE59KQAP,
1PE59KQAQ, 1PE59KQAR, 1PG59KQAP,
1PG59KQAQ, 1PG59KQAR

OHIP Fee Codes: Z630

Ureteroscopy

CIHI-DAD & NACRS CCI: 1PE57BAAM,
1PE57BAGX, 1PE59BAAG, 1PE59BAAS, 1PE59BAAT,
1PE59BAAZ, 1PG57BAAM, 1PG57BAGX,
1PG59BAAG, 1PG59BAAS, 1PG59BAAT,
1PG59BAAZ, 1PG59BAGX, 1PE59BAAS, 1PE59BAAT,
1PE59BAAZ

OHIP Fee Codes: Z628 AND (E760 or E761 or Z627)
Percutaneous
Nephrolithotomy

CIHI-DAD & NACRS CCI: 1PE57DTAG,
1PE57DTAM, 1PE57DTAS, 1PE57DTAZ, 1PE57DTBD,
1PE57DTGX

OHIP Fee Codes: Z624 AND Z627
Upper urinary tract stones CIHI-DAD & NACRS: N20, N132
Baseline Characteristics
Age

RPDB

Sex

RPDB

Rural location

RPDB

Neighbourhood Income

RPDB

Primary care physician
visits in the previous one
year

IPDB: Mainspeciality= GP/FP
OHIP
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Emergency department
visit in the previous one
year

NACRS

Urology clinic visit in the
previous one year

IPDB: Mainspeciality= Urology
OHIP

Abdominal imaging

OHIP Fee codes: J135, J128, X100, X101, X197, X409,
X410, X126, X451, X455

Urinary tract obstruction

CIHI-DAD & NACRS ICD-9 codes: 591, 5934, 5996
CIHI-DAD & NACRS ICD-10 codes: N130, N131,
N132, N133, N138
OHIP Dx codes: 591

Urinary tract infection

CIHI-DAD & NACRS ICD-9 codes: 5901, '5900, 5908',
5902, 5909, 5950, 5958, '5959, 5970, 5990, 6016, 6011,
6012, 6013, 6040, '6049
CIHI-DAD & NACRS ICD-10 codes: N10, 'N11, 'N12,
N136, 'N151, N159, N160, N300, N308, N309, N340,
N390, N410, N411, N412, N413, N431, N45, T835

Primary
hyperparathyroidism

CIHI-DAD & NACRS ICD-9 codes: 2520
CIHI-DAD & NACRS ICD-10 codes: E210, E211, E213,
E214, E215
OHIP Dx: 252
OHIP Fee: S792, S795, S796, Z772
CCP: 197, 1971, 1996, 1997
CCI: 1FV59HAX7, 1FV83NZ, 1FV83NZAG, 1FV83PZ,
1FV83PZAG, 1FV87NZ, 1FV87NZAG, 1FV87PZ,
1FV87PZAG, 1FV89NZ, 1FV89NZAG, 1FV89PZ,
1FV89PZAG

Gout

CIHI-DAD & NACRS ICD-9 codes: 274
CIHI-DAD & NACRS ICD-10 codes: M10
OHIP Dx codes: 274
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Obesity

CIHI-DAD & NACRS ICD-9 codes: 2780
CIHI-DAD & NACRS ICD-10 codes: E65, E660, E661,
E662, E668, E669
OHIP Dx codes: 278

Diabetes Mellitus

CIHI-DAD & NACRS ICD-9 codes: 250
CIHI-DAD & NACRS ICD-10 codes: E10, E11, E13,
E14
OHIP Dx codes: 250
OHIP Fee codes: K045, K046, K029, K030, Q040

Hypertension

CIHI-DAD & NACRS ICD-9 codes: 401, 402, 403, 404,
405
CIHI-DAD & NACRS ICD-10 codes: I10, I11, I12, I13,
I15
OHIP Dx codes: 401, 402, 403

Osteoporosis

CIHI-DAD & NACRS ICD-9 codes: 7330
CIHI-DAD & NACRS ICD-10 codes: M80, M81, M82
OHIP Dx codes: 733

Prior hospital encounter
or intervention for stone

CIHI-DAD, NACRS, & OHIP: composite of prior
hospital encounter for stone and prior intervention for
stone removal

Prior hospital encounter
for stone

CIHI-DAD & NACRS ICD-9 codes: 592,5920, 5921,
5929
CIHI-DAD & NACRS ICD-10 codes: N20, N132
OHIP Dx codes: 592

Prior intervention for
stone removal

CIHI-DAD & NACRS CCI codes: 1PE59KQAP,
1PE59KQAQ, 1PE59KQAR, 1PG59KQAP,
1PG59KQAQ, 1PG59KQAR, 1PE57BAAM,
1PE57BAGX, 1PE59BAAG, 1PE59BAAS, 1PE59BAAT,
1PE59BAAZ, 1PG57BAAM, 1PG57BAGX,
1PG59BAAG, 1PG59BAAS, 1PG59BAAT,
1PG59BAAZ, 1PG59BAGX, 1PE59BAAS, 1PE59BAAT,

142

1PE59BAAZ, 1PE57DTAG, 1PE57DTAM, 1PE57DTAS,
1PE57DTAZ, 1PE57DTBD, 1PE57DTGX

OHIP Fee codes: Z630 OR [Z628 AND (E760 or E761 or
Z627)] OR [Z624 AND Z627]

Inflammatory bowel
disease

CIHI-DAD & NACRS ICD-9 codes: 5550, 5551, 5552,
5559, 556
CIHI-DAD & NACRS ICD-10 codes: K50, K51
OHIP Dx: 555, 556

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CCI, Canadian Classification of
Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures;
CIHI-DAD Canadian Institute for Health Information Discharge Abstract Database; CORR, Canadian
Organ Replacement Register; ICD-9, International Classifications of Diseases, 9th revision codes; ICD-10,
International Classification of Diseases, 10th revision codes; IPDB, ICES Physician Database; NACRS,
National Ambulatory Care Reporting System; ODB, Ontario Drug Benefit; OHIP Dx, Ontario Health
Insurance Plan diagnosis codes; OHIP Fee, Ontario Health Insurance Plan fee for service codes; OLIS,
Ontario Laboratories Information System; RPDB, Registered Persons Database

6.2.6

Data analysis

In traditional regression analysis, there must be ten events for every covariate adjusted. 72
Since we anticipated the number of covariates to outnumber the number of events that
may be observed, we eliminated the difference in baseline distribution between the two
group using propensity scores. There are four common propensity score methods to
account for confounding: 1) propensity score matching; 2) inverse probability treatment
weighting (IPTW) based on propensity scores; 3) adjusting for propensity score in the
model; and 4) stratifying on propensity score. Propensity score matching eliminates a lot
more of the systematic differences between the study and control group compared to
stratifying on propensity score, and adjusting for propensity score as a covariate in a
regression model.73 Prior studies have shown that propensity score matching eliminates
just as much, or modestly more, systematic differences between the two groups compared
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to IPTW based on propensity.73 For these reasons, we first attempted propensity score
matching to ensure that the two groups had comparable baseline health. We matched each
patient with ADPKD on age (± two years), sex, start date of follow-up (± one years), and
log propensity score (± 0.2 standard deviation) a control to select patients with similar
indicators for baseline health, and discarded all unmatched patients. However, more than
20% of our ADPKD population was not matched to any control because our control
population was very different from our ADPKD cohort; we lost more than 20% of our
ADPKD population. As such, propensity score matching was not feasible given the loss
in our ADPKD population. As a result, we used IPTW based on propensity scores and
used average treatment effect in the treated weights to ensure the distribution of
indicators for baseline health were similar between controls and patients with ADPKD.
IPTW based on propensity scores involves assigning a weight of one to everyone in the
ADPKD group, and a weight of [propensity score/ (1-propensity score)] to the control
group (i.e. the inverse of the propensity score) so that the distribution of baseline
characteristics in the control group is similar to that in the ADPKD group. 74 This method
results in a pseudo-control population that has a similar distribution of measured baseline
characteristics as the ADPKD population while retaining all the individuals in the
original cohort. In the context of the study, propensity score is the likelihood that a
patient would be diagnosed with ADPKD conditional on their baseline characteristics.
We calculated propensity scores using logistic regression with ADPKD as the dependent
variable, and the following 20 covariates as the independent variables:
(1) Factors associated with stone and stone intervention: There are four sets of
variables that can be included in a propensity score model: a) all measured
baseline covariates; b) covariates associated with exposure; c) covariates
associated with outcome only (potential confounders); and d) covariates
associated with both the outcome and exposure.73 Adjusting for potential and/or
true confounders results in a more precise estimate. 73 We included and adjusted
for potential confounders instead of true confounders as independent variables in
our propensity score model since it is difficult to identify all true confounders.
Factors associated with our outcomes and those that can be identified using our
databases at ICES included: age, sex, acute kidney injury, urinary tract
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obstructions, urinary traction, primary hyperparathyroidism, obesity, diabetes
mellitus, hypertension, osteoporosis, prior hospital encounter with upper urinary
tract stone, prior stone intervention, and inflammatory bowel disease. Studies
have shown that lower education level, increased distance from the referral center,
income, and urologist density was associated with stone burden.75 As a result, we
also adjusted for average neighbourhood income quintile, rural vs. urban
residency, and health service region of Ontario (Local Health Integration
Network) as proxies for these risk factors.
(2) Abdominal imaging in the prior five years: If one group undergoes abdominal
imaging more often than the other group, then stones will be more likely be
incidentally found in the group that undergoes abdominal imaging more, and
surveillance bias would be introduced. We adjusted for abdominal imaging in the
prior five years to minimize the risk of surveillance bias.
(3) Urology clinic visits in the prior one year: People who visit the urology clinic
would be more likely to be incidentally diagnosed with urological conditions,
such as upper urinary tract stones. We adjusted for prior urology clinic visits to
minimize the surveillance bias introduced when one group visits the urology
clinic more than the other group.
(4) Primary care physician visits and emergency department visits in the prior one
year: These are indicators for propensity to seek care. Those who are likely to
seek care would be more likely to get diagnosed with any conditions; therefore,
surveillance bias would be introduced if one group visited the primary care
physician and emergency department more than the other group. We adjusted for
primary care physicians and emergency department visits as a proxy for
propensity to seek care.
When using IPTW based on propensity score, extreme weights can be problematic
because few individuals will drive results. According to Stürmer (2014), it is reasonable
to considers weights >10 as a sign of concern.76 A patient in our control group had a
weight of > 10 so we truncated the extreme weights to ensure that the weights were stable
and the extreme weights were not driving the results. We assigned every control with
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weights greater than 99th percentile as the 99th percentile weight, and every control with
weights less than the first percentile as the first percentile weight. 77
We described baseline characteristics for patients with and without ADPKD as mean and
standard deviation for continuous variables, and as frequencies and percentages for
binary or categorical variables before and after weighting. We assessed the imbalances in
baseline characteristics between the two groups using standardized differences, which are
insensitive to sample size. The standardized difference is the differences in means or
proportions divided by the pooled standard deviation, and a value of greater than 10%
suggests important imbalance.78
We plotted the cumulative incidence function for stones censoring the observational time
for death, end of follow-up, or emigration from the province. While cumulative incidence
function provides a visual representation of the rate of outcomes in both groups, it does
not quantify the extent to which the rate of outcomes is similar or different between the
two groups. In our primary analysis, we compared the rate of outcomes between the
ADPKD and control groups using a Cox proportional hazards regression model censoring
on end of follow up, death or emigration from the province given the follow-up period
was variable and patients died or emigrated from the province during the follow-up.
Competing risk is an event that hinders or alters the chance of an event of interest from
occurring.79 Not accounting for competing risk often overestimates the proportion of
patients experiencing an event.79 As a result, in an additional analysis, we treated death as
a potential competing event and calculated the subhazard ratio using Fine and Gray’s
model.80 The applicability of the Fine and Gray model when using inverse probability
exposure weighting remains unclear; therefore, we only conducted this analysis to
explore the potential impact of death as a competing event and confirm the
reproducibility of the results in our primary analysis.81 Based on the results of our
primary outcomes, accounting for death as a competing event did not alter the hazard
ratio estimates. Therefore, we did not account for death as a potential competing event for
all subsequent exploratory analyses.
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We estimated the 95% confidence intervals using bootstrapping-based methods rather
than traditional methods because traditional methods do not account for the within
subject correlation introduced by weighting; this results in biased variance estimate and
95% confidence intervals with inaccurate coverage rates. 82 Past studies show that
bootstrapping-based approach was the best method to estimate 95% confidence intervals
with approximately accurate coverage rate.82 We estimated the absolute between-group
difference in the rate of our outcomes by fitting a Poisson model using the PROC
NLMIXED procedure in SAS.
In exploratory subgroup analyses, we tested whether the associations between ADPKD
and our outcomes were modified by baseline age groups (18 to 40 years, 41 to 60 years,
and >60 years), sex, and prior stone history using Cox proportional hazards models. We
also assessed the association between age, sex, income quintile, and date of cohort entry
with both outcomes separately in patients with and without ADPKD using multivariable
Cox proportional hazards models. We assessed for multi-collinearity among the potential
risk factors by determining the variance inflation factors; all variance inflation factors
were less than 2 indicating this was of minimal concern.
Patients with ADPKD generally receive more abdominal imaging than patients without
ADPKD, which could explain why upper urinary tract stones may be detected more
frequently in patients with ADPKD. To gain insight into this potential surveillance bias,
we compared the rate of abdominal imaging during follow-up in patients with ADPKD
compared to controls using Cox proportional hazards regression.
We performed all analyses using SAS 9.4 (SAS Institute, Inc., Cary, North Carolina). We
present the 95% confidence intervals for all estimates, which corresponds to a level of
significance of 0.05. Prior to using each Cox proportional hazards model, we ensured the
proportional hazards assumption was met. First, we used log-minus-log curve (a
graphical method) to visually assess whether the proportional hazard assumption was
met. If the log-minus-log curves were not parallel or did not overlap, then the
proportional hazard assumption was considered violated. This method is subjective so we
also used a second approach where proportional hazards is assessed using a time-
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dependent covariate test (statistical test), which includes a time-independent variable and
time interaction term. If the p-value for the time-dependent variable and time interaction
term was <0.05, then there was no statistical evidence against proportional hazards
assumption. When proportional hazard assumption was violated and the hazards of both
groups did not cross during following-up, we reported the results as an average hazard
ratio over a 15-year period.83

6.3 RESULTS
6.3.1

Cohort selection & baseline characteristics

From 4,361 potentially eligible patients with ADPKD, the final cohort included 2,094
patients with ADPKD identified in Ontario (Figure 6-2). From 7,153,842 potentially
eligible non-ADPKD controls, 4,547,371 met the eligibility criteria. From the eligible
controls, we randomly sampled 50,000 controls which corresponded to 1,902 patients in
the weighted cohort after truncating weights (Figure 6-3). Table 6-2 summarize the
baseline characteristics of the two groups. After weighting, the mean (standard deviation,
SD) age was 57 (18) years for patients with ADPKD, and 57 (4) years for patients
without ADPKD, and 49% of patients with ADPKD and 52% of patients without
ADPKD were women. The two groups were similar in the mean number of visits to their
primary care physician, emergency department, and urologist in the prior year, and were
similar in baseline comorbidities.

148

Figure 6-2. Cohort selection of patients with autosomal dominant polycystic kidney
disease (ADPKD) using International Classification of Diseases codes for ADPKD.
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Figure 6-3. Cohort selection of patients without autosomal dominant polycystic kidney
disease using International Classification of Diseases, 10th revision codes.
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Table 6-2. Characteristics of the autosomal dominant polycystic kidney disease (ADPKD) cohort and controls at the time of cohort
entry before and after inverse probability exposure weighting based on propensity scores and truncating extreme weights.
ADPKD
(n=2,094)
Mean (SD) age (years)
Women, n (%)
Income fifthb
Quintile 1 (lowest)
Quintile 2
Quintile 3
Quintile 4
Quintile 5 (highest)
Rural Town, n(%)c
LHIN, n (%)
Erie St. Clair
South West
Waterloo Wellington
Hamilton Niagara Haldimand
Brant
Central West
Mississauga Halton
Toronto Central
Central
Central East
South East
Champlain
North Simcoe

Before Weighting
Non-ADPKD Standardized
(n=50,000)
Difference, %

After Weighting
ADPKD
NonStandardized
(n=2,094)
ADPKD
Difference, %
(n=2,101)
57 (18)
57 (4)
1
1,069 (49)
984 (52)
1

57 (18)
1,069 (49)

52 (20)
18,810 (38)

25
23

436 (21)
420 (20)
425 (20)
368 (18)
445 (21)
238 (11)

10,223 (20)
10,234 (21)
10,287 (21)
9,985 (20)
9,271 (19)
6,870 (14)

1
1
1
6
7
7

436 (21)
420 (20)
425 (20)
368 (18)
445 (21)
238 (11)

399 (21)
381 (20)
386 (20)
336 (18)
400 (21)
222 (12)

0
0
0
0
0
1

112 (5)
141 (7)
94 (4)
259 (12)

2,692 (5)
3,903 (8)
2,566 (5)
5,641 (11)

0
4
3
3

112 (5)
141 (7)
94 (4)
259 (12)

104 (5)
131 (6)
88 (4)
232 (11)

2
2
1
4

98 (5)
134 (6)
209 (10)
256 (12)
271 (13)
74 (4)
247 (12)
76 (4)

2,933 (6)
3,905 (8)
4,317 (9)
5,890 (12)
5,601 (11)
2,128 (4)
4,619 (9)
1,893 (4)

5
5
5
1
5
4
8
1

98 (5)
134 (6)
209 (10)
256 (12)
271 (13)
74 (4)
247 (12)
76 (4)

90 (4)
123 (6)
188 (9)
229 (11)
243 (12)
70 (3)
222 (11)
66 (3)

2
2
4
4
4
1
4
3
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North East
North West
No of visits to primary care
physician in previous year (%)
0
1 to 2
3 to 4
5 to 6
7 to 8
9 to 10
> 10
No of visits to emergency
department in the previous year (%)
0
1 to 3
4 to 6
7 to 9
10 to 12
> 12
No of visits to urologist visit in the
previous year (%)
0
1 to 2
3 to 4
5 to 6
7 to 8
9 to 10
> 11
Abdominal imaging in the past five
years, n (%)
Comorbidities in the past five years

90 (4)
33 (2)

2,740 (6)
1,172 (2)

6
5

90 (4)
33 (2)

84 (4)
32 (2)

2
0

95 (5)
258 (12)
246 (12)
265 (13)
251 (12)
180 (9)
799 (38)

2,053 (4)
6,567 (13)
7,919 (16)
7,692 (15)
6,442 (13)
4,927 (10)
14,440 (28)

2
2
12
8
3
4
20

95 (5)
258 (12)
246 (12)
265 (13)
251 (12)
180 (9)
799 (38)

84 (4)
229 (12)
228 (12)
243 (13)
231 (12)
169 (9)
719 (38)

1
1
1
0
0
1
1

350 (17)
1,427 (68)
252 (12)
44 (2)
13 (1)
8 (0)

18,275 (37)
28,780 (58)
2,381 (5)
350 (1)
135 (0)
79 (0)

46
22
26
12
4
4

350 (17)
1,427 (68)
252 (12)
44 (2)
13 (1)
8 (0)

340 (18)
1,308 (69)
201 (11)
35 (2)
12 (1)
6 (0)

3
1
5
2
0
1

1,495 (71)
344 (16)
122 (6)
71 (3)
34 (2)
13 (1)
15 (1)
1,885 (90)

45,296 (91)
2,503 (5)
1,107 (2)
615 (1)
278 (1)
104 (0)
97 (0)
20,810 (42)

5
38
18
15
1
6
7
119

1,495 (71)
344 (16)
122 (6)
71 (3)
34 (2)
13 (1)
15 (1)

1,406 (74)
282 (15)
105 (6)
59 (3)
29 (2)
10 (1)
11 (1)

6
4
1
2
1
1
2

1,885 (90)

1,693 (89)

3
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Acute kidney injury
Urinary tract obstruction, n (%)
Urinary Tract Infection, n (%)
Primary Hyperparathyroidism, n (%)
Gout, n (%)
Obesity, n (%)
Diabetes Mellitus, n (%)
Hypertension, n (%)
Osteoporosis, n (%)
Prior hospital encounter or
intervention for stone, n (%)
Prior hospital encounter for stone,
n (%)
Prior intervention for stone, n (%)
Inflammatory Bowel Disease, n (%)

17 (1)
111 (5)
594 (28)
43 (2)
290 (14)
155 (7)
509 (24)
1,662 (79)
209 (10)
281 (13)

69 (0)
516 (1)
3,877 (8)
249 (0)
1,428 (3)
3,653 (7)
8,036 (18)
19,459 (39)
3,274 (6)
1,324 (3)

10
25
56
14
40
0
15
90
13
41

278 (13)

1,315 (3)

40

58 (3)
72 (3)

403 (1)
899 (2)

15
10

17 (1)
111 (5)
594 (28)
43 (2)
290 (14)
155 (7)
509 (24)
1,662 (79)
209 (10)

10 (1)
85 (4)
465 (24)
27 (1)
208 (11)
144 (8)
460 (24)
1,471 (77)
178 (9)

4
4
9
5
9
1
0
5
2

281 (13)

209 (11)

7

278 (13)

208 (11)

7

58 (2)
72 (3)

49 (3)
62 (3)

1
1

Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; standard deviation, SD
Discharge date was date of entry into cohort for those identified with hospital admission records and was registration date for those identified with emergency
department records.
a

Standardized difference is the difference in means or proportions divided by the pooled standard deviation. Unlike hypothesis testing, standardized difference is
not influenced by sample size. A standardized difference of <10% indicates negligible difference.
b

Income was categorized by fifths of average neighborhood income. Income quintile was missing for <1% of the cohort. For these individuals we assumed that
their household income was part of the third quintile.
c

Rural/Urban residency status was missing for <1% of the cohort. For these individuals, we assumed they resided in an urban area.
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6.3.2

Follow-up period for stone event

The median length of follow-up for an upper urinary tract stone event was 5.4 years (5.0
years in patients with ADPKD, 5.8 years in controls, maximum 15.5 years). A total of
436 patients with ADPKD and 441 controls in the weighted cohort were followed for a
period of 10 years or more. The median (IQR) age at the time of last follow-up for the
entire cohort was 65 years (51 to 77). Of the 3,996 total individuals, 2,598 (65%) were
alive and event-free at the end of study follow-up (March 31st, 2017), 76 (2%) were
censored at time of emigration from the province, 1,170 (29%) died and 152 (4%) had the
event of interest during follow up. The total person-years of follow-up was 24,223
(12,254 for patients with ADPKD, 11,969 for non-ADPKD controls). Less than 2% of
the ADPKD and control groups experienced two or more stone events or stone
intervention events in follow-up (and we only considered the time to the first event).

6.3.3

Follow-up period for stone intervention event

The median length of follow-up was 5.5 years (5.2 years in patients with autosomal
dominant polycystic kidney disease [ADPKD], 5.8 years in controls, maximum 15.5
years). A total of 450 patients with ADPKD and 444 controls in the weighted cohort were
followed for a period of 10 years or more. The median (interquartile range [IQR]) age at
the time of last follow-up for the entire cohort was 65 (50-77). Of the 3,996 individuals
(2,094 patients with ADPKD, 1,902 controls), 2,635 (66%) were alive at the end of study
follow-up (31 March 2017) and had not experienced a stone intervention event, 76 (2%)
were censored at a time of emigration from the province, 1,186 (30%) died and 99 (3%)
had the event of interest during follow-up. The total person years of follow-up was
24,483 (12,472 patients with, 12,011 control).

6.3.4

Outcomes

Figure 6-4 and Table 6-3 present the main outcomes. The proportional hazard assumption
test was assessed graphically using log-minus-log curves (Figure 6-5 and Figure 6-6) and
statistically using the time-dependent covariate test. If the log-minus-log curves were not
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parallel or overlap each other, and if the time-dependent covariate p-value was <0.05,
then there is statistical evidence against the proportional hazard assumption. There was
no statistical evidence against proportional hazards assumption for the outcome of
hospital encounter with upper urinary tract stones both for the main analysis and when
death was treated as a competing event (ADPKD status and time interaction term, P=0.2
and P=0.2, respectively). The same was also true for the outcome of stone intervention
(ADPKD status and time interaction term, P=0.7 and P=0.8, respectively).
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Figure 6-4. Cumulative incidence function of (A) time to first hospital encounter with
upper urinary tract stone; and (B) time to first stone intervention.
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Table 6-3. Comparison of the hazards of (i) time to first hospital encounter with stone, and (ii) time to first stone intervention between
patients with autosomal dominant polycystic kidney disease cohort (ADPKD) and patients without ADPKD with similar baseline
health.
Hospital encounter for stone

Median (IQR) follow-up, years

ADPKD
5.0 (2.2 to 9.1)

Non-ADPKD
5.8 (2.7 to 9.7)

12,254
676 (32)
37 (2)
92 (4)

11,969
494 (26)
39 (2)
60 (3)

Stone intervention
NonADPKD
ADPKD
5.2 (2.3 to 9.2)
5.8 (2.7 to
9.7)
12,472
12,011
688 (33)
498 (26)
37 (2)
39 (2)
52 (2)
47 (2)

Total follow-up, person-years
No. who died, (%)
No. who emigrated, (%)
No. of unique patients with event, (%)
Type of Intervention
Shockwave lithotripsy or percutaneous
nephrolithotomy or combination of two
or more intervention performed on the
same day or within the same hospital
admission
Ureteroscopy
No. of events per 1000 person-years
Hazards ratio (95% CI)*

N/A

N/A

17 (1)

19 (1)

N/A
7.5
1.5 (1.2 to 1.9)

35 (1)
4.2
1.0 (0.8 to 1.4)

Subhazards ratio (95% CI)

1.4 (1.1 to 1.8)

Risk difference per 1000 person-years
(95% CI)

2.5 (0.5 to 4.5)

N/A
5.0
1.0
(Reference)
1.0
(Reference)
0.0
(Reference)

28 (1)
3.9
1.0
(Reference)
1.0
(Reference)
0.0
(Reference)

1.0 (0.7 to 1.4)
0.25 (-1.3 to 1.8)
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Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; confidence interval, CI; interquartile range, IQR; not applicable, N/A
a

Hazards ratio was obtained by censoring for death, end of follow-up, and emigration from Ontario. The estimates were weighted using inverse probability
exposure weighting based on propensity scores. There was no statistical evidence against proportional hazards assumption, for both the hospital encounter with
stone outcome (ADPKD status and time interaction term, P=0.2) and stone intervention outcome (ADPKD status and time interaction term, P=0.7).
b

Hazards ratio was obtained by censoring for emigration and end of follow-up from Ontario, and accounting for death as a competing event. The estimates were
weighted using inverse probability exposure weighting based on propensity scores. There was no statistical evidence against proportional hazards assumption for
both the hospital encounter with stone outcome (ADPKD status and time interaction term, P=0.2) and stone intervention outcome (ADPKD status and time
interaction term, P=0.8).
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a) primary analysis

b) additional analysis

Figure 6-5. Log-minus-log curve of the hospital encounter with upper urinary tract stone
outcome.
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a) primary analysis

b) secondary analysis

Figure 6-6. Log-minus-log curve of the hospital encounter with stone intervention outcome
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There was no statistical evidence against proportional hazards assumption for all exploratory
subgroup analyses, and all risk factors except sex for the control group for both the healthcare
encounter with stones outcome (ADPKD status and time interaction term, P=0.02) and stone
intervention outcome (ADPKD status and time interaction term, P=0.0045). The reported hazard
ratio in instances where the proportional hazards assumption is violated is the average hazard
ratio over a 15-year period.
The rate of a hospital encounter with upper urinary tract stones was significantly higher in the
ADPKD group than the control group (92 of 2,094 patients with ADPKD [4.4%] vs 60 of 1,902
patients without ADPKD [3.2%]; 7.5 vs. 5.0 events per 1000 person-years; hazard ratio [HR]
1.5, 95% confidence interval [CI] 1.2 to 1.9). The results were similar when accounting for death
as a competing event (average subHR over 15 years 1.4, 95% CI 1.1 to 1.8).
There was no statistically significant difference, on average, in the rate of stone intervention in
patients with ADPKD compared to controls (52 of 2,094 [2.4%] vs 47 of 1,902 [2.5%]; 4.2 vs.
3.9 events per 1000 person-years; average HR over 15 years 1.0; 95% CI 0.8 to 1.4). The results
were similar when treating death as a competing event (average subHR over 15 years 1.0, 95%
CI 0.7 to 1.4). Ureteroscopy was the most common type of intervention in both groups.
Sex, age, and stone event in the prior five years did not significantly modify the effects of
ADPKD on the rate of stones, or stone intervention (Table 6-4).
The rate of abdominal imaging was significantly higher in patients with ADPKD compared to
controls (1,826 of 2,094 [87.2%] vs 1,310 of 1,902 [68.9%]; 169.5 vs 121.7 events per 1000
person-years; HR 1.3, 95% CI 1.2 to 1.3).
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Table 6-4 Hazard ratio of hospital encounter with upper urinary tract stone and stone
intervention among patients with autosomal dominant polycystic kidney disease versus
patients without ADPKD with similar indicators for baseline health in various subgroups.
No. of events/ No. at
No. of events per
risk
1000 person-years
Hazards ratio
(95% CI)
NonNonADPKD
ADPKD
ADPKD
ADPKD
Hospital encounter with upper urinary tract stone
92/2,094 60/1,902
7.5
5
1.5 (1.2 to 1.9)
Overall
Sex
58/1,025
36/918
10.7
6.6
1.6 (0.8 to 1.7)
Male
34/1,069
25/984
5
3.8
1.3 (0.5 to 1.4)
Female
Age, years
38/440
16/422
11.6
5.1
2.3 (1.5 to 3.3)
18 to 40
35/748
23/571
6.8
5.8
1.2 (0.8 to 1.7)
41 to 60
19/906
21/909
4.9
4.3
1.1 (0.6 to 1.8)
> 60
Stone intervention or hospital encounter with stone in the prior five years
53/281
32/209
36.5
24.8
1.4 (1.0 to 1.9)
Yes
39/1,813 28/1693
3.6
2.6
1.4 (1.0 to 2.0)
No
Stone intervention
52/2,094 47/1,902
4.2
3.9
1.0 (0.8 to 1.4)
Overall
Sex
33/1,025
27/918
5.9
5.0
1.2 (0.8 to 1.7)
Male
19/1,069
20/984
2.7
3.0
0.9 (0.5 to 1.4)
Female
Age, years
18/440
8/422
5.3
2.5
2.2 (1.2 to 3.8)
18 to 40
21/748
18/571
4.0
4.6
0.9 (0.5 to 1.4)
41 to 60
13/906
21/909
3.4
4.3
0.7 (0.4 to 1.4)
> 60
Stone intervention or hospital encounter with stone in the prior five years
34/281
32/209
21.6
24.5
0.8 (0.6 to 1.2)
Yes
18/1,813 15/1,693
1.7
1.4
1.2 (0.7 to 1.9)
No
a

Hazards ratio was obtained by censoring for death, end of follow-up, and emigration from Ontario. The
estimate was weighted using inverse probability exposure weighting based on propensity scores. The
proportional hazard assumption was assessed using time-dependent covariate test, and was met for all
subgroup-analyses.
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6.3.5

Multi-variable risk factor analysis

The adjusted hazard ratios for each of the studied risk factors are summarized in Table 65. Older age was significantly associated with a lower rate of a hospital encounter with
stones in patients with ADPKD only, and a higher rate of stone interventions in patients
without ADPKD only. Male sex was associated with a higher risk of hospital encounter
with upper urinary tract stone and stone intervention in both the ADPKD and nonADPKD group.
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Table 6-5. Risk factors for hospital encounter with upper urinary tract stones and stone interventions in patients with
autosomal dominant polycystic kidney disease (ADPKD) and patients without ADPKD with similar indicators for baseline
health when each group was analyzed separately.
Risk Factors
Age
41 to 60 (vs. 18 to 40)
60+ (vs. 18 to 40)
Male (vs. female)
Income quintiles
Quintile 2 (vs. quintile 1)
Quintile 3 (vs. quintile 1)
Quintile 4 (vs. quintile 1)
Quintile 5 (vs. quintile 1)
Date of Entry into Cohort
April 1st, 2007 to March 31st, 2012 (vs.
before April 1st, 2007)
After March 31st, 2012 (vs. before
April 1st, 2007)

Hospital encounter with stone
ADPKD
Non-ADPKD

Stone Intervention
ADPKD
Non-ADPKD

0.5 (0.3 to 0.7)
0.3 (0.2 to 0.5)
2.5 (1.6 to 4.0)

1.0 (0.7 to 1.4)
0.7 (0.5 to 1.0)
1.7 (1.3 to 2.2)

0.6 (0.3 to 1.3)
0.4 (0.2 to 1.0)
2.4 (1.3 to 4.4)

1.7 (1.1 to 2.5)
1.5 (1.0 to 2.2)
1.5 (1.1 to 2.0)

0.9 (0.5 to 1.8)
0.9 (0.5 to 1.7)
0.9 (0.4 to 1.8)
1.0 (0.6 to 1.9)

1.4 (0.9 to 2.2)
1.4 (0.9 to 2.1)
1.4 (0.9 to 2.2)
1.2 (0.8 to 1.9)

1.2 (0.5 to 2.9)
0.8 (0.3 to 2.2)
0.8 (0.3 to 2.2)
1.1 (0.4 to 2.7)

1.2 (0.8 to 2.0)
1.4 (0.9 to 2.4)
1.6 (1.0 to 2.7)
1.2 (0.7 to 2.1)

1.1 (0.7 to 1.9)

1.0 (0.8 to 1.3)

1.5 (0.7 to 3.1)

0.9 (0.6 to 1.3)

0.8 (0.4 to 1.5)

1.5 (1.0 to 2.4)

1.1 (0.4 to 3.0)

1.2 (0.8 to 1.9)

Abbreviation: autosomal dominant polycystic kidney disease, ADPKD
Separate multivariable Cox proportional hazards regression models created for ADPKD group and non-ADPKD group with similar indicator for
baseline health.
The date of entry into cohort was discharge date for those identified using hospital admission records and registration date for those identified with
emergency department records.
Hazards ratio was obtained by censoring for death, end of follow-up and emigration from Ontario. The estimate was weighted using inverse probability
exposure weighting based on
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6.4 DISCUSSION
It is uncertain whether the incidence of hospital encounters with upper urinary tract
stones and stone interventions in patients with ADPKD differs from patients with similar
baseline health status without ADPKD. It is also not clear whether some factors
associated with these events are similar between the two groups. Our study addresses
these knowledge gaps. We found the rate of first hospital encounter with upper urinary
tract stones was significantly higher in patients with ADPKD compared to similar
patients without ADPKD, although the rate of stone interventions was not significantly
differ between the two groups. Ureteroscopy was also the most prevalent intervention
type for both patients with and without ADPKD.
There are several possible explanations for the increased rate of hospital encounters with
stones in patients with ADPKD. Cysts may lead to more urinary stasis, which favours
urinary crystals to form, cause stones to stagnate, and promotes stone growth leading to
more upper urinary tract stones. Given their ongoing renal concerns, patients with
ADPKD may also be more likely to present to hospital when they develop a stone
compared to patients without ADPKD. We found no statistical difference in the rate of
stone intervention between patients with ADPKD and similar patients without ADPKD.
It is possible urologists were less inclined to perform interventions in patients with
ADPKD with complex anatomy, choosing to favour medical treatments. Uric acid stones
are the most prevalent stone in patients with ADPKD, and urologists may use dissolution
treatment to treat these stones first, even in situations where the stones are large.84,85
Studies examining the burden of upper urinary tract stones in patients with ADPKD
relative to a non-ADPKD population are scarce. To date, only six cross-sectional studies
report the prevalence of upper urinary tract stones in both patients with ADPKD and their
unaffected family members.6–11 Two of six studies that performed statistical comparisons
found that the prevalence of stones was not different between the two groups.7,8 The
prior studies also did not adjust for any covariates in their analyses. To the best of our
knowledge, our study is the first longitudinal study that adjusted for covariates and
compared the rate of hospital encounter with upper urinary tract stones and stone
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intervention between patients with ADPKD and controls with similar baseline health. It is
also the largest study to date on this topic, and loss to follow-up was minimal with only
about 2% of persons in the cohort emigrating from Ontario. We expect patients identified
with ADPKD with the administrative coding algorithm truly had ADPKD given the high
positive predictive value of ICD-10 codes that we used to identify patients with
ADPKD.66 Additionally, we used inverse probability exposure weighting based on
propensity scores to ensure our two groups had similar baseline indicators of health
status; this allowed us to adjust for a large number of covariates prior to conducting
statistical analyses.73
Our study is not without limitations. A small number of events meant some estimates
were imprecise. We did not have information on upper urinary tract stone events outside
of the hospital, which represents a large proportion of stone events not captured in this
study. This deficiency should be addressed in future studies. Some relevant information
such as the amount of daily water consumed was also not available in our healthcare data
sources, and some measures in our data sources could be miscoded. We also did not have
information on the type of stone. These factors along with the observational design of our
study raise the possibility of residual confounding. With our data sources we could only
enter ADPKD patients with a history of at least one hospital encounter into the cohort, so
the results may generalize less well to healthier segments of the ADPKD population. We
could not ascertain which type of procedure was performed first in a small subset of our
patients in both groups, because two or more different types of interventions were
performed on the same day or within the same hospitalization.

6.5 CONCLUSION
Overall, our results suggest that ADPKD increases the rate of hospital encounters with
upper urinary tract stones, and that urologists are not more or less aggressively managing
stones in patients with ADPKD than in patients without ADPKD with otherwise similar
baseline health. Future studies should focus on further quantifying the burden of upper
urinary tract stones in patients with ADPKD in all settings, and strategies to prevent their
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development and minimize their impact on patient health. Additionally, future studies
should explore whether additional, important subgroups, such as patients with larger total
kidney volume, have a higher chance of developing stones.
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7.1 INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disorder
with no cure.1,2 It is characterized by focal cyst development which leads to progressive
enlargement of both kidneys, and eventual kidney function loss. 3–5 Much of the current
research on patients with ADPKD is focused on delaying time to the onset of end-stage
kidney disease (ESKD). However, ADPKD is a systemic disorder with other morbidities
that warrant attention to prevent loss of health-related quality of life.6 One such morbidity
is upper urinary tract stones.7 Stones in patients with ADPKD are a significant
determinant of pain, and may be associated with a higher risk of ESKD. 7,8 Currently,
there is limited evidence on how best to manage upper urinary tract stones in patients
with ADPKD.
In the general population, stones less than four millimeters in size usually do not require a
surgical intervention, and will often pass within four weeks of symptom onsets. 9 Pain
may be managed with narcotics or nonsteroidal anti-inflammatory drugs (NSAIDs).9
However, urgent intervention is often required in the presence of infection/urosepsis,
intractable pain, vomiting, impending acute renal failure, and/or significant obstruction. 10
Currently, shockwave lithotripsy (SWL), ureteroscopy, and percutaneous
nephrolithotomy (PCNL) are potential treatment options; however, ureteroscopy is the
most common intervention used in both patients with and without ADPKD. 11
A comprehensive systematic review conducted by our team confirms there is limited
information on the risk of ureteroscopic complications in patients with ADPKD. 12 All
studies were either clinical case series or reports, and most studies reported data from a
single center. Overall, these limitations lead to uncertainty in how to counsel patients
with ADPKD on expected post-operative ureteroscopic complications. In this study, we
described the 30-day cumulative incidence of selected ureteroscopic complications, allcause hospital presentation, all-cause hospital admission, and all-cause emergency
department visits following ureteroscopy in patients with compared to patients without
ADPKD.
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7.2 PATIENTS AND METHODS
7.2.1

Design and setting

We conducted a retrospective cohort study using linked healthcare administrative
databases held at ICES (a not-for-profit research institute). Healthcare services in Ontario
are funded through the Ontario Health Insurance Plan (OHIP) program, with the
exception of outpatient medications, which are only funded for segments of the
population, including all people 65 years of age and older. These healthcare encounters
are recorded in administrative databases, which are linked using unique, encoded
identifiers and held at ICES. The use of ICES data in this project was authorized under
section 45 of Ontario’s Personal Health Information Protection Act, which does not
require review by a Research Ethics Board. No informed consent from patients was also
required. We reported this study following guidelines set up for studies conducted using
observational routinely-collected data.

7.2.2

Data sources

We created the study cohorts, described baseline characteristics, defined the exposure,
and ascertained outcomes using administrative codes detailed in Table 7-1 and seven
databases: CIHI-DAD, SDS, NACRS, OHIP, RPDB, CORR, and ODB. A detailed
description of each of the Ontario healthcare administrative databases is described in
Table A-1. All variables were complete, except for average neighbourhood income
(missing in 0.18%) and urban or rural residency status (missing in 0.05%); we assigned
the middle average neighbourhood income quintile and urban residence for these missing
values, respectively.
Table 7-1. Database and coding definitions for restriction criteria, baseline characteristics
and outcome measurements.
Variable
Study Population
Ureteroscopy

Database & Administrative Codes
CIHI-DAD & NACRS CCI: 1PE57BAAM, 1PE57BAGX,
1PE59BAAG, 1PE59BAAS, 1PE59BAAT, 1PE59BAAZ,
1PG57BAAM, 1PG57BAGX, 1PG59BAAG, 1PG59BAAS,
1PG59BAAT, 1PG59BAAZ, 1PG59BAGX, 1PE59BAAS,
1PE59BAAT, 1PE59BAAZ
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OHIP Fee Codes: Z628 AND (E760 or E761 or Z627)
Exposure
Autosomal dominant
polycystic kidney disease
Exclusion Criteria
Shockwave lithotripsy
performed in the previous
90 days

CIHI-DAD & NACRS ICD-10 codes: Q612, Q613

CIHI-DAD & NACRS CCI: 1PE59KQAP, 1PE59KQAQ,
1PE59KQAR, 1PG59KQAP, 1PG59KQAQ, 1PG59KQAR

OHIP Fee Codes: Z630
Percutaneous
CIHI-DAD & NACRS CCI: 1PE57DTAG, 1PE57DTAM,
nephrolithotomy performed 1PE57DTAS, 1PE57DTAZ, 1PE57DTBD, 1PE57DTGX
in the previous 90 days
OHIP Fee Codes: Z624 AND Z627
Open stone surgery
CIHI-DAD & NACRS CCI: 1PE57LAAM, 1PE57LAGX,
performed in the previous
1PE57QWGX, 1PE59LAAG, 1PG57LAAM, 1PG57LAGX,
90 days
1PG59LAAG, 1PG59LAGX
Kidney transplant
CIHI-DAD & NACRS CCP: 6759
CIHI-DAD & NACRS CCI: 1PC85
OHIP fee code: S435, S434
CORR – RECIPIENT_TREATMENT dataset
[Treatment_Code]: 171
[Treatment_Date]
[Transplanted_Organ_Type_Code] [1-3]: 10, 11, 12, 18, 19
ADPKD (only for control
CIHI-DAD & NACRS ICD-9 codes: 7531
group
CIHI-DAD & NACRS ICD-10 codes: Q611, Q612, Q613
OHIP Dx codes: 753, 593
Outcomes
Acute kidney injury
CIHI-DAD & NACRS ICD-10 codes: N17
Urinary tract infection
CIHI-DAD & NACRS ICD-10 codes: N10, 'N11, 'N12, N136,
'N151, N159, N160, N300, N308, N309, N340, N390, N410,
N411, N412, N413, N431, N45, T835
Sepsis
CIHI-DAD & NACRS ICD-10 codes: A021, A392, A393, A394,
A400, A401, A402, A408, A409, A410, A411, A412, A403,
A414, A4159, A413, A4150, A4151, A4152, A4158, A4180,
A4188, A427, A419
Baseline Characteristics
Age
RPDB
Sex
RPDB
Rural
RPDB
Household income
RPDB
quintiles
Local Health Integration
RPDB
Network (LHIN)

180

Emergency department
visits in the previous one
year
Primary care physician
visits in the previous one
year
Hospital admission in the
previous one year
ICU admission in the
previous one year

Estimated glomerular
filtration rate
Acute interstitial nephritis
Acute kidney injury
Anemia

Atrial Fibrillation
Chronic liver disease

Chronic lung disease

Coronary artery disease

NACRS

IPDB: Mainspecialty= GP/FP

CIHI-DAD
CIHI-DAD CCP codes: 1361, 1362
CIHI-DAD CCI codes: 1GZ31CAND, 1GZ31CRND,
1GZ31GPND
OHIP Fee codes: G557, G558, G559, G400, G401, G402, G405,
G406, G407
OLIS
CIHI-DAD & NACRS ICD-9 codes: 5837, 5838, 5839
CIHI-DAD & NACRS ICD-10 codes: N10, N12
CIHI-DAD & NACRS ICD-9 codes: 584
CIHI-DAD & NACRS ICD-10 codes: N17
CIHI-DAD & NACRS ICD-9 codes: 280, 281, 282, 283, 284,
285
CIHI-DAD & NACRS ICD-10 codes: D50, D51, D52, D53,
D55, D58, D59, D61, D62, D63, D64
OHIP dx codes: 280, 281, 282, 283, 284, 285
CIHI-DAD & NACRS ICD-9: 4273
CIHI-DAD & NACRS ICD-10: I48
CIHI-DAD & NACRS ICD-9 codes: 4561, 4562, 070, 5722,
5723, 5724, 5728, 573, 7824, V026, 2750, 2751, 7891, 7895, 571
CIHI-DAD & NACRS ICD-10 codes: B16, B17, B18, B19, I85,
R17, R18, R160, R162, B942, Z225, E831, E830, K70, K713,
K714, K715, K717, K721, K729, K73, K74, K753, K754, K758,
K759, K76, K77
OHIP dx codes: 571, 573, 070
OHIP fee codes: Z551, Z554
CIHI-DAD & NACRS ICD-9 codes: 491, 492, 493, 494, 495,
496, 500, 501, 502, 503, 504, 505, 5064, 5069, 5081, 515, 516,
517, 5185, 5188, 5198, 5199, 4168, 4169
CIHI-DAD & NACRS ICD-10 codes: I272, I278, I279, J40, J41,
J42, J43,J44, J45, J47, J60, J61, J62, J63, J64, J65, J66, J67, J68,
J701, J703, J704, J708, J709, J82, J84, J92, J941, J949, J953, J961,
J969, J984, J988, J989, J99
OHIP dx codes: 491, 492, 493, 494, 496, 501, 502, 515, 518, 519
OHIP fee codes: J889, J689
CIHI-DAD & NACRS ICD-9 codes: 412, 410, 413, 414, 4292,
4296, 4297, 411
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Cystoscopy
Depression

Diabetes Mellitus

Hemorrhage

CIHI-DAD & NACRS ICD-10 codes: I20, I21, I22, I23, I24, I25,
Z955, Z958, Z959, R931, T822
CIHI-DAD & NACRS CCI codes: 1IJ26, 1IJ27, 1IJ54, 1IJ57,
1IJ50, 1IJ76
CIHI-DAD & NACRS CCP codes: 4801, 4802, 4803, 4804,
4805, 481, 482, 483
OHIP fee codes: R741, R742, R743, G298, E646, E651, E652,
E654, E655, G262, Z434, Z448
OHIP dx codes: 410, 412, 413
OHIP fee codes: Z606, Z607, Z628, Z632, Z633, Z634
CIHI-DAD & NACRS ICD-9 codes: 2962, 2963, 3000, 3002,
3003, 3004, 3091, 311
CIHI-DAD & NACRS ICD-10 codes: F063, F064, F320, F321,
F322, F323, F328, F329, F330, F331, F332, F333, F334, F338,
F339, F341, F400, F401, F402, F408, F409, F410, F411, F412,
F413, F418, F419, F420, F421, F422, F428, F429, F430, F431
OHIP dx codes: 311
OMHRS DSM-IV codes: 29189, 29284, 29289, 29383, 29384,
29620, 29621, 29622, 29623, 29624, 29625, 29626, 29630, 29631,
29632, 29633, 29634, 29635, 29636, 30000, 30001, 30002, 30021,
30022, 30023, 30029, 30030, 30040, 30113
CIHI-DAD & NACRS ICD-9 codes: 250
CIHI-DAD & NACRS ICD-10 codes: E10, E11, E13, E14
OHIP Dx codes: 250
OHIP Fee codes: K045, K046, K029, K030, Q040
CIHI-DAD & NACRS ICD-9 codes: 430, 431, 432, 5307, 5310,
5312, 5314, 5316, 5320,
5322, 5324, 5326, 5330, 5332, 5334, 5336, 5340, 5342,
5344, 5346, 5780, 5781, 5693, 5789, 7191, 7192, 4590,
5997, 5307, 5310, 5312, 5314, 5316, 5320, 5322, 5324,
5326, 5330, 5332, 5334, 5336, 5340, 5342, 5344, 5346,
5693, 53501, 53511, 53521,7847, 7863, 6238, 6262
CIHI-DAD & NACRS ICD-10 codes: I600, I601, I602, I603,
I604, I605, I606,
I607, I609, I61, I62, I850, I9820, I983, K2210, K2211,
K2212, K2214, K2216, K226, K228, K250, K252, K254, K256,
K260, K262, K264, K266, K270, K272, K274, K276, K280,
K282, K284, K286, K290, K3180, K6380, K920, K921, K5520,
K625, K922, M2509, M2501, M2502, M2503, M2504, M2505,
M2506, M2507, M2508, M2500, M1229, M1221, M1222, M1223,
M1224, M1225, M1226, M1227, M1228, M1220, R58, N020,
N021, N022, N023, N024, N025, N026, N027, N028, N029,
R310, R311, R318, K226, K250, K252, K254, K256, K260,
K262, K264, K266, K270, K272, K274, K276, K280, K282,
K284, K286, K625, R040, R042, R048, R049, N898, N920,
N921
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Hypertension

Kidney tumor

Obesity

Percutaneous tube/Ureteral
stent
Prostatic hyperplasia

Surgery

CIHI-DAD & NACRS CCP codes: 1302, 1303, 1304, 1305,
1306, 1307, 1308, 1309
CIHI-DAD & NACRS CCI codes: 1LZ19HMU1, 1LZ19HMU2,
1LZ19HMU9, 1LZ19HHU9A, 1LZ19HHU9J,
1LZ19HHU1A, 1LZ19HHU1J, 1LZ19HHU3J, 1LZ19HHU4J,
1LZ19HHU2A,
1LZ19HHU2J, 1LZ19HHU5J
CIHI-DAD & NACRS ICD-9 codes: 401, 402, 403, 404, 405
CIHI-DAD & NACRS ICD-10 codes: I10, I11, I12, I13, I15
OHIP Dx codes: 401, 402, 403
CIHI-DAD & NACRS ICD-9 codes: 1890, 1891, 2230
CIHI-DAD & NACRS ICD-10 codes: C64, C65, D300
OHIP Dx: 189, 2230
CIHI-DAD & NACRS ICD-9 codes: 2780
CIHI-DAD & NACRS ICD-10 codes: E65, E660, E661, E662,
E668, E669
OHIP Dx codes: 278
OHIP Fee codes: E773, E776, E818, Z623, J046, Z629
CIHI-DAD & NACRS ICD-9 codes: N40
CIHI-DAD & NACRS ICD-10 codes: 600
OHIP Dx codes: 600
OHIP Fee codes: S002, S003, S004, S005, S006, S007, S010,
S011, S012, S013, S014, S015, S018, S019, S020, S021, S023,
S024, S025, S028, S030, S031, S032, S033, S034, S035, S036,
S042, S043, S044, S045, S046, S047, S049, S050, S057, S058,
S059, S061, S062, S063, S065, S066, S067, S068, S069, S103,
S104, S113, S114, S115, S116, S118, S119, S208, S209, S222,
S223, S225, S226, S227, S228, S229, S231, S233, S234, S236,
S237, S241, S242, S243, S246, S247, S248, S249, S251, S253,
S256, S257, S258, S259, S260, S265, S266, S267, S268, S269,
S270, S271, S272, S273, S274, S275, S276, S278, S280, S281,
S282, S283, S284, S285, S287, S291, S292, S293, S294, S295,
S297, S298, S299, S300, S301, S302, S303, S304, S305, S306,
S307, S308, S309, S310, S311, S312, S313, S314, S315, S316,
S317, S318, S319, S320, S321, S322, S323, S325, S326, S328,
S329, S330, S332, S333, S334, S335, S336, S337, S338, S339,
S340, S342, S343, S344, S345, S346, S347, S348, S349, S355,
S372, S400, S401, S402, S403, S404, S405, S406, S407, S408,
S409, S410, S411, S412, S413, S415, S416, S417, S418, S420,
S421, S422, S423, S424, S426, S427, S428, S429, S430, S431,
S432, S433, S434, S435, S436, S437, S438, S440, S441, S442,
S443, S444, S445, S446, S447, S448, S449, S450, S451, S452,
S453, S454, S455, S456, S457, S458, S459, S460, S461, S462,
S463, S465, S466, S467, S468, S470, S471, S476, S477, S478,
S479, S480, S481, S482, S483, S484, S485, S487, S488, S489,
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S490, S491, S502, S512, S513, S518, S519, S520, S521, S522,
S523, S524, S525, S530, S531, S532, S533, S534, S535, S536,
S537, S538, S539, S540, S541, S542, S543, S544, S545, S546,
S547, S548, S549, S550, S551, S552, S553, S554, S555, S556,
S557, S558, S559, S560, S561, S562, S563, S564, S566, S567,
S568, S569, S570, S571, S572, S573, S574, S575, S576, S577,
S578, S579, S580, S581, S588, S589, S590, S591, S592, S593,
S595, S596, S597, S598, S599, S600, S601, S602, S606, S611,
S616, S618, S619, S623, S625, S626, S630, S631, S636, S640,
S641, S642, S643, S644, S645, S646, S647, S648, S649, S650,
S651, S652, S653, S654, S655, S656, S700, S701, S702, S703,
S704, S705, S706, S707, S708, S709, S710, S711, S712, S713,
S714, S715, S716, S717, S718, S719, S720, S721, S722, S723,
S724, S725, S726, S727, S728, S729, S730, S731, S732, S733,
S734, S735, S736, S737, S738, S739, S740, S741, S742, S743,
S744, S745, S746, S747, S748, S749, S750, S751, S752, S753,
S754, S755, S756, S757, S758, S759, S760, S761, S762, S763,
S764, S765, S766, S767, S768, S769, S770, S771, S772, S773,
S774, S775, S776, S777, S778, S779, S780, S781, S782, S783,
S784, S785, S786, S787, S788, S789, S790, S791, S792, S793,
S795, S796, S797, S798, S799, S800, S805, S806, S807, S808,
S810, S811, S812, S813, S815, S816, S900, R107, R108, R109,
R110, R111, R112, R113, R114, R115, R116, R117, R118, R119,
R120, R121, R122, R123, R124, R143, R144, R145, R146, R147,
R148, R149, R150, R151, R152, R153, R154, R155, R156, R181,
R182, R191, R192, R193, R194, R195, R196, R197, R198, R199,
R200, R201, R202, R203, R204, R205, R206, R207, R208, R209,
R210, R211, R212, R213, R214, R215, R216, R217, R218, R219,
R220, R221, R222, R223, R224, R225, R226, R227, R228, R229,
R230, R231, R232, R233, R234, R235, R236, R237, R238, R239,
R240, R241, R242, R243, R244, R245, R246, R247, R248, R249,
R250, R251, R252, R253, R254, R255, R256, R257, R258, R259,
R260, R261, R262, R263, R264, R265, R266, R267, R268, R269,
R270, R271, R272, R273, R274, R275, R276, R277, R278, R279,
R280, R281, R282, R283, R284, R285, R286, R287, R288, R289,
R290, R291, R292, R293, R294, R295, R296, R297, R298, R299,
R301, R302, R303, R304, R305, R306, R307, R308, R309, R310,
R311, R312, R313, R314, R315, R316, R317, R318, R319, R320,
R321, R322, R323, R324, R325, R326, R327, R328, R329, R330,
R331, R332, R333, R334, R335, R336, R337, R338, R339, R340,
R341, R342, R343, R344, R345, R346, R347, R348, R349, R350,
R351, R352, R353, R354, R355, R356, R357, R358, R359, R360,
R361, R362, R363, R364, R365, R366, R367, R368, R369, R370,
R371, R372, R373, R374, R376, R377, R378, R379, R380, R381,
R382, R383, R384, R385, R386, R387, R388, R389, R390, R391,
R392, R393, R394, R395, R396, R397, R398, R399, R400, R401,
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R402, R403, R404, R405, R406, R407, R408, R409, R410, R411,
R412, R413, R414, R415, R416, R417, R418, R419, R420, R421,
R422, R423, R424, R425, R426, R427, R428, R429, R430, R431,
R432, R433, R434, R435, R436, R437, R438, R439, R440, R441,
R442, R443, R444, R445, R446, R447, R448, R449, R450, R451,
R452, R453, R454, R455, R456, R457, R458, R459, R460, R461,
R462, R463, R464, R465, R466, R467, R468, R469, R470, R471,
R472, R473, R474, R475, R476, R477, R478, R479, R480, R481,
R482, R483, R484, R485, R486, R487, R488, R489, R490, R491,
R492, R493, R494, R495, R496, R497, R498, R499, R500, R501,
R502, R503, R504, R505, R506, R507, R508, R509, R510, R511,
R512, R513, R514, R515, R516, R517, R518, R519, R520, R521,
R522, R523, R524, R525, R526, R527, R528, R529, R530, R531,
R532, R533, R534, R535, R536, R537, R538, R539, R540, R541,
R542, R543, R544, R545, R546, R547, R548, R549, R550, R551,
R552, R553, R554, R555, R556, R557, R558, R559, R560, R561,
R562, R563, R564, R565, R566, R567, R568, R569, R570, R571,
R572, R573, R574, R575, R576, R577, R578, R579, R580, R581,
R582, R583, R584, R585, R586, R587, R588, R589, R590, R591,
R592, R593, R594, R595, R596, R597, R598, R599, R600, R601,
R602, R603, R604, R605, R606, R607, R608, R609, R610, R611,
R612, R613, R614, R615, R616, R617, R618, R619, R620, R623,
R621, R627, R628, R629, R632, R633, R634, R635, R636, R637,
R638, R639, R640, R641, R642, R643, R644, R645, R646, R647,
R648, R649, R650, R651, R652, R653, R654, R655, R656, R657,
R658, R659, R675, R676, R677, R678, R679, R680, R681, R682,
R683, R684, R685, R686, R687, R688, R689, R690, R691, R692,
R693, R694, R695, R696, R697, R698, R706, R709, R710, R711,
R751, R752, R753, R775, R776, R778, R781, R818, R819, R820,
R821, R822, R823, R824, R825, R826, R827, R828, R829, R834,
R835, R836, R837, R838, R839, R840, R841, R842, R843, R844,
R846, R848, R849, R850, R851, R852, R853, R854, R866, R867,
R868, R869, R870, R872, R873, R874, R878, R879, R885, R905,
R907, R910, R911, R912, R913, R914, R915, R916, R940, R941,
R942, R943, R944, R945, R946, R950, R951, R952, R953, R954,
R956, R957, R958, R959, R960, R961, R962, R963, R964, R965,
R966, R967, R968, R969, R970, R971, R972, R973, R974, R975,
R976, R977, R978, R979, R990, R991, R993, R999, F000, F001,
F002, F218, F627, Z219, Z220, Z221, Z273, Z279, Z280, Z281,
Z290, Z291, Z296, Z297, Z298, Z299, Z301, Z302, Z303, Z304,
Z305, Z306, Z308, Z309, Z310, Z311, Z312, Z313, Z314, Z315,
Z316, Z317, Z318, Z319, Z320, Z321, Z322, Z323, Z324, Z325,
Z326, Z327, Z328, Z329, Z330, Z331, Z332, Z333, Z334, Z335,
Z336, Z337, Z338, Z339, Z340, Z341, Z342, Z343, Z344, Z345,
Z346, Z347, Z348, Z349, Z350, Z351, Z353, Z354, Z355, Z356,
Z357, Z358, Z359, Z399, Z400, Z401, Z402, Z408, Z409, Z410,
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Urinary tract infection

Urinary tract obstruction

Angiotensin-converting
enzyme inhibitors or
angiotensin II receptor
blocker
Antibiotics
Anti-diabetics

Z411, Z412, Z413, Z414, Z415, Z422, Z423, Z424, Z425, Z426,
Z427, Z428, Z429, Z430, Z431, Z432, Z433, Z434, Z435, Z436,
Z437, Z438, Z439, Z440, Z441, Z442, Z443, Z444, Z445, Z446,
Z447, Z448, Z449, Z450, Z451, Z452, Z453, Z454, Z455, Z456,
Z457, Z458, Z459, Z460, Z461, Z462, Z463, Z464, Z465, Z466,
Z470, Z475, Z477, Z478, Z480, Z496, Z497, Z498, Z499, Z512,
Z513, Z514, Z515, Z520, Z523, Z524, Z525, Z526, Z527, Z528,
Z529, Z530, Z531, Z532, Z533, Z534, Z535, Z536, Z537, Z538,
Z539, Z540, Z541, Z542, Z543, Z544, Z545, Z546, Z547, Z548,
Z549, Z550, Z551, Z552, Z553, Z554, Z555, Z556, Z557, Z558,
Z559, Z560, Z561, Z562, Z563, Z564, Z565, Z566, Z567, Z568,
Z569, Z570, Z571, Z572, Z573, Z574, Z575, Z576, Z577, Z578,
Z579, Z580, Z581, Z582, Z583, Z584, Z585, Z586, Z587, Z590,
Z591, Z592, Z593, Z594, Z595, Z596, Z597, Z600, Z601, Z602,
Z603, Z604, Z605, Z606, Z607, Z608, Z609, Z610, Z611, Z612,
Z615, Z616, Z617, Z618, Z619, Z620, Z621, Z622, Z623, Z624,
Z625, Z626, Z627, Z628, Z629, Z630, Z631, Z632, Z633, Z634,
Z635, Z636, Z637, Z638, Z640, Z662, Z700, Z701, Z702, Z703,
Z704, Z705, Z706, Z707, Z708, Z709, Z710, Z711, Z712, Z713,
Z714, Z715, Z716, Z717, Z718, Z719, Z720, Z721, Z722, Z723,
Z724, Z725, Z726, Z727, Z728, Z734, Z735, Z736, Z737, Z738,
Z739, Z740, Z741, Z742, Z743, Z744, Z745, Z746, Z747, Z748,
Z749, Z750, Z751, Z752, Z753, Z754, Z755, Z756, Z757, Z758,
Z759, Z760, Z761, Z762, Z763, Z764, Z765, Z766, Z767, Z768,
Z769, Z771, Z772, Z773, Z774, Z775, Z776, Z777, Z778, Z779,
Z780, Z781, Z782, Z783, Z784, Z785, Z787, Z788, Z800, Z801,
Z802, Z803, Z804, Z805, Z806, Z807, Z808, Z809, Z810, Z811,
Z812, Z813, Z814, Z815, Z816, Z817, Z818, Z819, Z820, Z821,
Z823, Z824, Z825, Z826, Z827, Z869, Z870, Z873, Z941, Z942,
Z943, Z944
CIHI-DAD & NACRS ICD-9 codes: 5901, 5900, 5908, 5902,
5909, 5950, 5958, 5959, 5970, 5990, 6016, 6011, 6012, 6013,
6040, '6049
CIHI-DAD & NACRS ICD-10 codes: N10, N11, N12, N136,
N151, N159, N160, N300, N308, N309, N340, N390, N410,
N411, N412, N413, N431, N45, T835
CIHI-DAD & NACRS ICD-9 codes: 591, 5934, 5996
CIHI-DAD & NACRS ICD-10 codes: N130, N131, N132, N133,
N138
OHIP Dx codes: 591
ODB

ODB
ODB
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Calcium channel blocker
Diuretic
Proton pump inhibitors

ODB
ODB
ODB

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CCI, Canadian Classification of
Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures;
CIHI-DAD Canadian Institute for Health Information Discharge Abstract Database; CORR, Canadian
Organ Replacement Register; ICD-9, International Classifications of Diseases, 9th revision codes; ICD-10,
International Classification of Diseases, 10th revision codes; IPDB, ICES Physician Database; NACRS,
National Ambulatory Care Reporting System; OHIP Dx, Ontario Health Insurance Plan diagnosis codes;
OHIP Fee, Ontario Health Insurance Plan fee for service codes; Registered Persons Database, RPDB

7.2.3

Population and timeline

We identified all patients who underwent ureteroscopy between April 1 st, 2002 and
March 31st, 2018 using OHIP fee and Canadian Classification of Health Intervention
(CCI) codes. OHIP fee codes are submitted by physicians so they are paid for the
interventions/procedures they perform. The OHIP fee codes for ureteroscopy have been
extensively used in prior studies, and are expected to have excellent validity similar to
other fee-for-service codes.13–15 CCI is a health-related intervention classification system
developed by Canadian Institute for Health Information for administrative purposes. An
accrual end date of March 31st, 2018 ensures that each patient had the potential for at
least 30 days of follow-up. We excluded the following patients:
(1) Missing or invalid encrypted unique identifiers, missing date of birth or sex,
patients aged over 105 years, and those who died before cohort entry date for data
cleaning purposes;
(2) Visiting non-Ontarians who received care from a healthcare facility in Ontario to
limit our study population to Ontarians. We will not have follow-up data on nonOntarians;
(3) Patients aged 18 and under to exclude patients with autosomal recessive
polycystic kidney disease who may have been misclassified as patients with
ADPKD;
(4) Patients with database codes for open stone surgery, SWL, and PCNL in the
previous 90 days to ensure that ureteroscopy was the first stone intervention
performed for the stone; and
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(5) Kidney transplant recipients to ensure the ureteroscopy was performed in the
polycystic kidneys.
Any stone intervention codes that appeared within 90 days of each other were considered
interventions performed for the same stone.
The cohort entry date, to reflect the time of the ureteroscopic procedure, was either the
hospital discharge date (for patients who underwent ureteroscopy in a hospital),
registration date (for patients who underwent ureteroscopy at the emergency department),
or the date of the ureteroscopy (for patients who had the procedure performed in the
outpatient setting). We looked back from cohort entry date until April 1st, 2002 (earliest
date when could identify patients with ADPKD using our administrative databases and
hence also defined our accrual start date) for International Classification of Diseases, 10 th
revision (ICD-10) codes related to ADPKD, and classified patients as having or not
having ADPKD.16 ICD-10 codes related to ADPKD in our province have a positive
predictive value of 85% (95% confidence interval [CI]: 79% to 89%), only identify
patients who presented at the hospital with ADPKD, and differentiate patients with
ADPKD from patients with other cystic kidney diseases. 16,17 After classifying each
patient as affected or not affected with ADPKD, we excluded patients with OHIP
diagnosis codes for congenital anomalies of the urinary system (753) and other renal
cystic disease (593) from the patients without ADPKD cohort only; although these OHIP
diagnosis codes identify a lot of patients with ADPKD, the codes also indiscriminately
capture a lot of patients with similar conditions. 17 Therefore, excluding patients with
OHIP diagnosis 753 and 593 would ensure that there are no patients with ADPKD in the
control group. We also excluded patients with baseline characteristics that were present
in one group but not the other as an approach to account for confounders (see Table 6-2).
For patients who underwent more than one ureteroscopy, we included only the first
ureteroscopy event. We followed each patient for 30 days from cohort entry date to
ascertain outcomes. A follow-up of 30 days would ensure that there is sufficient time to
ascertain outcome yet still be somewhat confident that the observed outcome is due to the
intervention.
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Table 7-2. List of baseline characteristics that were present in one study group but not the
other group.
Category
Variables
a
Health care use Intensive care unit admission
Comorbiditiesb Brain injury, cirrhosis, chronic obstructive pulmonary disease,
hepatic failure, hepatorenal syndrome, HIV, microangiopathy,
multiple sclerosis, neurogenic bladder, peripheral vascular disease,
pneumonia, renal vein thrombosis, rheumatoid arthritis,
schizophrenia or other psychotic disorders, sclerosis, sickle cell
disease, spinal cord injury, urinary diversion, vasculitis,
vesicoureteral reflux, vitamin D deficiency
Medicationsc
Aliskiren, anti-convulsant, anti-histamine, anti-neoplastic
medications, carmustine, cisplatin, cyclosporine, glucocorticoid,
gold compounds, methotrexate, leucovorin calcium, lithium,
tacrolimus, or TMP-SMX antibiotics
a

The look-back period for health care use was 1-year.
The look-back period for comorbidities was 5-years.
c
The look-back period for medications was 120 days.
b

7.2.4

Outcomes

Outcomes assessed in the 30-days following ureteroscopy were hospital presentation with
ureteroscopic complications (which was a composite outcome of either emergency
department visit or hospital admission with acute kidney injury [AKI], urinary tract
infection [UTI], or sepsis), all-cause hospital presentation (which is either emergency
department visit or hospital admission for any reason), all-cause hospital admission, and
all-cause emergency department visit. We identified hospital presentation with AKI, UTI,
and sepsis using ICD-10 codes.18–20 The sensitivity and specificity of ICD-10 codes for
each of the components of the composite outcome is as followed:
•

Sepsis presented during hospital admission or emergency department visit:
Sepsis is a life-threatening condition characterized by a systemic inflammatory
response to a severe infection.21 I will identify all hospital encounters for sepsis
using the validated ICD-10 codes using CIHI-DAD and CIHI-NACRS (Table F1). Based on a previous validation study of ICD-10 codes related to sepsis, the
sensitivity ranged from 5.9 to 51.1%, specificity > 92%, positive predictive value
ranged from 9.8 to 93.9%, and negative predictive value ranged from 86.8 to
98.3%.22
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•

AKI presented during hospital admission or emergency department visit:
AKI is characterized by a sudden increase in serum creatinine.23 It is associated
with increased mortality and longer hospital stay.23 I will identify patients with
AKI using the validated ICD-10 codes with moderate sensitivity for patients who
present with AKI at the emergency department (37.9%; 95% CI 32.1% to 43.1%),
and hospital admission (61.1%; 95% CI: 57.5% to 65.5%), and high specificity
(>95%) in both settings.

•

UTI presented during hospital admission or emergency department visits: I
will identify all urinary tract infections presented at hospital admissions (CIHIDAD), or emergency department visits (CIHI-NACRS) using the validated ICD10 codes with a sensitivity of 49.5% (95% CI: 39.5% to 59.5%), specificity of
96.6% (95% CI: 94.5% to 98.1%), and a positive predictive value of 77.3% (95%
CI: 65.3% to 86.7%) (Table F-1).24 I will consider all recurrent events.24
However, two or more codes billed within seven days will be considered as
hospital encounters for a single infection.25

Since the sensitivity of each of the ICD-10 codes for each of the component of the
composite outcome is low, the estimated 30-day risk of ureteroscopic complication would
be underestimated. However, the specificity of each of the ICD-10 codes for the three
component is >95%, indicating that the codes differentiate patients with the conditions
from those without the conditions. Although the risk of 30-days ureteroscopic outcome
would be underestimated, the ICD-10 codes are likely capturing the more severe cases of
AKI, UTI, and sepsis.

7.2.5

Data analysis

We assessed the baseline characteristics of both cohorts as mean and standard deviation
for continuous variables, and as frequencies and percentages for binary or categorical
variables. We used standardized difference, which are insensitive to sample size, to
compare the baseline characteristics between patients with and without ADPKD. A
standardized difference greater than 10% indicates important imbalance.
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We assessed the unadjusted and adjusted relative and absolute risk difference of
outcomes and its respective 95% confidence intervals using modified Poisson regression
with robust variance estimator, and binomial regression model with an identity link
function, respectively. Although logistic regression is the most common model used to
analyze binary outcome, we used modified Poisson to compare relative risk because
modified Poisson model provides relative risk directly which is more easily interpretable
than odds ratio. The outcomes were the dependent variable and the variables listed in
Table 6-3 (risk factors of our outcome) were independent variables.
Table 6-3. List of variables considered to be adjusted in the regression models.
Category
Demographic
and
Socioeconomic
variables
Health care usea
Comorbiditiesb

Proceduresb
Medicationsc

Lab Values

Variables
Date of cohort entry, age, sex, neighbourhood income quintile,
rural vs. urban residency, health service region of Ontario (local
health integration network),
Hospital admission, emergency department visit, and primary care
physician visit
Acute interstitial nephritis, acute kidney injury, anemia, atrial
fibrillation, chronic liver disease, chronic lung disease, coronary
artery disease, depression, diabetes mellitus, hemorrhage,
hypertension, kidney tumor, obesity, prostatic hyperplasia, urinary
tract infection, urinary tract obstruction
Cystoscopy, stent placed on cohort entry date, surgery
Angiotensin converting enzyme inhibitor or angiotensin receptor
blockers, proton pump inhibitors, diuretics, anti-diabetic
medications, antibiotics, and calcium channel blocker
Estimate glomerular rate greater than or less than 60
mL/min/1.73m2

a

The look-back period for health care use was 1-year.
The look-back period for comorbidities was 5-years.
c
The look-back period for medications was 120 days.
b

We assessed for multicollinearity between all considered covariates using variance
inflation factor (a variance inflation factor of >2 indicates presence of multicollinearity.
The variance inflation factor was greater than two for proton pump inhibitors, diuretics,
anti-diabetic medication, antibiotics, and calcium channel blockers. After omitting the
latter four variables, the variance inflation factor was less than two for all remaining
covariates in the adjusted model.
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As post-hoc analysis, we examined the most common reasoning for presenting to
the emergency department and median [interquartile range, IQR] time to the outcomes
for both patients with and without ADPKD. All statistical analyses were performed using
SAS 9.4 (SAS Institute, Inc, Cary, NC). We present the 95% confidence interval for all
estimates, which corresponds to a significance level of 0.05.

7.3 RESULTS
7.3.1

Cohort selection and baseline characteristics

Our cohort included 73 patients with ADPKD, and 81,445 patients without ADPKD who
underwent ureteroscopy (Figure 7-1). Ureteroscopy was performed across 40 unique
institutions for patients with ADPKD, and across 228 unique institutions for patients
without ADPKD. The characteristics of both groups are summarized in Table 7-4.
Compared to patients without ADPKD, patients with ADPKD were younger (median age
44 vs. 53 years), and equally likely to come from a rural area (12% vs. 12%). About 40%
of the patients with ADPKD and 39% of the patients without ADPKD were women.
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Figure 7-1. Cohort selection.
*Control groups were restricted to baseline characteristics present in ADPKD group to improve
comparability between both groups
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Table 7-3. Characteristics of patients with and without autosomal dominant polycystic
kidney disease at the time of cohort.
ADPKD
Standardized
Differencea
Yes
No
(%)
(n=73)
(n= 81,445)
Median (IQR) age, years
44 (38-60)
53 (42-64)
37
Women, n (%)
29 (40)
31,521 (39)
2
b
Income fifth:
Quintile 1 (lowest)
16 (22)
15,034 (19)
0
Quintile 2
18 (25)
16,669 (21)
0
Quintile 3
14 (19)
16,610 (20)
0
Quintile 4
6 (8)
17,007 (21)
0
Quintile 5 (highest)
19 (26)
16,125 (20)
0
Rural Townc, n (%)
9 (12)
9,891 (12)
1
Median no. of visits to primary
8 (3-12)
8 (3-13)
11
care physician in prior year (IQR)
No. of hospital admissions in the
prior year (%)
0
37 (51)
65,359 (80)
64
1
24 (33)
12,687 (16)
40
2+
12 (16)
3,399 (4)
41
Median no. of visits to emergency
1 (1-3)
1 (1-2)
11
department in the prior year
(IQR)
Procedures in the prior five years
unless specified otherwise, n (%)
Cystoscopy
61 (84)
68,631 (84)
2
Any type of surgery
41 (56)
33,795 (41)
30
Comorbidities, in the prior five
years, n (%)
Acute interstitial nephritis
10 (14)
3,006 (4)
36
Acute kidney injury
14 (19)
2,261 (3)
54
Anemia
10 (14)
7,919 (10)
12
Atrial fibrillation
6 (8)
6,645 (8)
0
Chronic liver disease
7 (10)
3,130 (4)
23
Chronic lung disease
9 (12)
15,303 (19)
18
Coronary artery disease
12 (16)
12,209 (15)
4
Depression
7 (10)
7,925 (10)
0
Diabetes mellitus
13 (18)
18,422 (23)
12
Hemorrhage (any type)
24 (33)
14,013 (17)
37
Hypertension
42 (58)
33,057 (41)
34
Kidney tumor
6 (8)
1524 (2)
29
Obesity
7 (10)
7,417 (9)
2
Prostatic hypertrophy
7 (10)
9,905 (12)
8
Urinary tract infection
25 (34)
14,674 (18)
38
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Urinary tract obstruction
Medication use in the prior 120
days, n (%)d
ACE inhibitors or ARBs
Antibiotics
Calcium channel blockers
Diabetic medicationse
Proton pump inhibitors
Kidney function, n (%)f
> 60 mL/min/1.73m²
< 60 mL/min/1.73m²

ADPKD
Yes
No
(n=73)
(n= 81,445)
33 (45)
26,261 (32)

Standardized
Differencea
(%)
27

10 (31)
15 (47)
7 (22)
6 (19)
6 (19)

9,803 (31)
14,800 (47)
4,985 (16)
5,564 (18)
4,694 (15)

0
0
15
3
11

34 (83)
7 (17)

33,402 (88)
4,753 (12)

14
14

Abbreviations: angiotensin II receptor blockers, ARBs; angiotensin converting enzyme inhibitors, ACE
inhibitors; autosomal dominant polycystic kidney disease, ADPKD; interquartile range, IQR
Date of cohort entry is discharge date for patients that underwent ureteroscopic procedure during same day
surgery, or inpatient setting, registration date for patients that underwent ureteroscopy in the emergency
department, and procedure date for patients who underwent ureteroscopy in an outpatient setting.
a
Unlike hypothesis testing, standardized difference is not influenced by sample size. A standardized
difference of <10% indicates negligible difference.
b
Average neighbourhood income was categorized into fifths on index date. Income quintile was missing
for 0.18% of the entire study cohort. For these individuals, middle income quintile was assigned.
c
Rural/urban residency status was missing for 0.05% of the entire study cohort. For these individuals we
assumed they resided in an urban area
d
Data on prescription filled was only available in 32 patients with ADPKD, and 31,411 patients without
ADPKD.
e
Diabetic medications represent a combination of insulin and anti-glycemic medications.
f
Data on kidney function was only available in 41 patients with ADPKD and 38,155 patients without
ADPKD.
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7.3.2

Follow-up

None of the 73 (0%) patients with ADPKD and 142 of 81,445 (0.2%) patients without
ADPKD died during 30-day follow-up.

7.3.3

Outcome

The risk of ureteroscopic complications was not significantly different between patients
with and without ADPKD, although the estimates were imprecise (6 of 73 [8%] patients
with ADPKD vs. 3,537 of 81,445 [4%] patients without ADPKD; adjusted RR 1.52, 95%
CI 0.72 to 3.24) (Table 7-5). Median [IQR] time to ureteroscopic complication among
those who had one was 16 (5 to 20) days in patients with ADPKD vs. 8 (4 to 15) days in
patients without ADPKD.
Compared to patients without ADPKD, patients with ADPKD were more likely to
present to hospital after their procedure (26 of 73 [36%] patients with ADPKD vs. 16,345
of 81,445 [20%] patients without ADPKD; adjusted RR 1.62, 1.19 to 2.20), which
included a statistically significant increase in the risk of presenting to the emergency
department (33% vs. 19%; adjusted RR 1.58, 95% CI 1.15 to 2.19) but not hospital
admissions (8 of 73 [11%] vs. 4,076 of 81,445 [5%]; adjusted RR 1.78, 0.92 to 3.43)
(Table 7-5). The most common diagnosis for those coming to the emergency room was
renal colic or abdominal pain; nine patients with ADPKD and 3,908 patients without
ADPKD presented to the emergency department with one of these diagnoses. Median
[IQR] time to emergency department visit (6 [2 to15) days in patients with ADPKD vs 5
(2 to 11) days in patients without ADPKD) is approximately the same between patients
with and without ADPKD.

196

Table 7-4. Unadjusted, and adjusted 30-days risk of ureteroscopic complications, hospital presentation, hospital admission,
and emergency department visits in patients with compared to patients without autosomal dominant polycystic kidney disease
(ADPKD).
Events, n (%)
ADPKD

Outcome
Ureteroscopic complication
All-cause hospital
presentation
All-cause hospital
admission
All-cause emergency
department visits

Yes
(n=73)

No
(n=81,445)

6 (8)

3,537 (4)

26 (36)

16,345 (20)

8 (11)

4,076 (5)

24 (33)

15,479 (19)

Unadjusted
Relative Risk
(95%CI)

Unadjusted
Risk Difference
(95% CI)

Adjusted
Relative Risk
(95% CI)

1.89
(0.88 to 4.08)
1.77
(1.30 to 2.42)
2.19
(1.14 to 4.21)
1.73
(1.25 to 2.40)

0.04
(-0.02 to 0.10)
0.16
(0.05 to 0.27)
0.06
(-0.01 to 0.13)
0.14
(0.03 to 0.25)

1.52
(0.72 to 3.24)
1.62
(1.19 to 2.20)
1.78
(0.92 to 3.43)
1.58
(1.15 to 2.19)

Abbreviations: autosomal dominant polycystic kidney disease, ADPKD; confidence interval, CI
Estimates were obtained using modified Poisson regression with outcomes as the dependent variable and ADPKD as the independent variable.
b
Estimates were obtained using binomial regression with identity link function with outcomes as the dependent variable and ADPKD as the
independent variable.
c
Estimates were obtained using modified Poisson regression with outcomes as the dependent variable and the following as the independent variables:
ADPKD, date of cohort entry, age, sex, rural residency status, income quintile, LHIN, healthcare encounter in the prior one year (hospital admission,
emergency department visit, primary care physician visit, and intensive care unit visit), comorbid conditions (acute interstitial nephritis, acute kidney
injury, anemia, atrial fibrillation, chronic liver disease, chronic lung disease, coronary artery disease, depression, diabetes mellitus, hemorrhage,
hypertension, kidney tumor, obesity, prostatic hyperplasia, urinary tract infection, urinary tract obstruction), procedures performed in the prior five years
(cystoscopy, percutaneous stent, and surgery), prescription filled in the prior 120 days (angiotensin converting enzyme inhibitor or angiotensin receptor
blockers, proton pump inhibitors), and estimated glomerular filtration rate value greater than or less than 60 mL/min/1.73m²
a
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7.4 DISCUSSION
The distorted kidney anatomy in patients with ADPKD may make performing
ureteroscopy challenging compared to the general population. We described the 30-day
risk of ureteroscopic complications, all-cause hospital presentation, all-cause hospital
admission, and all-cause emergency department visit in patients with ADPKD, and
compared it to patients without ADPKD. In general, all outcomes were common
(although not necessarily statistically significant) in the ADPKD population. Specifically,
the 30-days risk of ureteroscopic complications was not significantly different between
patients with and without ADPKD, however, patients with ADPKD were more likely to
present to hospital after ureteroscopy, which was driven by a statically significant
increase in risk of presenting to the emergency department.
Our group recently conducted a thorough systematic review summarizing the outcomes
of the three commonly used stone interventions in patients with ADPKD. Currently, there
are only six case series describing the post-ureteroscopy outcome in a total of 43 patients
with ADPKD with the largest case series consisting of 13 patients with ADPKD.26–32
According to the six published case series, the overall risk of complication ranged
between 0% and 27%; post-operative complications described in the literature includes
fever, pain, and hematuria.26–32 While case series and report provide insight into postoperative outcomes of ureteroscopy experienced by patients with ADPKD, it does not
provide strong empirical evidence into whether ADPKD is truly associated with
ureteroscopic complications. Our cohort study is the first and largest study to date to
examine this association (approximately six times larger than the largest published case
series). Additionally, our study had minimal loss to follow-up; no patient with ADPKD
died, and it is unlikely that many people would have travelled out of Ontario during the
30-day follow-up.
There may be reasons why patients with ADPKD presented to the emergency department
after ureteroscopy more than patients without ADPKD. It is possible that patients with
ADPKD may experience a ureteroscopic related complications that is not part of our
composite outcome. For example, pain is a post-ureteroscopic complication according to
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the two case series published in the literature; as this was is nonspecific we did not
include it in our composite outcome.28,32 Our post-hoc analysis showed that pain is the
most common reason for presenting to the emergency department and confirm that
presenting to the emergency department with pain is more prevalent in patients with
ADPKD compared to patients without ADPKD.
Our study is not without limitations. First, the codes for ureteroscopy have not been
formally validated, so we had to rely on clinical expertise and knowledge of billing
practices to define the outcomes. However, we expect the codes for ureteroscopy to have
excellent validity similar to other fee-for services codes. The study is also limited by
what is available in the healthcare administrative databases. We could not adjust for all
important covariates, such as surgeon characteristics, and the accuracy and validity of
each covariate was not perfect; this may have introduced residual confounding and
affected the association between ADPKD and outcomes. We selected ureteroscopy
complications that we thought would represent common issues encountered postoperatively, and rare complications such as ureteral perforation, or common
complications such as retained stone fragments/incomplete stone treatment could not be
accurately measured with administrative data. Lastly, the low event number led to
imprecision around the relative risk estimates. As a result, future studies with larger
number of patients are needed.

7.5 CONCLUSION
In this study of patients who underwent ureteroscopy for upper urinary tract stones, those
with ADPKD did not have a statistically significant higher 30-day risk of selected
ureteroscopic complications. However, they did have a significantly higher 30-day risk of
all-cause hospital presentation and all-cause emergency department visits. Past caseseries and reports and the results of this current study do not provide strong evidence
against the use of ureteroscopy to remove upper urinary tract stones in patients with
ADPKD. However, future studies with a larger number of patients are needed.
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Discussion and conclusions
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8.1 SUMMARY OF KEY FINDINGS
This doctoral thesis identifies knowledge gaps and explores the epidemiology of upper
urinary tract stone and stone interventions, and the consequences of upper urinary tract
stone management in patients with ADPKD. Our first systematic review of 49 studies
showed that the prevalence estimates ranged widely from 3% to 59% for upper urinary
tract stones and from 1% to 8% for stone interventions in the literature.1 The betweenstudy difference in prevalence estimates is due to inconsistent stone definitions, different
distributions of stone risk factors, potential recall bias in studies that relied on patient
self-reported data to identify stone events, and relying on past imaging reports done for
reasons other than stone identifications. UTI and flank pain were the predominant
precursor to diagnosis of stone, and uric acid stones are the most prevalent stone
compositions in patients with ADPKD. Only six studies compared the prevalence of
upper urinary tract stones in patients with ADPKD to unaffected family members.2–7 The
two of six studies with controls that statistically compared the prevalence of upper
urinary tract stones between the two groups showed no significant difference. 2–7
However, none of the studies adjusted for confounders. The wide-ranging prevalence
estimates along with the discovery that no published studies clearly reported stone
incidence confirms that there is poor consensus on how often patients with ADPKD
develop or undergo intervention for upper urinary tract stones.
Our second systematic review of 25 studies describing 311 patients (32 patients that
underwent SWL, 42 patients that underwent ureteroscopy, and 237 patients that
underwent PCNL) showed that percentage of patients who were stone-free after one
session ranged from 0-69% after SWL, 73-100% after ureteroscopy, and 45-100% after
PCNL.8 The percentage of patients with ADPKD that experienced at least one postoperative complication ranged from 0-33% for SWL, 0-27% for ureteroscopy, and 0100% for PCNL. The wide-ranging estimates, which were limited by the sample size,
shows that the efficacy and safety of stone interventions in patients with ADPKD remains
uncertain.8
The methodological quality of the published studies included in both systematic reviews
was poor.1,8 Our systematic reviews call for more methodologically robust studies to

204

better characterize the risk of upper urinary tract stones and stone intervention in patients
with ADPKD, and to better understand the consequences of these three common stone
interventions in patients with ADPKD. Conducting large cohort studies using healthcare
administrative databases can help address this knowledge gap. However, validation of
whether administrative codes related to ADPKD can reliably identify patients with
ADPKD is first required. Our validation study shows that most patients with ICD-10
codes Q61.2 (ADPKD) and Q6.13 (unspecified polycystic kidney disease) truly had
ADPKD according to our strict clinical criteria.9 Another validation study that we
conducted showed that ICD-10 codes related to ADPKD differentiate patients with
ADPKD from patients with similar conditions.10 The second validation study also
showed that OHIP diagnosis codes for congenital anomalies of the urinary system and
other cystic kidney diseases identifies most patients with ADPKD but is indiscriminately
also identifying patients without ADPKD. 10 Therefore, we can use the ICD-10 codes
related to ADPKD to build a robust cohort of patients with ADPKD and hospital
encounters. We can also use OHIP diagnosis codes for congenital anomalies of the
urinary system and other cystic kidney diseases as exclusion codes to exclude patients
with ADPKD from the control group to ensure that the ADPKD and control groups are
mutually exclusive. We used the ICD-10 codes to assemble our ADPKD cohorts for our
two cohort studies and OHIP diagnosis codes to exclude patients with ADPKD from the
control cohort.
Our first cohort study fills some of the knowledge gap identified in our first systematic
review. The results show that ADPKD is associated with an increased rate of hospital
encounter with upper urinary tract stone in patients with ADPKD than patients without
ADPKD with otherwise similar baseline health.11 The cysts may be compressing the
collecting system leading to urinary stasis, which favours urinary crystals to form, stones
to stagnate, and promote stone growth. Given their ongoing renal concerns, patients with
ADPKD may be more likely to present to hospital when they develop a stone compared
to patients without ADPKD. The increased surveillance may also explain the increased
rate of hospital encounter with upper urinary tract stones. The results also showed no
statistical difference in the rate of stone intervention between patients with ADPKD and
similar patients without ADPKD. It is possible urologists were less inclined to perform
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interventions in patients with ADPKD with complex anatomy, choosing to favour
medical treatments. Uric acid stones are the most prevalent stone in patients with
ADPKD, and urologists may use dissolution treatment to treat these stones first, even in
situations where the stones are large.12,13 Our first cohort study also showed that
ureteroscopy is the most common type of stone intervention used to treat stone in both
patients with and without ADPKD.
Our second cohort study examined the post-operative ureteroscopic complications, allcause hospital presentation, all-cause hospital admission, and all-cause emergency
department visit of the most commonly performed stone intervention, ureteroscopy. The
results show that risk of ureteroscopic complication did not differ between patients with
and without ADPKD. Patients with ADPKD were more likely to present to the hospital
after the intervention, which included an increased risk of presenting to the emergency
department but not hospital admission.14 There may be reasons why patients with
ADPKD presented to the emergency department after ureteroscopy more than patients
without ADPKD. It is possible that patients with ADPKD may experience a
ureteroscopic related complications that is not part of our composite outcome. For
example, pain is a post-ureteroscopic complication according to the two case series
published in the literature; as this was is nonspecific we did not include it in our
composite outcome.15,16 Our post-hoc analysis showed that pain is the most common
reason for presenting to the emergency department and confirm that presenting to the
emergency department with pain is more prevalent in patients with ADPKD compared to
patients without ADPKD. Interestingly, this does not appear to be driven by stent related
pain, as the placement of ureteral stents was similar between groups.

8.2 IMPLICATIONS
8.2.1

Laid the foundation for future research in ADPKD using
administrative databases

Understanding the performance of administrative codes related to ADPKD is important
to ensure our ADPKD study cohort is robust; this affects the internal validity of the study.
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Chapter 5 of this thesis show that patients with ICD-10 codes related to ADPKD truly
have ADPKD according to a strict clinical criterion.9 Another validation study conducted
by our team shows that ICD-10 codes also differentiate patients with ADPKD from
patients with similar conditions, but only identifies a subset of the ADPKD population.10
The study also shows that OHIP diagnosis codes for congenital anomalies of the urinary
system and other cystic kidney diseases capture most patients with ADPKD, but also a lot
of patients with similar conditions.10 Therefore, future studies that use administrative
databases can use ICD-10 codes to build a robust cohort of patients with ADPKD and can
use OHIP diagnosis codes to exclude patients with ADPKD.

8.2.2

Implications for clinical practice guidelines

Many popular educational materials and clinical practice guidelines state that upper
urinary tract stones are common in patients with ADPKD, and its prevalence may be five
to ten times higher than the general population.17,18 Our systematic review and metaanalysis of the prevalence and incidence of upper urinary tract stones in patients with
ADPKD (Chapter 2) revealed that these assertions are based on weak evidence.
Results from our first cohort study (Chapter 6) did show that rate of hospital encounter
with upper urinary tract stone is higher in patients with ADPKD compared to patients
without ADPKD with similar baseline health. However, the percentage of patients with
ADPKD who experienced at least one hospital encounter with a stone (4%) and stone
intervention (2%) is still relevantly uncommon. We acknowledge that the way stone is
defined in the study does not identify many stone events, such as when the stone is
passed at home or when it only requires care in an outpatient clinic, We recommend
repeating this study in the future with more rigorous methodology.
Although clinically significant stones are fairly uncommon in patients with ADPKD,
stones remain a major determinant of pain.24 Stones are also known to accelerate disease
progression in patients with CKD and this is suggested to be true in patients with
ADPKD. 25,26 According to the exploratory risk factor analysis in Chapter 6, male sex is a
risk factor for hospital encounter with stone and stone intervention. Therefore, a
nephrologist may wish to monitor high-risk stone formers, such as males, with ADPKD
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for upper urinary tract stones. They may also place a greater emphasis on preventing
upper urinary tract stone formation by monitoring and managing any metabolic
abnormalities. For example, hypocitraturia is a prevalent metabolic abnormality observed
in patients with ADPKD and upper urinary tract stones.19–22 Hypocitraturia is when there
is a low amount of citrate in the urine, and citrate is an inhibitor of stone formation.
Screening for hypocitraturia and treating it with potassium citrate may help prevent upper
urinary tract stones in high-risk stone formers with ADPKD. Nephrologists may also
consider the use of foam sclerotherapy to eliminate predominant cysts that obstruct upper
urine flow.23 Foam sclerotherapy is a procedure that reduces cyst volume by removing
the fluid within the cyst and by instilling sodium tetradecyl sulfate to ablate cyst lining. 23
Even if stones are not frequent in patients with ADPKD, we still need to ensure that
interventions are safe and efficacious in those patients who require intervention. If upper
urinary tract stones do develop and grow to the extent that surgical intervention is
needed, it is clear that we cannot draw conclusions about whether the three common
stone interventions (SWL, ureteroscopy, and PCNL) are safe and efficacious in patients
with ADPKD based on the evidence available from the published literature (Chapter 3).
Our final cohort study (Chapter 7) provided preliminary results on the risk of
complications after the most common stone intervention.14 The results show that ADPKD
is not associated with a significant increase in ureteroscopic complications but is
associated with an increased 30-day risk of all-cause emergency department visits.14 Posthoc analysis showed that the most common reason for emergency department is pain,
which can be managed with medications. Therefore, based on the preliminary insight
from our final cohort study, there are not sufficient evidence against performing
ureteroscopy in patients with ADPKD. However, this needs to be further investigated in
future studies.

8.2.3

Clinical prognostication

Identifying risk factors for upper urinary tract stones in patients with ADPKD can help
target patients who may warrant closer monitoring and increased efforts to prevent upper
urinary tract stone formation. Our exploratory analysis from Chapter 6 shows that men
(vs. women) are at higher risk of being hospitalized with upper urinary tract stones and
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undergo stone interventions. Nephrologists may wish to monitor males with ADPKD
more closely for any metabolic abnormalities or any cyst that may obstruct the collecting
system.

8.3 STRENGTHS
The strength of this thesis is described in detail in the discussion section of each chapter
of the thesis. However, the key strengths are highlighted below.
First, we conducted two comprehensive systematic review to gain a thorough
understanding of the current literature on the epidemiology and management of upper
urinary tract stones in patients with ADPKD. We used a very comprehensive search
strategy to identify relevant literature, and two reviewers independently screened and
abstracted data carefully using a robust form in duplicate to minimize human error and
bias.
Second, we validated administrative codes related to ADPKD and our study showed that
patients identified ADPKD-related ICD-10 codes truly have ADPKD (Chapter 5). The
same codes also differentiate patients with ADPKD from patients with conditions similar
to ADPKD. We used the codes validated in Chapter 5 to assemble our study population
for chapter 6 and 7; therefore, our study populations were robust and internal validity of
the studies were not compromised by the administrative codes used to assemble our study
population.
Third, to the best of our knowledge, Chapter 6 was the first and largest, longitudinal
study that adjusted for covariates, and compared the rate of hospital encounter with upper
urinary tract stones and stone intervention between patients with ADPKD and controls
with similar baseline health. Additionally, Chapter 7 was the first and largest cohort study
to date examining the association between ADPKD and complications post-ureteroscopy.
Both studies had minimal or no loss to follow-up.
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8.4 LIMITATIONS
Limitations of the thesis is described in details in the discussion section of each data
chapter, and are reiterated in this section of the thesis.
First, our two systematic reviews only included conference proceedings and original
journal articles published in English.
Second, we only reviewed medical charts from two hospitals within the London Health
Sciences Center for our validation study (Chapter 4). While coding practices are
standardized across hospitals in Ontario, there still may be slight difference in coding
practices between the two hospitals and other hospitals across Ontario. Additionally,
coding practices vary across the world. For example, in Ontario, physician fee diagnostic
and fee-for service codes (OHIP codes) are submitted by physicians for the remuneration
for the services they provide. ICD-10 codes are traditionally used for administrative
purposes, such as assessing healthcare use and needs in hospital settings. In other regions,
ICD-10 codes are used in outpatient settings as well. Therefore, findings from our
validation study must be generalized to other regions with caution.
Third, ICD-10 codes for ADPKD only identifies patients with a hospital encounter with
ADPKD and does not identify patients with ADPKD who did not have any hospital
encounter. Therefore, findings from chapter 6 and 7 must be generalized to patients with
ADPKD without any hospital encounter with caution.
Fourth, codes for stone interventions has not been formally validated, so we had to rely
on clinical expertise and knowledge from billing practices to define stone intervention.
However, we expect the codes for stone intervention to have excellent validity similar to
other fee-for service codes.
Fifth, chapters 6 and 7 were limited by what is available in healthcare administrative
databases held at ICES. Therefore, we could not adjust for all important covariates, such
as stone size and location, water intake for chapter 6, and surgeon characteristics for
Chapter 7. Additionally, the validity of all the included covariates is not perfect, and
therefore there may be residual confounding.
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Sixth, the number of upper urinary tract stones events is under-reported in chapter 6
because we used ICD-10 codes to identify upper urinary tract stone events. ICD-10 codes
only identify patients who had a hospital encounter with upper urinary tract stones and
does not capture upper urinary tract stone events presented at an outpatient clinic or that
simply passed at home.
Last, the small number of events in both chapters 6 and 7 led to some imprecise
estimates.

8.5 FUTURE DIRECTIONS
While this thesis addressed many knowledge gaps, and addressed many questions about
the epidemiology of upper urinary tract stones in patients with ADPKD, there still
remains many unanswered questions.
First, linking a registry of a large number of patients with ADPKD and their unaffected
family members with precise collection of baseline and outcome measures will provide a
better estimate of risk. In our studies, we were limited by what was available through
healthcare administrative databases held at ICES. As a result, we could not identify
patients with ADPKD with a wide spectrum of disease. We also could not adjust for
important confounders such as diet and water intake. By comparing the outcomes to an
unaffected family member, we would be indirectly adjusting for lifestyle and by linking a
registry with prospectively collected baseline data we can supplement the data from
administrative databases with registry data to minimize residual confounding.
Second, while we know that upper urinary tract stones accelerate disease progression in
patients with CKD, this is only suggested to be true in patients with ADPKD.25,26 Future
studies should determine whether upper urinary tract stones truly accelerate disease
progression to ESKD in patients with ADPKD.
Third, while Chapter 6 gives some insights into risk factors for upper urinary tract stone
in patients with ADPKD, more ADPKD-specific risk factors for upper urinary tract
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stones, such as total kidney volume and mutation type, should be explored. Identifying
risk factors for upper urinary tract stones would help clinicians identify which particular
patients should be monitored more closely and targeted for preventative therapy for upper
urinary tract stones.
Fourth, while chapter 7 provided preliminary insight into the complication rates of
ureteroscopy in patients with ADPKD compared to patients without ADPKD with
otherwise similar baseline health, the estimates were imprecise. The same study should
be repeated with a larger sample size achieved by conducting national level study or a
longer accrual period in the future to get a better understanding of the complication rates
of ureteroscopy in the future.
Last, this thesis did not explore the success and complication rates of SWL and PCNL.
Chapter 3 confirms that evidence for the success and complication rates of SWL and
PCNL is limited. Therefore, future, large, multi-center, prospective or retrospective
cohort studies should be conducted to understand the safety and efficacy of SWL and
PCNL in patients with ADPKD.

8.6 CONCLUSION
Kidney failure is not the only manifestation of ADPKD. ADPKD is a systemic disorder
with many other manifestations that warrant attention to maintain or improve quality of
life. This thesis confirms that hospital encounters with upper urinary tract stones are a
manifestation of ADPKD. The urologists are not more or less likely to manage stones
compared to patients with otherwise similar baseline health. The distorted kidney
anatomy may make performing stone interventions more challenging. Of all three
commonly used interventions (SWL, ureteroscopy, and PCNL), ureteroscopy is the most
prevalent intervention used to manage stones in both patients with and without ADPKD.
Our final thesis study shows that ADPKD is not associated with a statistically significant
increase in ureteroscopic complications and all-cause hospital admission but is associated
with an increased 30-days risk of all-cause hospital presentation and emergency

212

department visits. Currently, there is insufficient evidence to show that we should
discontinue using ureteroscopy to manage upper urinary tract stones. The knowledge
gained from this thesis identifies this knowledge gap and lays the foundation for future
studies on ADPKD using healthcare administrative databases. It clarifies the rate of
hospital encounters with upper urinary tract stones and the rate of stone interventions, and
provides the best evidence we have to date to inform clinical practice.

8.7 TAKE HOME MESSAGE
•

We can reasonably identify patients with a hospital encounter with ADPKD using
ICES data

•

Incidence and prevalence of upper urinary tract stone and stone intervention in
ADPKD, and the safety and efficacy of the three common stone interventions
(SWL, ureteroscopy, and PCNL) are unclear.

•

The rate of a hospital encounter with upper urinary tract stone is higher in patients
with ADPKD than patients without ADPKD with similar baseline health. The
percentage of patients with ADPKD who experience a clinically significant stone
event remains relatively uncommon (4%)

•

Urologists are not more or less aggressive in their management of stones in
patients with ADPKD compared to patients without ADPKD.

•

Patients with ADPKD are more likely to visit to the emergency department within
30 days of ureteroscopy for stone disease compared to patients without ADPKD
with similar baseline health.
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Table A-1. Detailed description of ICES data sources used in Chapters 5 to 7.
DATABASE
DESCRIPTION
Canadian Institute for Health Information
CIHI-DAD contains administrative, demographic, and clinical information
(CIHI) Discharge Abstract Database
on hospital discharges of patients admitted to acute care hospitals in Ontario,
(DAD), CIHI Same Day Surgery (SDS), and SDS contains information on same day surgery, and NACRS contains
CIHI National Ambulatory Care Reporting information on all emergency department visits. The diagnostic and
System (NACRS)
procedural information are coded using the 9th edition of the Canadian
Modified International Classification of Diseases (ICD-9-CM) and the
Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures
(CCP) codes, respectively, prior to April 1st, 2002, and coded using the 10th
edition of the Canadian Modified International Classifications of Diseases
(ICD-10-CM) and the Canadian Classification for Health Interventions
(CCI) codes, respectively, from April 1st, 2002 and onwards.119
Ontario Health Insurance Plan (OHIP)
OHIP contains most claims covered under the provincial health insurance
Database
plan. Approximately 95% of the specialist and 50% of the family care
physicians in Ontario get paid on a fee for service basis.
Ontario Registered Persons Database
RPDB contains reliable demographic and vital statistics, such as birth and
(RPDB)
death data, of all Ontarians with a valid health card number.
ICES Physician Database (IPDB)
IPDB is created by ICES and contains information about all physicians,
including practice location, and clinical specialties. It comprises information
from the OHIP Corporate Provider Database (CPDB), the Ontario Physician
Human Resource Data Centre database, and the OHIP database of physician
billing.
Canadian Organ Replacement Register
CORR is a national information system that contains detailed information on
(CORR)
everyone who has received an organ transplantation or is on chronic
dialysis.120 At ICES, we only have access to data from Ontario.
Ontario Drug Benefits (ODB)
ODB contains information on outpatient prescriptions dispensed to patients
aged 65 years and older, patients who live in a Long-Term Home or Home
for Special Care, patients enrolled in Home Care Program, patients enrolled
in the Trillium Drug Program, and patients who receive social assistance
from Ontario Works or the Ontario Disability Support program. The data
available from this database is highly reliable with an error rate of <1%. 122
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The health card number of Ontarians is encoded using a unique ICES key number, which is used as a common identifier to link databases at ICES
together.
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